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Abstract 
The increasing prevalence of infections attributed to antibiotic-resistant bacteria has 
prompted renewed interest in exploiting the antibacterial properties of Ag
+
 to treat such 
infections. However, the antibacterial mode of action (MOA) and bactericidal activity 
of Ag
+
 are poorly understood, and there are concerns that the prolific and unrestricted 
use of Ag
+
 in consumer products will select bacterial Ag
+
 resistance, thus limiting the 
clinical utility of Ag
+
. Ag
+
 resistance already exists, although aspects of the molecular 
basis of Ag
+
 resistance, and the current prevalence of Ag
+
-resistant pathogens are 
unclear. This thesis sought to address these issues. 
Ag
+
 was found to be bacteriostatic in culture media and bactericidal in buffer, and was 
unable to eradicate Staphylococcus aureus biofilms in vitro. MOA studies indicated that 
the primary antibacterial target of Ag
+
 is the cell membrane. Evidence was obtained 
suggesting that Ag
+
 does not interfere with the phospholipid component of the 
membrane, but instead probably damages integral membrane proteins to produce an 
antibacterial effect. 
A survey of hospital staphylococcal isolates (n=1006) found universal susceptibility to 
Ag
+
, and Ag
+
 resistance could not be selected in S. aureus and several other pathogens 
in vitro. However, in Escherichia coli, high-level Ag
+
 resistance arose rapidly and was 
not associated with a fitness cost likely to prevent its emergence in the clinical setting. 
Ag
+
-resistant strains contained mutations in genes regulating expression of an 
Ag
+ 
efflux mechanism and outer membrane porins. A detailed characterisation of a 
known Ag
+
-resistance determinant (the sil operon), was also conducted to provide 
further insights into the mechanism of Ag
+
 resistance conferred by this determinant. 
v 
Collectively, these studies provide further insights into the MOA of Ag
+
 and the 
mechanisms of Ag
+
 resistance, which could potentially be applied to optimising the 
future uses of Ag
+
 as an antibacterial agent.  
vi 
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Chapter one: Introduction 
1.1. The use of antibacterial chemotherapy in the treatment of infectious disease 
1.1.1. Infectious disease in the pre-antibiotic era 
The debilitating and deadly impact of bacterial infection on human health has been 
noted from the start of written history. Accounts from ancient Greece and Egypt 
describe diseases that are indicative of leprosy, tuberculosis and diphtheria (Watts, 
1999). The causative agent of bubonic plague, Yersinia pestis, is believed to have 
caused the death of approximately 90% of the population of Europe during the 
12
th
 Century, to have killed a further 40 million people worldwide in the 14
th
 Century, 
and remained the cause of high-mortality epidemics until the early 19
th
 Century (Rosen, 
1993; Nelson et al., 2007). Other diseases attributed to infectious processes were also 
prevalent and made a substantial contribution to human morbidity and mortality at the 
time; these included syphilis, leprosy, cholera, typhoid fever and dysentery (caused by 
Treponema pallidum, Mycobacterium leprae, Vibrio cholerae, Salmonella Typhi and 
Shigella spp./Entamoeba histolytica, respectively) (Rosen, 1993; Watts, 1999; Nelson et 
al., 2007). Syphilis was considered endemic across Europe during the 18
th
 and 
19
th
 Century and is proposed to have been responsible for the deaths of numerous 
famous philosophers, painters and musicians at the time, including Nietzsche, Manet 
and Mozart (Franzen, 2008). Prior to the 20
th
 Century, any condition that required 
medical or surgical intervention carried the risk of severe infection, for example 
puerperal fever following childbirth, or streptococcal, staphylococcal, and clostridial 
infections in surgical wounds (Finch et al., 2010).   
Following the introduction of experimental evidence supporting the germ-theory of 
disease by Pasteur, and the work of individuals such as Semmelweis, Snow, Jenner and 
2 
Lister in preventing infectious disease through the use of improved sanitation, 
education, vaccines and antiseptics, fewer people acquired the infections that had been 
so prevalent in the past (Mandell et al., 2009). This led to the percentage of deaths 
attributed to infectious disease decreasing from an estimated 75% in the 17
th
 Century to 
~40% by the end of the 19
th
 Century (Omran, 1971). Nevertheless, although 
transmission of infectious disease could be prevented to an extent, there was still little 
that could be done to cure individuals of infection once it had been acquired.  Indeed, in 
the early 20
th
 Century childhood diseases such as diphtheria, pneumonia and rheumatic 
fever were still associated with death rates approaching 40% (Armstrong et al., 1999). 
In the case of systemic Staphylococcus aureus infections, mortality rates were >80% 
prior to the 1940‘s (Fuda et al., 2005).  
1.1.2. A brief history of antibacterial chemotherapy 
From the late 19
th
 Century onwards, antiseptics used for the sterilisation of surgical 
equipment (e.g. carbolic acid, boric acid, hydrogen peroxide and perchlorite solutions) 
were also used in an attempt to sterilize infected wounds (Fleming, 1919). Although 
reducing bacterial burden at the site of the wound, this approach could not be used to 
treat systemic infection owing to the toxicity of the compounds used (Fleming, 1919, 
Manring et al., 2009). The concept of using a compound as a systemic agent in patients 
that could kill bacteria without causing significant damage to the host (i.e. the 
―magic bullet‖) is attributed to Erlich, whose research group subsequently discovered 
that the synthetic compound arsphenamine could be used systemically for the treatment 
of syphilis (Schwartz, 2004, Lloyd et al., 2005). This was followed with the 
introduction of the first sulphonamide, Prontosil (sulphanilamide) in 1932, which was 
less toxic than arsphenamine and could treat infections caused by a wider range of 
3 
bacteria, such as streptococci and Neisseria species (Mandell et al., 2009; Finch et al., 
2010).  
In addition to the synthetic compounds described above, a number of organisms were 
found to produce antibacterial compounds as secondary metabolites (i.e. compounds not 
essential for basic metabolic function of an organism) that had the potential to be 
employed in the treatment of infectious disease (Duckett, 1999). An early example of 
this is the development of penicillin. Although published studies in the late 19
th
 and 
early 20
th
 Century had commented on the antibacterial properties of the genus 
Penicillium (Tyndall, 1876; Duckett, 1999), it was not until the early 1940‘s that the 
potential medical application of this discovery began to be truly exploited (Drews, 
2000). Named penicillin by Fleming (1929), the secondary metabolite of Penicillium 
chrysogenum was successfully extracted and purified by Florey and colleagues, and 
could effectively treat systemic infection caused by a range of microorganisms 
including T. pallidum, S. aureus and Streptococcus spp. with relatively few side-effects 
(Drews, 2000). 
The realisation that compounds such as arsphenamine, penicillin and sulphanilamide 
could cure infections that were previously fatal prompted efforts to identify further 
compounds displaying selective antibacterial activity. This ultimately led to the 
discovery of a range of antibacterial compounds between the 1940‘s and 1970‘s, of 
which a number were subsequently introduced into clinical practice for the treatment of 
infectious disease (Table 1.1). These compounds consist of secondary metabolites (also 
known as ‗natural products‘, for example streptomycin and vancomycin), 
semi-synthetic derivatives of natural products (e.g. rifampicin and flucloxacillin), or 
entirely synthetic compounds (e.g. ciprofloxacin and linezolid), and are collectively 
referred to as ‗antibiotics‘ (although this term was originally used to refer solely to 
4 
natural products with antibacterial activity, its definition has since been extended) 
(Fischbach & Walsh, 2009). 
The introduction of antibiotics into clinical practice revolutionised healthcare. For 
example, following the introduction of the sulphonamides, mortality attributed to 
puerperal fever decreased from ~4 deaths per 1000 births to <1 death per 1000 births by 
the 1970‘s (Finch et al., 2010). In the USA, mortality attributed to systemic 
staphylococcal infection is presently ~20%, having decreased from >80% in the 
pre-antibiotic era (Fuda et al., 2005; van Hal et al., 2012). Furthermore, the introduction 
of antibiotics is believed to have contributed to an increase in the average life 
expectancy of approximately 30 years in developed countries; either as a direct 
consequence of treating infection, or indirectly in their use as a prophylactic to reduce 
the risk of infection from invasive surgical procedures (Walsh, 2003). 
1.1.3. Mode of action (MOA) of antibiotics 
Antibiotics are compounds that, at a low concentration, selectively inhibit 
(bacteriostatic) or kill (bactericidal) bacteria, by interfering with the function of one or 
more macromolecules within the target organism (Walsh, 2003). The selective toxicity 
of antibiotics against bacteria is usually a consequence of the fact that their 
macromolecular ‗targets‘ are either not found in eukaryotes (e.g. enzymes involved in 
peptidoglycan synthesis), are of a sufficiently different structure to an equivalent 
eukaryotic homologue (e.g. the ribosome), or are protected by a component of the 
eukaryotic cell (e.g. the mitochondrial membrane(s) acting as a barrier to prevent 
ribosomal inhibitors from reaching the mitochondrial ribosome)  (Walsh, 2003). This 
property allows for the use of antibiotics in treating infectious disease without (in most 
cases) harming the patient. Antibiotics in clinical use typically disrupt processes 
5 
involved in DNA replication, transcription, translation and peptidoglycan synthesis; 
alternatively, compounds such as the polymyxins and daptomycin elicit an antibacterial 
effect by damaging the bacterial cell membrane(s) (Finch et al., 2010). A list of the 
antibacterial targets for each antibiotic class in clinical use can be found in Table 1.1. 
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Table 1.1. Antibiotic classes in clinical use (Adapted from Walsh, 2003; Silver, 2011, 
Mandell et al., 2009; Conly & Johnston, 2005)  
Class Year of first 
reported 
discovery/patent
 
Year of first 
regulatory 
approval/introduction 
to clinical practice
 
Antibacterial target 
-lactams 1929
1 
1941 Transpeptidases  
Sulphonamides 1932 1935 Dihydropterate 
synthase 
Aminoglycosides 1943 1946 30S ribosomal 
subunit 
Bacitracin
2 
1945 1948 Undecaprenyl 
pyrophosphate 
Nitrofurans 1946 1952 Multiple targets
3
 
Phenicols 1947 1949 50S ribosomal 
subunit 
Polymyxins 1947 1959 Cell membranes 
Tetracyclines 1945 1948 30S ribosomal 
subunit 
Pleuromutilins 1950 2007 50S ribosomal 
subunit 
Macrolides 1949 1952 50S ribosomal 
subunit 
Isoniazid
2
 1952 1952 Multiple targets
3
 
Glycopeptides 1953 1955
 
D-ala-D-ala terminus 
of peptidoglycan 
precursors 
Streptogramins 1953 1955 50S ribosomal 
subunit 
D-cycloserine
2 
1955 1956 Alanine racemase and 
D-ala-D-ala ligase 
Aminocoumarins 1951 1960 DNA gyrase 
Rifamycins 1957 1959 RNA polymerase  
Nitroimidazoles 1959 1959 Multiple targets
3 
Fusidic acid
2 
1961 1962 Elongation factor G 
Lincosamides 1955 1961 50S ribosomal 
subunit 
Trimethoprim
2
 1961 1965 Dihydrofolate 
reductase 
Quinolones 1961 1962 DNA 
gyrase/topoisomerase 
Fosfomycin
2 
1969 1971 MurA/MurZ 
Mupirocin
2
 1971 1985 Isoleucyl-tRNA 
synthetase 
Oxazolidinones 1978 2000 50S ribosomal 
subunit 
Lipopeptides 1987 2003 Cytoplasmic 
membrane 
Fidaxomicin
2
 1975 2011 RNA polymerase 
 1Date of publication noting the antibacterial activity of filtrates from P. chrysogenum cultures 
(Fleming, 1929). 
2
Names correspond to compounds, as they are the only members of their 
class. 
3
Nitrofurans, nitroimidazoles and isoniazid are all metabolised by the host organism into 
reactive intermediates that inhibit multiple cellular macromolecules.  
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1.1.4. Antibiotic resistance  
The continued and widespread use of antibiotics in the treatment of infectious disease 
provides the selection pressure necessary for the emergence of antibiotic resistance; a 
phenotype that enables a bacterium to survive and proliferate in the presence of an 
antibiotic at concentrations that are inhibitory against other bacterial populations. 
Infections caused by antibiotic-resistant bacteria cannot be treated effectively with 
antibiotics that the causative bacteria are resistant to (Walsh, 2003; Hawkey, 2008).  
Bacterial resistance to antibiotics can arise by endogenous (mutational) or exogenous 
(horizontally-acquired) mechanisms (Finch et al., 2010), with endogenous resistance 
resulting from the selection of bacterial strains harbouring mutations in genes or 
non-coding elements of DNA already present in the cell (Mayers et al., 2009). These 
mutations typically lead to resistance by altering the target of the antibacterial such that 
the binding affinity is reduced (e.g. rpoB and rifampicin resistance), by increasing 
expression of the antibacterial target (e.g. alrA and D-cycloserine resistance), or 
increasing expression of antibacterial detoxification mechanisms, such as efflux pumps 
(e.g. norA and ciprofloxacin resistance) (Nikaido, 2009; Wright, 2011). In contrast, 
exogenous resistance arises when the host bacterium acquires foreign DNA via 
horizontal gene transfer (i.e. conjugation, transformation, or transduction) that encodes 
an antibiotic resistance determinant. These determinants can encode efflux pumps (e.g. 
tet(A) and tetracycline resistance), antibiotic-inactivating enzymes (e.g. cat and 
chloramphenicol resistance), and mechanisms to modify the target (e.g. ermC and 
erythromycin resistance), or produce a functional homologue of the antibiotic target that 
is resistant to antibiotic inhibition (e.g. mupA and mupirocin resistance) (Chopra & 
Roberts, 2001; Wright, 2011). For every antibiotic class in clinical use, bacteria have 
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evolved one or more mechanisms to resist their action; these mechanisms are 
summarised in Table 1.2. 
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Table 1.2. Mechanisms of bacterial resistance to antibiotic classes in clinical use 
Class Example(s) of mechanisms conferring resistance Reference 
Aminocoumarins Point mutation(s) in gene (gyrA) encoding target, reducing antibiotic binding affinity; 
MexAB-/AcrAB-mediated efflux 
(Confreres & 
Maxwell, 1992; 
Nikaido, 2009) 
Aminoglycosides MexAB-/AcrAD-mediated efflux; enzymatic inactivation of antibiotic by adenylation, acetylation or 
phosphorylation 
(Mayers et al., 
2009, Nikaido, 
2009) 
Bacitracin Increased production of target; BcrABC-mediated efflux (putative) (Manson et al., 
2004)  
D-cycloserine Overexpression of gene encoding target (alanine racemase) (Caceres et al., 
1997) 
Fidaxomicin Point mutation(s) in genes (rpoB, rpoC) encoding target, reducing antibiotic binding affinity
1 
 (Babakhani et al., 
2004) 
Fosfomycin Point mutation(s) in gene (murA/Z) encoding target; enzymatic inactivation by glyoxylase-family enzymes (Rigsby et al., 
2005; Takahata et 
al., 2010) 
Fusidic acid Point mutation(s) in gene (fusA) encoding target, reducing fusidic acid binding affinity; acquisition of genes 
(fusB, fusC) encoding target protection mechanisms 
(Besier et al., 2003; 
Cox et al., 2012) 
Glycopeptides Modification of target (lipid II) to reduce affinity of glycopeptide binding (mediated by VanHAX) (Bugg et al., 1991) 
Isoniazid Point mutation(s) in gene encoding catalase (katG), resulting in reduced conversion of isoniazid into reactive 
intermediates 
(Heym et al., 1995) 
Lincosamides Lsa-mediated resistance (unknown mechanism); enzymatic modification (methylation) of target (23S rRNA) 
to reduce antibiotic binding affinity  
(Reynolds et al., 
2003; Mayers et al., 
2009) 
Lipopeptides Modification of target (cell membrane) via point mutation(s) in mprF, yycG and rpoB/C, to reduce binding 
affinity of daptomycin 
(Friedman et al., 
2006) 
Macrolides MexAB-/AcrAB-mediated efflux; enzymatic modification (methylation) of target (23S rRNA) to reduce 
antibiotic binding affinity 
(Mayers et al., 
2009; Nikaido, 
2009) 
Mupirocin Point mutation(s) in gene (ileS) encoding target, reducing mupirocin-binding affinity; acquisition of 
isoleucyl-tRNA synthetase (MupA, MupB) resistant to inhibition  
(Hurdle et al., 2004; 
Hurdle et al., 2005) 
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Table 1.2. (Continued) 
Nitrofurans Point mutation(s) in genes encoding nitroreductases, preventing conversion of nitrofurans into reactive 
intermediates 
(Sandegren et al., 
2008) 
Nitroimidazoles Enzymatic inactivation of antibiotic by nim-encoded proteins; point mutation(s) in gene (rdxA) encoding a 
nitroreductase, presumably preventing conversion of nitroimidazoles into reactive intermediates  
(Dhand & 
Snydman, 2009) 
Oxazolidinones Enzymatic modification (methylation) of target (23S rRNA) to reduce antibiotic binding affinity (Mayers et al., 
2009) 
Phenicols MexAB-/AcrAB-mediated efflux; enzymatic inactivation of antibiotic by acetylation (Mayers et al., 
2009; Nikaido, 
2009) 
Pleuromutilins Enzymatic modification (methylation) of target (23S rRNA) to reduce antibiotic binding affinity   (Long et al., 2006) 
Polymyxins Enzymatic modification of target (Lipid A) to reduce polymyxin binding affinity (Falagas et al., 
2010) 
Quinolones NorA/AcrAB-mediated efflux; point mutation(s) in genes (gyrA, parC) encoding targets, reducing antibiotic 
binding affinity 
(Kaatz et al., 1993; 
Hooper, 1999) 
Rifamycins Point mutation(s) in gene (rpoB) encoding target, reducing rifamycin binding affinity (O'Neill et al., 
2001) 
Streptogramins Vga/Lsa-mediated resistance (unknown mechanism); enzymatic modification of target (23S rRNA) to reduce 
antibiotic binding affinity 
(Reynolds et al., 
2003; Mayers et al., 
2009) 
Sulphonamides MexAB-mediated efflux; point mutation(s) in gene encoding dihydropterate synthase; acquisition and 
production of dihydropterate synthase resistant to inhibition 
(Sköld, 2000, 
Nikaido, 2009) 
Tetracyclines Efflux (mediated by Tet(A)-(L)); protection of target (mediated by Tet(M), (O), (S) or (W)); Tet(X)-mediated 
inactivation of antibiotic 
(Chopra & Roberts, 
2001) 
Trimethoprim Point mutation(s) in gene encoding target (dihydrofolate reductase), reducing trimethoprim binding affinity; 
acquisition and production of dihydrofolate reductase resistant to inhibition; MexAB-/AcrAB-mediated efflux 
(Huovinen et al., 
1995; Nikaido, 
2009) 
-lactams Inactivation by -lactamases; production of penicillin-binding protein with reduced affinity for -lactam 
binding (e.g. MecA) 
(Davies & Davies, 
2010) 
1
Mechanism of resistance identified from resistant isolates selected under laboratory conditions. Clinically-relevant fidaxomicin resistance has been identified 
in Clostridium difficile, but the mechanism of resistance is unknown (Babakhani et al., 2004). 
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1.1.5. History and impact of antibiotic resistance 
Bacterial resistance to penicillin was encountered soon after its clinical introduction, 
with the first report of staphylococcal penicillin resistance in 1942 (Fuda et al., 2005). 
This soon became widespread, with >50% of all S. aureus isolates resistant to penicillin 
by the 1950‘s (compared with 6% in the early 1940‘s) (Fuda et al., 2005). A similar 
trend was observed following the introduction of other antibiotic classes, such as the 
tetracyclines and the macrolides (Finch et al., 2010). However, due to the rapid 
discovery and introduction of new antibiotics between 1940 and 1970 (termed the 
‗golden age‘ of antibiotic discovery) (Silver, 2011), and the structural modification of 
existing antibiotic classes to overcome resistance mechanisms (e.g. the 
penicillinase-stable -lactams oxacillin and meticillin) (Fischbach & Walsh, 2009), it 
was believed by many in the 1960‘s to 1970‘s that antibiotic resistance would not be a 
barrier to the continued success of antibiotics in treating infectious disease (Fauci, 2001; 
Spellberg, 2008) . However, due to a number of reasons (described later in this chapter), 
the rate of introducing new antibiotics into clinical practice diminished, whilst the 
prevalence of antibiotic-resistant bacteria has continued to rise (Fischbach & Walsh, 
2009). 
In the present day, antibiotic resistance has been described as representing a 
‗catastrophic threat‘ to the prevention and treatment of infectious disease (Davies, 
2013). For example, S. aureus resistant to the penicillinase-stable -lactams (termed 
meticillin-resistant S. aureus [MRSA]) comprise up to 60% of all total S. aureus 
isolated in the USA, which has increased from ~25% in 1995 (Boucher & Corey, 2008). 
Infections caused by MRSA are estimated to kill between 18,000-25,000 people per 
year in the USA and Europe, and are associated with higher rates of mortality compared 
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with those caused by meticillin-susceptible S. aureus (MSSA) (Whitby et al., 2001, 
Cosgrove et al., 2003). This has in part been attributed to the need to use antibiotics 
such as linezolid, vancomycin and daptomycin, which are inferior to -lactams (the 
treatment of choice for MSSA infections) in treating staphylococcal infection (Whitby 
et al., 2001; Stryjewski et al., 2007). Furthermore, strains resistant to one or more of 
these antibiotics have been isolated from patients, suggesting that their future utility 
may be limited.  
Amongst Gram-negative bacteria, Escherichia coli, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacter spp. are routinely 
responsible for hospital-acquired urinary tract infections (UTIs), surgical site infections 
(SSIs), bloodstream infections (BSIs) and pneumonia (Weinstein et al., 2005). 
Infections attributed to these bacteria are typically treated with -lactams 
(e.g. extended-spectrum cephalosporins, monobactams and carbapenems), 
aminoglycosides or fluoroquinolones; however the prevalence of isolates resistant to 
one or more of these classes is increasing (Chopra et al., 2008). For example, in the UK 
the number of Enterobacteriaceae reported to be carbapenem-resistant has increased 
from <20 in 2003 to ~550 in 2011 (Davies, 2013). Resistance to -lactams, 
aminoglycosides and fluoroquinolnes are typically the consequence of the 
expression/overexpression of efflux pumps with a broad substrate range, such as those 
of the resistance-nodulation-division (RND) superfamily (e.g. MexAB in P. aeurginosa, 
AdeAB in A. baumannii) (Nikaido, 2009), and (in the case of -lactams) the acquisition 
of -lactamases with activity against 3rd-generation cephalosporins and carbapenems 
(e.g. AmpC, IMP, VIM and NDM-1) (Thomson & Bonomo, 2005). Alarmingly, strains 
of A. baumanni, P. aeruginosa and K. pneumoniae have been isolated from patients that 
are resistant to all clinically-used antibiotic classes, rendering any chemotherapeutic 
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intervention ineffective against infections caused by such strains (Falagas & Bliziotis, 
2007). 
Given the lack of new compounds active against multi-drug resistant (MDR) and 
pan-drug resistant (PDR) bacteria, it has been suggested that we are entering a 
‗post-antibiotic era‘ wherein mortality rates associated with infectious disease and 
surgical procedures with a high risk of infection are likely to return to the levels seen 
prior to the introduction of penicillin (Alanis, 2005; Falagas & Bliziotis, 2007; Davies 
2013). It is therefore apparent that new antibiotics, or alternative approaches to the 
treatment and prevention of infection, are urgently needed to prevent this scenario from 
occurring (Fischbach & Walsh, 2009; Silver, 2011). 
1.1.6. The antibiotic discovery ‘void’ and the need for alternative strategies to treat 
infectious disease 
Between 2000 and 2011, only four new antibiotic classes were introduced into clinical 
practice (the oxazolidinones, lipopeptides, pleuromutilins and the macrocycle, 
fidaxomicin), which is in stark contrast to the myriad of compounds introduced between 
the 1940‘s and 1960‘s (Fischbach & Walsh, 2009). In addition, only two of these 
classes (oxazolidinones and lipopeptides) are approved for the systemic treatment of 
bacterial infection, and none of these classes is effective in treating infection caused by 
Gram-negative bacteria (Silver, 2011). The lack of new classes has been described as an 
antibiotic discovery ‗void‘ and is attributed to two main factors (Silver, 2011). The first 
is the failure of modern antibiotic discovery methods to identify potential antibiotic 
compounds. Methods such as high-throughput screening (HTS) of chemical libraries 
and structure-based drug design (SBDD) focus on identifying compounds with in vitro 
activity against a single enzyme target. However, the resultant ‗hits‘ frequently have no 
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antibacterial activity in vivo (as they cannot pass through the bacterial membrane), or 
display ‗off-target‘ antibacterial activity, which typically correlates with the compound 
being toxic to a patient if used systemically (Silver, 2011). This is exemplified by a 
publication in 2006, which revealed that GlaxoSmithKline identified only 5 compounds 
with the potential to be developed as an antibiotic, following HTS of 
260,000-530,000 compounds against 70 antibacterial targets (Payne et al., 2006). 
Further HTS campaigns by 34 different pharmaceutical companies failed to yield any 
potential antibiotic candidates (Chan et al., 2004). In addition, the estimated time to 
identify, develop and gain regulatory approval for the clinical use of an antibiotic is 
approximately 12-14 years, at a cost of >$800 million (Conly & Johnston, 2005). As 
antibiotics are only prescribed for short periods (when compared with medications for 
chronic conditions), and have a limited therapeutic lifespan (due to the inevitable 
emergence of resistance), the revenue obtained from sales of antibiotics is relatively low 
(Payne et al., 2006; Fischbach & Walsh, 2009). As a consequence of the above, a 
number of the large pharmaceutical companies are withdrawing from the field of 
antibiotic discovery and development, thus further reducing the rate at which new 
antibiotics are likely to be discovered (Silver, 2011).  
Alternative strategies for the treatment of infectious disease have been proposed in an 
attempt to mitigate the decline in antibiotic discovery. These include the use of 
‗phage-based systems to deliver toxic compounds (or genes encoding their production) 
into pathogenic bacteria (Fairhead, 2009); anti-virulence compounds to prevent bacterial 
colonisation at a potential site of infection, or prevent a pathogen from expressing other 
virulence factors (Rasko & Sperandio, 2010); and the use of antibiotic ‗adjuvants‘, 
compounds that disable or disrupt intrinsic antibiotic resistance mechanisms of 
Gram-negative bacteria (e.g. efflux pumps and the outer membrane), allowing for 
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previously ineffective antibiotics (i.e. Gram-positive-specific antibiotics such as 
vancomycin and telavancin) to reach their antibacterial target and display 
clinically-relevant levels of activity (Kalan & Wright, 2011; Hornsey et al., 2012). 
However, each of these strategies have the same barrier to their clinical introduction, in 
that regulatory approval for their use is first required, which is typically an expensive 
and long (~6-8 year) process (Payne et al., 2006).  
Another strategy without this disadvantage is to reevaluate the use of underexploited 
antibacterial agents; such agents have received regulatory approval, but are rarely used 
or have been neglected due to limitations in the range of their potential applications (e.g. 
a topical antibacterial agent opposed to one that could be used systemically), or due to 
their relatively high toxicity when compared with current antibiotics (Falagas et al., 
2008; Fabbretti et al., 2011). One example is colistin (polymyxin E), which was 
originally approved for clinical use in the 1950‘s, however as a consequence of its 
reported nephrotoxicity, its use was abandoned in the 1970‘s (Falagas et al., 2008). Due 
to the increasing prevalence of MDR Gram-negative bacteria, the use of colistin has 
increased as a ‗last resort‘ compound for treating infections caused by these organisms. 
Another example is the use of compounds containing silver. As described later in this 
chapter, silver has been used for centuries as an antibacterial agent and, although its use 
decreased with the introduction of antibiotics, the increased prevalence of 
antibiotic-resistant bacteria has led to a resurgence in its use. The remainder of this 
chapter will discuss the history of antibacterial silver, its current and potential 
applications in the treatment of infectious disease, and then describe the antibacterial 
MOA of silver and the potential for bacteria to resist its antibacterial effect. 
 
16 
 
1.2. Silver as an antibacterial agent 
1.2.1. History of silver 
Silver (Ag) is an element with the atomic number 42 and a relative atomic mass of 
107.8682 g/mol (Silver, 2003). The electron configuration of silver classifies it as a 
transition metal element (McNaught & Wilkinson, 1997), and it can also be described as 
a ‗heavy‘ metal (as it has a specific gravity >5) (Duxbury, 1986) or, when it is in its 
ionised state (Ag
+
), a soft (Lewis) acid (Gadd, 1992). The antibacterial properties of 
silver have been exploited for millennia; there are reports suggesting that silver 
containers were used by the ancient Greeks, Romans and Egyptians to prevent the 
spoilage of food and water when stored or transported (Alexander, 2009). Furthermore, 
a Roman pharmacopeia, believed to have been published in 69 B.C.E., noted the use of 
silver nitrate (AgNO3) presumably as a treatment for medical conditions (Klasen, 
2000a).  
Between the start of the Common Era and the 18
th
 Century, silver was used to treat a 
number of medical conditions, including those that are now known to be a consequence 
of infectious disease (Klasen, 2000a; Weber & Rutala, 2001; Alexander, 2009). For 
example, AgNO3 was applied to wounds in the 14
th
 Century in a likely attempt to 
prevent the onset of infection (Klasen, 2000a), and in the 15
th
 Century ‗maladies of the 
brain‘, including epilepsy, were thought to be curable by ingesting a silver coin (Grier, 
1968; Alexander, 2009). The use of hardened AgNO3 (referred to as lapis infernalis) 
was recommended as an alternative to using a scalpel for opening abscesses in an 
18
th
 Century surgical text book (Klasen, 2000a), and in the same Century, AgNO3 was 
used for the treatment of venereal diseases such as condylomata (genital warts; now 
known to be caused by human papilloma virus, or as a symptom of secondary syphilis) 
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and chancre, an eroding ulcer that is typically attributed to primary syphilis (Klasen, 
2000a).  
Following the proposal of the germ theory of infectious disease in the 19
th
 Century, it 
was soon discovered that silver compounds possessed antibacterial activity against 
organisms such as S. aureus and Bacillus anthracis (Schneider, 1984). In 1880, a 
2% (w/v) solution of AgNO3 was found to prevent ophthalmia neonatorum, a 
gonococcal or chlamydial infection of the conjunctiva in new-borns that frequently 
leads to blindness. The use of AgNO3 in this manner caused a noticeable decrease in the 
prevalence of this infection, from 13.6 to 0.5% of all new-born children in Germany 
(Alexander, 2009). Further success at employing silver as prophylaxis against infection 
was noted throughout the remainder of the 18
th
-, 19
th
- and the early 20
th
 Century 
(Schneider, 1984; Klasen, 2000a); for example, silver compounds and silver-containing 
dressings were noted to prevent infection in burns and other wounds, and 
silver-containing sutures were routinely used for the repair of hernias and fistulas. Silver 
was also used to directly treat infection at this time; for example silver suspensions were 
used to treat streptococcal sepsis and various infections of the eye (Roe, 1915, 
Sanderson-Wells, 1918). A derivative of Salvarsan (arsphenamine) was created using 
silver (silver Salvarsan), which was found to be more soluble than the original 
compound, and less toxic when used systemically for the treatment of syphilis (Vecki & 
Ottinger, 1921). 
Following the introduction of antibiotics into clinical practice, the use of silver as an 
antibacterial agent declined (Klasen, 2000b). However, in the 1960‘s AgNO3 was 
recommended as a cheap and effective alternative to antibiotics in the prevention of 
infection in burns (Moyer et al., 1965). Following a burn, the body attempts to maintain 
homeostasis by promoting coagulation at the site of injury and hyperaemia in the 
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surrounding, undamaged skin (Edwards-Jones & Greenwood, 2003). This action 
produces an immunosuppressed, moist environment that promotes colonisation and 
subsequent infection by bacteria such as S. aureus, Streptococcus pyogenes and 
P. aeruginosa, which can rapidly lead to further tissue destruction, sepsis and death. At 
a concentration of 0.5% (w/v), AgNO3 was found to prevent growth of the above 
organisms whilst having no impact on the successful grafting of donor skin (Moyer et 
al., 1965). A retrospective study indicated that using AgNO3 in the treatment of burns 
covering >40% of the body resulted in a 20% reduction in mortality and a reduced 
length of hospitalisation (from ~180 days to ~70) when compared with using other burn 
wound treatments (Ziffren, 1968). However, there were disadvantages in using 
AgNO3 in this manner. For example, to remain effective at preventing infection, 
AgNO3 had to be reapplied to the wound up to 12 times a day, in a process that was 
found to be painful for the patient (Klasen, 2000b). In attempts to overcome these 
shortcomings, silver was combined with the sulphonamide sulphadiazine to produce 
silver sulphadiazine (AgSu) (Stanford et al., 1969; Klasen, 2000b). Used at a 
concentration of 1% (w/v) in a hydrophilic cream, AgSu prevented wound colonisation 
with one application per day in an animal model, and caused no pain to patients upon its 
application (Stanford et al., 1969). Indeed, AgSu was found to be superior to both 
AgNO3 and gentamicin in preventing burn wound infection in a retrospective study of 
454 patients (Hummel et al., 1970), and AgSu-treated burn wounds were less likely to 
be infected compared with wounds treated with mafenide acetate; a sulphonamide 
derivative frequently used in the prevention of wound infection (Pegg et al., 1979).  
1.2.2. Current applications of antibacterial silver 
Today, AgNO3 is still used as prophylactic agent in some countries to prevent 
ophthalmia neonatorum (Mullick et al., 2005), and AgSu is considered to be the 
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treatment of choice to prevent burn wound infection, with one recent review describing 
it as ―the gold standard in topical burn treatment‖ (Atiyeh et al., 2007). Nevertheless, 
AgSu still has limitations; for example, reapplication of AgSu may first require removal 
of a pseuedoeschar that can form when using AgSu, which is known to be painful to the 
patient (Dunn & Edwards-Jones, 2004) and, as AgSu requires daily reapplication, 
pseudoeschar removal can be time consuming for medical staff. Another potential issue 
with AgSu is that its use may prolong wound healing, as it delays epithelialisation in 
three separate animal burn models (Muller et al., 2003; Cho Lee et al., 2005; 
Maghsoudi et al., 2011). These issues have led to the development of dressings that are 
impregnated with various formulations of silver, including AgSu, silver phosphate and 
silver nanoparticles (metallic silver contained in clusters <100 nm in diameter) (Atiyeh 
et al., 2007). Examples of commercially available silver dressings are presented in 
Table 1.3. These dressings are all purported to release concentrations of silver over a 
prolonged period (between 3-7 days, depending on the dressing), and therefore do not 
require removal and reapplication as frequently as previous silver formulations. In 
addition, silver dressings are claimed to be easier to apply and remove, whilst causing 
only minimal pain to the patient (Lansdown, 2006). Given the increasing prevalence of 
antibiotic-resistant bacteria, the use of silver-containing medical products has expanded 
from the prevention of burn wound infection to treatment of a variety of heavily 
colonised and infected wounds, including acute and chronic wounds, decubitus 
(pressure) ulcers, or ulcers arising as a consequence of diabetic neuropathy and 
peripheral vascular disease (Lansdown, 2006; Edwards-Jones, 2009).  
Although there is an array of studies demonstrating the antibacterial activity of 
silver-containing dressings in vitro (reviewed by Mooney et al. [2006]), the efficacy of 
these dressings in vivo are disputed. For example, one randomised controlled trial 
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(RCT) between AgSu and a dressing containing silver nanoparticles (Acticoat) for the 
treatment of burn wounds revealed that wounds treated with Acticoat were less likely to 
become infected and healed faster compared with those treated with AgSu (Gravante et 
al., 2009). A meta-analysis of 4 RCTs evaluating healing of infected venous ulcers 
exposed to another silver dressing (Contreet) or dressings without an antibacterial 
additive indicated that ulcers treated with Contreet healed quicker (Leaper et al., 2013). 
In contrast, a separate RCT found no significant difference between an additive-free 
dressing and Aquacel, Acticoat, Contreet and Urgotul silver-containing dressings in 
healing of venous ulcers (Michaels et al., 2009), whereas two Cochrane meta-analyses 
noted that there was insufficient evidence to recommend silver dressings in the 
treatment of diabetic foot ulcers, and that there was no appreciable difference between 
silver dressings and additive-free dressings in resolution of infection in chronic or acute 
wounds (Bergin & Wraight, 2006; Vermeulen et al., 2007). Despite the contention 
regarding the utility of silver-containing dressings, their use in the prevention and 
treatment of wound infection is obvious and widespread (Silver et al., 2006; Atiyeh et 
al., 2007; Edwards-Jones, 2009; NHS National Prescribing Centre, 2010). 
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Table 1.3. Examples of commercially available silver-containing dressings  
Dressing Composition Manufacturer Reference 
Acticoat Three layers of polyethylene 
gauze coated with 
nanocrystalline silver (silver 
nanoparticles <20nm 
diameter) 
Smith and Nephew (Silver et al., 
2006) 
Actisorb Nylon dressing containing 
activated charcoal bound to 
silver  
Johnson and Johnson (Silver et al., 
2006) 
Aquacel Ag Silver impregnated within a 
carboxymethylcellulose 
fibre dressing 
Convatec (Silver et al., 
2006) 
Arglaes Polymer film containing 
silver phosphate 
Medline (Mooney et al., 
2006) 
Calgitrol Ag Calcium alginate dressing 
containing silver 
Magnus Bio-medical (Silver et al., 
2006) 
Contreet (Biatain 
Ag) 
Hydrocolloid dressing 
containing silver 
Coloplast (Ip et al., 2006) 
PolyMem Silver Polyurethane membrane 
with a starch copolymer 
containing silver 
Ferris (Ip et al., 2006) 
SilvaSorb Silver halides suspended 
within a polyacrylate 
dressing 
Acrymed (Castellano et 
al., 2007) 
Silvercel Carboxymethylcellulose 
fibre dressing blended with 
a metallic silver-coated 
nylon fibre 
Johnson and Johnson (Castellano et 
al., 2007) 
Silverlon Polymeric fabric coated 
with metallic silver 
Argentum Medical (Mooney et al., 
2006) 
Urgotul SSD Hydrocolloid dressing 
impregnated with Vaseline 
and silver sulphadiazine 
Urgo (Ip et al., 2006) 
 
In addition to the treatment of wounds, silver is frequently incorporated into implanted 
medical devices such as central venous catheters, urinary catheters and endotracheal 
tubes, with the intention to prevent bacterial colonisation of the device and subsequent 
infection in the patient (Weber & Rutala, 2001; Silver et al., 2006). In contrast to silver 
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dressings, a number of RCTs and subsequent meta-analyses have confirmed the utility 
of such devices in preventing bacterial colonisation and infection when compared with 
medical devices coated with other antibacterial agents, or additive-free devices (Saint et 
al., 1998; Veenstra et al., 1999; Li et al., 2012). Outside of the clinical setting, an 
increasing number of products are available that also contain various formulations of 
silver (examples of such formulations are presented in Table 1.4) to exploit its 
antibacterial effect. Examples of such products include clothing, water purifiers, 
deodorants, paint, kitchen appliances and children‘s toys (Silver, 2003; Luoma, 2008).  
Table 1.4. Examples of antibacterial silver formulations 
Name Composition Active 
species 
Uses Reference 
Silver chloride AgCl, AgCl2
-
, 
AgCl3
2-
 (depending on 
concentration in solution) 
Ag
+ Antibacterial additive in 
certain deodorants 
(Edwards-Jo
nes, 2009) 
Silver citrate 
 
Ag
+ Antibacterial additive in 
certain deodorants 
(Edwards-Jo
nes, 2009) 
Silver 
nanoparticles 
Metallic silver contained 
in clusters <100 nm 
diameter 
Ag
+
 
(possibl
y Ag
0
) 
Prevention and treatment of 
burns and chronic wound 
infections. Incorporated 
into a variety of consumer 
products 
(Rai et al., 
2009) 
Silver nitrate 
 
Ag
+ Prevention and treatment of 
burns, chronic wound 
infections and opthalmia 
neonatorum 
(Klasen, 
2000b) 
Silver 
sulphadiazine 
 
Ag
+ Prevention and treatment of 
burns and chronic wound 
infections 
(Klasen, 
2000b) 
Silver zeolite Silver ions contained in 
an immunosillicate matrix  
Ag
+
, 
reactive 
oxygen 
species 
Incorporated into plastics 
and water filters   
(Matsumura 
et al., 2003) 
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Exploitation of the antibacterial properties of silver has increased dramatically over the 
past decade. In 2004, the NHS spent £858,000 on silver dressings (Chambers et al., 
2007); this increased to ~£25 million in 2010 (NHS National Prescribing Centre, 2010). 
Furthermore, the number of consumer products containing antibacterial silver increased 
from ~30 in 2006 to ~300 by 2011 (Project on Emerging Nanotechnologies, 
http://www.nanotechproject.org/inventories/consumer/analysis_draft/, last accessed 
17
th
 September 2013). The number of products containing antibacterial silver is 
expected to increase further over the next few years, with one publication suggesting 
that by 2015 ~90 tonnes of silver per year will be required for their manufacture, 
compared with 15 tonnes per year in 2010 (GFMS, 2011). However, there are concerns 
that the increasing and unrestricted use of antibacterial silver will lead to the emergence 
of bacterial silver resistance, thus impacting the utility of silver-containing products in 
the prevention and treatment of infectious disease (Chopra, 2007). This will be 
discussed later in this chapter. 
1.2.3. Antibacterial activity of silver 
1.2.3.1. Inhibitory activity of silver 
The silver cation (Ag
+
) is responsible for the antibacterial activity of silver-containing 
compounds (Grier, 1968; Clement & Jarrett, 1994; Nies, 1999). Ag
+
 has been shown to 
inhibit the growth of a range of Gram-positive and Gram-negative bacteria, including 
human pathogens such as S. aureus, Streptococcus spp., E. coli, P. aeruginosa, 
A. baumannii  and K. pneumoniae, as well as antibiotic-resistant populations of these 
species (Ip et al., 2006a; Ip et al., 2006b). However, although Ag
+
 can inhibit the 
growth of these organisms, the minimum concentration of Ag
+
 required to achieve this 
(termed the minimum inhibitory concentration [MIC]) is unclear (Chopra, 2007). 
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For example, depending upon the study, the MIC of silver compounds against strains of 
S. aureus is 8, 32, 80, or 128 g/ml (Carr et al., 1973; Maple et al., 1992; 
Hamilton-Miller et al., 1993; Ug & Ceylan, 2003). A similar variation is seen for 
Gram-negative bacteria (Carr et al., 1973; Vasishta et al., 1989; Hamilton-Miller et al., 
1993; Ip et al., 2006b). These disparities in MIC data are likely to result from a number 
of factors. The first is that there is no apparent standardisation in MIC methodology 
between studies; for example the inoculum density of bacterial culture and the 
incubation temperature/time differ between studies, all variables known to affect the 
MIC of antibiotics (Andrews, 2001; Wayne, 2012). In addition, studies also vary in the 
choice of bacteriological culture media when determining Ag
+
 MICs. Both the chloride 
anion (Cl
-
) and the thiol-containing amino acid cysteine are usually present in culture 
media and can bind with a strong affinity to Ag
+
, producing a product that has no 
antibacterial activity (Liau et al., 1997; Gupta et al., 1998). The relative concentrations 
of Cl
-
 and thiol-containing compounds vary between different culture media 
formulations (Atlas, 2010), thus the amount of active Ag
+
 (and therefore the MIC 
against any one bacterial strain) will also likely differ depending on the media it is used 
in. A further issue is that published studies utilise different silver formulations (e.g. 
AgNO3, AgSu, silver nanoparticles) for MIC determinations. The results from such 
studies cannot be directly compared, as the relative amounts of Ag
+
 released into 
solution by each of these formulations (and therefore the antibacterial activity) varies 
(Atiyeh et al., 2007). This lack of standardisation (either in MIC methodology, or 
choice of silver formulation) between studies is an important reason why there are no 
estimates into the current prevalence of bacterial silver resistance amongst clinical 
isolates; this will be discussed later in this chapter.  
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1.2.3.2. Bactericidal activity of silver 
The in vitro definition of a bactericidal antibacterial agent is a compound that can 
reduce the number of viable cells in a bacterial population (of a density ≥5x105 cfu/ml) 
by ≥99.9% (i.e. a 3-log10 reduction) following 24 h exposure (Pankey & Sabath, 2004; 
Wayne, 2012). In addition, some studies suggest that the concentration of antibacterial 
agent that produces a ≥99.9% reduction in viability needs to be ≤4 times the MIC 
(Wayne, 2012). 
When using bacteriostatic agents to manage infection (e.g. tetracyclines, sulphonamides 
and fusidic acid) treatment success is reliant upon clearance of growth-inhibited bacteria 
by the host immune system, as upon cessastion of therapy, bacterial growth (and any 
infectious process) would resume (Peterson & Shanholtzer, 1992). In comparison, 
bactericidal agents (e.g. -lactams, aminoglycosides and fluoroquinolones) are less 
reliant upon contribution from the host immune system and therefore prove 
advantageous in treating infections where the efficacy of the immune system is 
compromised (such as in cases of bacterial endocarditis or meningitis) (Pankey & 
Sabath, 2004). Nevertheless, there are situations in which the use of bacteriostatic 
agents is favoured. For example, in the treatment of haemolytic uremic syndrome a 
bactericidal agent that induces cell lysis (e.g. -lactams) would promote the release of 
additional endotoxin as the target bacterium died, thus potentially causing further harm 
to the patient (Dundas et al., 2005). Because of the different properties afforded by 
bacteriostatic and bactericidal agents, it is vital to assess the cidal properties of all 
antibacterial compounds so that their advantages can be effectively exploited whilst 
mitigating any disadvantages. 
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It is unclear if Ag
+
 is a bactericidal compound when using the above definition. Whilst 
some studies suggest that the activity of Ag
+
 is cidal (i.e. ≥3-log10 drop after 24 h) 
(Matsumura et al., 2003), others indicate that Ag
+
 is bacteriostatic (Gordon et al., 2010). 
It is likely that this difference is once again a consequence of methodological variations 
between studies (e.g. inoculum density, choice of media), although this has yet to be 
confirmed. 
1.2.4. Toxicity of silver 
Heavy metals such as mercury, cadmium, arsenic and lead are toxic to humans at 
relatively low concentrations (Ibrahim et al., 2006); however, silver appears to be well 
tolerated when used topically, with adverse reactions typically limited to skin irritation 
(Weber & Rutala, 2001). In addition, there have been no reports of toxicity in patients 
with implanted medical devices containing silver (e.g. catheters, endotracheal tubes) 
that are currently in clinical use (Veenstra et al., 1999). However, when repeatedly 
ingested or used systemically (for example the use of silver Salvarsan), silver can 
become deposited in a range of tissues, including the skin, liver, kidneys, spleen, lungs 
and the brain (Lansdown, 2007). Deposition of silver in the skin and mucous 
membranes can lead to a visible blue-grey discolouration of these tissues, which is 
termed argyria, a condition that is not known to be life threatening and typically 
resolves upon cessation of silver therapy (Lansdown, 2007). Deposition of silver into 
the other tissues described above does not appear to affect their function, except in the 
case of silver deposition the brain and nervous system, which has been associated with 
the development of neurological conditions such as peripheral neuropathy, seizures and 
myoclonic status epilepticus (Vik et al., 1985; Ohbo et al., 1996; Mirsattari et al., 
2004). Nevertheless, given its current medical applications, the toxicity associated with 
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silver does not currently appear to be a barrier to its continued use as an antibacterial 
agent (Lansdown, 2007). 
1.2.5. Antibacterial MOA of Ag
+
 
As alluded to earlier, Ag
+
 has a strong binding affinity for a number of nucleophiles, 
including those containing sulphur (e.g. S
2-
, S
-
, SCN
-
, S2O3
2-
), or halides (e.g. Cl
-
, I
-
 and 
Br
-
) (Grier, 1968). As sulphur-containing compounds (e.g. cysteine) are prevalent in 
biological systems, it seems likely that the affinity of Ag
+
 to these compounds is related 
to the antibacterial activity of Ag
+
. Indeed, Nies et al. (1999) demonstrated that the 
inhibitory activity of metal cations against bacteria is directly proportional to their 
binding affinity to sulphur-containing nucleophiles (as determined by the dissociation 
constant Kd). Nevertheless, the mechanism by which Ag
+
 exerts an antibacterial effect is 
not currently understood. Several targets which Ag
+
 is known to interact with in some 
manner (and therefore could potentially contribute to the MOA of Ag
+
) have however 
been identified and are discussed below. 
1.2.5.1. DNA 
Initial studies into the antibacterial MOA of Ag
+
 discovered that DNA from cells treated 
with AgNO3 or AgSu had a higher sedimentation rate than untreated cells, signifying 
that silver compounds bind to DNA in some manner (Rosenkranz & Rosenkranz, 1972). 
It was revealed later that Ag
+
 could inhibit the incorporation of radiolabelled thymidine 
into DNA of P. aeruginosa, suggesting that Ag
+
 inhibited DNA replication (Rosenkranz 
& Carr, 1972). Given that the bases within DNA contain nitrogen (a known binding 
partner of Ag
+
), Fox (1969) proposed that Ag
+
 binds to nitrogen atoms involved in the 
hydrogen bonding of bases between opposite DNA strands (i.e. N1 of adenine and 
guanine, N3 of cytosine and thymine), thus altering the Watson-Crick structure of DNA 
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sufficiently to prevent its replication. Using Fourier transform infrared spectroscopy, it 
was later confirmed that Ag
+
 can form complexes with DNA (and RNA) in vitro; 
however, unlike Fox‘s hypothesis, Ag+ preferentially bound N7 of guanine and adenine 
(Arakawa et al., 2001). This binding appeared to affect the ultrastructure of DNA 
in vivo; as using transmission electron microscopy and X-ray microanalysis, DNA of 
S. aureus and E. coli exposed to Ag
+
 was found to be in a condensed form (Feng et al., 
2000). The authors proposed that in this state, DNA could not replicate. However, as 
this study only visualised cells after a protracted (4 h) exposure to Ag
+
, it is unclear if 
this effect is secondary to other forms of cell damage mediated by Ag
+
. 
1.2.5.2. Protein 
It has long been known that silver binds and forms complexes with amino acids; for 
example, silver is used to stain proteins in polyacrylamide gels (Clement & Jarrett, 
1994). In addition to binding to thiols present on cysteine residues, Ag
+
 can form 
co-ordination complexes with residues harbouring sulphur or nitrogen-containing side 
chains (e.g. arginine, lysine, histidine and methionine) (Jover et al., 2008). It is likely 
that the binding of Ag
+
 to these residues would disrupt the tertiary structure of some 
proteins, or inhibit the catalytic function of certain enzymes. Indeed, in vitro studies 
have identified enzymes that are inhibited by Ag
+
, including succinate dehydrogenase, 
aconitase, NADH dehydrogenase, NADH quinone reductase and phosphoribosyl 
1-pryrophosphatase (Martin, 1963; Bragg & Rainnie, 1974; Semeykina & Skulachev, 
1990; Gordon et al., 2010; Xu & Imlay, 2012). However, the ability of Ag
+
 to inhibit 
these enzymes in vitro does not necessarily imply this will occur in vivo, or that this 
property contributes to the antibacterial MOA of Ag
+
. Nevertheless, it is known that 
Ag
+
 can inhibit dehydratase-family enzymes of E. coli in vivo (Xu & Imlay, 2012), thus 
these enzymes may represent an antibacterial target of Ag
+
. 
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Dehydratase-family enzymes contain iron-sulphur clusters (4Fe-S) used for catalysis, 
and Ag
+
 inhibits this function by binding the sulphur in these clusters and releasing Fe
2+
 
into solution (Xu & Imlay, 2012). This release of Fe
2+
 was proposed to be a potential 
mechanism by which Ag
+
 causes cell death, as Fe
2+
 can generate toxic reactive oxygen 
species (ROS) via the Fenton reaction (Xu & Imlay, 2012). ROS as a mechanism of 
Ag
+
-induced cell death will be discussed in section 1.2.5.4. 
1.2.5.3. Cell membrane 
Exposure of P. aeruginosa to radiolabelled Ag
+
 (in the form of 
110
AgSu) for 1 h 
indicated that 80% of total Ag
+
 bound to the membrane (with the remaining 19 and 1% 
binding the cell wall and DNA/RNA, respectively) (Rosenkranz & Carr, 1972), and 
subsequent studies using TEM revealed that AgSu exposure caused the cytoplasmic 
membrane to detach from the cell wall in S. aureus, and led to distortion of 
P. aeurginosa cell membranes (Coward et al., 1973a; Coward et al., 1973b). However 
the relevance of these results with respect to the antibacterial MOA of Ag
+
 is unclear. 
Nevertheless, further studies have shown that Ag
+
 can cause rapid (≤ 10 min) 
dissipation of the proton motive force in E. coli and Vibrio cholerae, which is generated 
at the membrane by the export of protons from oxidative phosphorylation (Dibrov et al., 
2002; Holt & Bard, 2005). This result would therefore imply that the structure and/or 
the function of the membrane is somehow perturbed by Ag
+
. Evidence to support this 
has been provided by Lok et al. (2006), with the observation that Ag
+
 exposure led to a 
rapid and substantial leakage of K
+
 and ATP from cells of E. coli, which is indicative of 
generalised damage to the membrane. In addition, Ag
+
 caused electron transfer to stall 
at complex I (NADH dehydrogenase) of the oxidative phosphorylation pathway, 
suggesting that Ag
+
 inhibited this complex (Holt & Bard, 2005). It is likely that both of 
these mechanisms would impact cell viability and could therefore contribute the 
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antibacterial MOA of Ag
+
. In addition, the stalling of electron transport may lead to the 
generation of ROS, an additional mechanism by which Ag
+
 could exert an antibacterial 
effect (Holt & Bard, 2005). This is discussed below. 
1.2.5.4. Generation of reactive oxygen species 
During normal cellular metabolism, molecular oxygen (O2) can be reduced into a 
variety of reactive states dependent upon the number of electrons received (Figure 1.1). 
These states are superoxide (O2
-
), hydrogen peroxide (H2O2) and the hydroxyl radical 
(HO
.
) and are collectively known as reactive oxygen species (ROS).  
 
Figure 1.1. The reduction series of oxygen. Adapted from (Imlay, 2013)  
The interaction of molecular oxygen with flavin- or quinone-containing components of 
the electron transport chain, or with non-respiratory flavoproteins can lead to the 
formation of O2
-
 or H2O2, which are relatively short-lived species with minimal toxic 
effects (Imlay, 2013). However, these species can damage iron-sulphur (Fe-S) clusters 
found in a variety of enzymes, such as respiratory and non-respiratory dehydratases, 
ferredoxins and dehydrogenases, leading to the release of free iron in the form of Fe
2+
 
which itself can react with H2O2 to produce HO
. 
via the Fenton reaction (Imlay, 2013): 
 
31 
 
Unlike O2
-
 and H2O2, HO
. 
has a strong oxidation potential and can lead to damage of 
DNA (by base-pair oxidation), proteins (by amino-acid carbonylation) and cell 
membranes (by lipid peroxidation) and can ultimately cause to cell death (Kohanski et 
al., 2007). The toxic effects of ROS are normally mitigated in the bacterial cell by the 
presence of scavenging enzymes, with catalases and peroxidases scavenging H2O2 and 
superoxide dismutases scavenging O2
-
. However, under certain environmental 
conditions (e.g. hyperbaria or the presence of exogenous oxidants), these protection 
mechanisms can become overwhelmed (Seaver & Imlay, 2001). Indeed, this process is 
exploited by the innate immune system in a variety of eukaryotes to kill invading 
pathogens (Miller & Britigan, 1995). Metal ions other than Fe
2+
, such as Cu
2+
, Ni
2+
 and 
Co
2+
 (Lloyd & Phillips, 1999) can also be utilised in the Fenton reaction to produce HO
.
 
and may provide some insight into their antibacterial activity. Although silver can exist 
in a variety of oxidation states, there is no evidence to suggest it can be substituted into 
the Fenton reaction; however, there are studies indicating that Ag
+
 can induce ROS 
formation, this is discussed below. 
Given the propensity of Ag
+
 to bind to thiol groups, it has been proposed that Ag
+
 
inhibition of thiol-containing enzymes of the electron transport chain such as NADH 
and succinate dehydrogenase would stall electron transfer and generate favourable 
conditions for O2
-
 generation (Bragg & Rainnie, 1974; Messner & Imlay, 1999). Indeed, 
up-regulation of soxS, encoding a transcription factor activated by superoxide stress, has 
been observed in cultures of E. coli exposed to Ag
+ 
(Holt & Bard, 2005; Park et al., 
2009) and a strain of E. coli deficient in catalase was more susceptible to killing by Ag
+
 
than its parental strain (Matsumura et al., 2003). In S. epidermidis, it was shown that 
exposure to Ag
+
 leads to the formation of HO
.
 (as detected by the HO
.
-responsive dye, 
hydroxyphenyl fluorescein [HPF]), and in the presence of thiourea (a quencher of ROS) 
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the antibacterial activity of Ag
+
 decreased. This not only suggests that ROS are 
produced, but that they contribute to the activity of Ag
+
 (Gordon et al., 2010). However, 
it was recently demonstrated that HPF does not specifically detect HO
.
 alone, as in 
E. coli grown under anaerobic conditions (where HO
. 
would not be present), activated 
HPF can still be detected (Keren et al., 2013). Furthermore thiourea can exist in two 
tautomers, one of which contains a thiol group. As it is known that thiols can bind and 
inactivate Ag
+
 (Liau et al., 1997), it is unclear if the loss of Ag
+
 activity observed by 
Gordon et al. is a consequence of the thiol-binding or quenching properties of thiourea. 
In addition, Ag
+
 still maintains antibacterial activity (albeit at a reduced level) against 
E. coli and S. aureus under anaerobic conditions where ROS generation would not 
occur (Park et al., 2009), and it is therefore clear that the generation of ROS and any 
subsequent cell damage cannot be the sole mechanism by which Ag
+
 exerts an 
antibacterial effect. Nevertheless, given the limited information regarding the role of 
ROS in contributing to the antibacterial MOA of Ag
+
, further studies are required to 
define their role.  
In summary, although the studies described above have revealed that Ag
+
 can bind and 
disrupt a number of cellular targets, it is unclear which of these events are the primary 
causes of Ag
+
-mediated cell death and which events are secondary to this action. 
1.2.6. Bacterial resistance to Ag
+
 
With a myriad of potential targets, it is unlikely that the antibacterial MOA of Ag
+
 relies 
upon the inhibition of one target alone. This is in contrast to most antibiotics, which 
typically achieve antibacterial activity through binding and inhibition of a single 
enzyme (Walsh, 2003). The possibility that Ag
+
 targets multiple cellular processes 
would imply that spontaneous mutation to Ag
+
 resistance is unlikely to occur, as 
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bacteria would potentially need to accrue mutations in each target to render them 
insusceptible to Ag
+
. Evidence to support this hypothesis has been provided by Maple et 
al. (1992), with the demonstration that spontaneous mutation to Ag
+
 resistance in 
S. aureus did not arise at a limit of detection of 1x10
-9
. In comparison, resistance to 
antibiotics with a single target (e.g. mupirocin and rifampicin) typically arise at 
frequencies between 10
-7 
and 10
-8 
(O'Neill & Chopra, 2004). Nevertheless, since the 
re-introduction of Ag
+
 as an antibacterial agent, Ag
+
 resistance has been encountered in 
clinical and environmental bacterial isolates (Table 1.5), which in a number of cases has 
been attributed to the horizontal acquisition of an exogenous Ag
+
 resistance element. 
For example, Ag
+
 resistance in Salmonella enterica serovar Typhimurium isolated from 
a burns unit was associated with a 180 kb conjugative plasmid that also encoded 
resistance to mercuric chloride, ampicillin, chloramphenicol, tetracycline, streptomycin 
and sulphonamide antibiotics (McHugh et al., 1975). This plasmid was named 
pMG101 and was later found to confer Ag
+
 resistance by encoding mechanisms to 
sequester and efflux Ag
+
 from the periplasmic space. These mechanisms will be 
described in more detail later in this chapter. Psuedomonas stutzeri  isolated from a 
silver mine contained a non-conjugative 75 kb plasmid (pKK1) conferring Ag
+
 
resistance (Haefeli et al., 1984). Unlike pMG101, pKK1 did not contain any other 
resistance determinants and was proposed to confer resistance to Ag
+
 by encoding 
mechanisms leading to the intracellular detoxification of Ag
+
, presumably by the 
increased expression of sulphur-rich compounds that sequester Ag
+
. However, there are 
only limited experimental data to support this. A similar mechanism of Ag
+
 
detoxification is believed to be conferred by the 54 kb conjugative plasmid pUPI199, 
and plasmid pJT1, which were originally identified in an environmental isolate of 
A. baumannii and a burn wound isolate of E. coli, respectively (Starodub & Trevors, 
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1989; Deshpande & Chopade, 1994). However, this again has not been conclusively 
demonstrated. 
 
Table 1.5. Examples of clinical and environmental bacterial isolates resistant to 
Ag
+
 
Organism (year of 
isolation/publication of 
result) 
Source of isolate Source of 
resistance 
mechanism 
Reference 
Enterobacter cloacae  (1974) Burn wound Unknown 
(unstable 
resistance) 
(Rosenkranz et 
al., 1974) 
Salmonella Typhimurium 
(1975) 
Burn wound pMG101 (McHugh et 
al., 1975) 
Enterobacter cloacae  (1976) Burn wound Unknown 
(unstable 
resistance) 
(Annear et al., 
1976) 
Enterobacter cloacae  (1978) Burn wound Unknown (Gayle et al., 
1978) 
Pseudomonas aerugionosa 
(1979) 
Burn wound Unknown 
(unstable 
resistance) 
(Bridges et al., 
1979) 
Enterobacteriaceae (1979) Burn wounds and patients 
with silver-impregnated 
tracheostomy tubes 
Unknown (Hendry & 
Stewart, 1979) 
Pseudomonas stutzeri  (1984) Silver mine pKK1 (Haefeli et al., 
1984) 
Pseudomonas aeruginosa  
(1989) 
Clinical culture collection Unknown (Vasishta et al., 
1989) 
Escherichia coli (1989) Burn wound pJT1 (Starodub & 
Trevors, 1989) 
Pseudomonas aeruginosa 
(2003) 
Burn wound Unknown 
(unstable 
resistance) 
(Pirnay et al., 
2003) 
Acinetobacter baumannii  
(1994) 
Environmental isolate pUPI199 (Deshpande & 
Chopade, 
1994) 
Enterobacter cloacae  (2006) Burn wound Unknown (Ip et al., 2006) 
Enterobacter cloacae  (2007) Leg ulcer pMG101 (Lansdown & 
Williams, 
2007) 
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Although Ag
+
 resistance has been encountered in environments where it is employed 
therapeutically, it does not appear to be prevalent; only 10 cases of Ag
+
 resistance have 
been reported in the past 49 years. However, the Ag
+
-susceptibility of wound isolates 
from patients about to receive, or undergoing Ag
+
 therapy, is not routinely tested 
(Warriner & Burrell, 2005), nor are there any routine large scale surveys into the 
prevalence of Ag
+
 resistance amongst clinical bacterial isolates. Indeed, in the past 
seven years, there has only been one such study, with a relatively small number of 
isolates tested (n=117) from a single hospital (Ip et al., 2006). The true prevalence of 
bacterial Ag
+
 resistance may therefore be greater than currently believed, and it is clear 
that a sufficiently large survey of bacterial Ag
+
 susceptibility of isolates from a range of 
hospitals is required to assess this. However, as discussed earlier, a standardised 
methodology is first required for assessing bacterial Ag
+
 susceptibility. This will 
prevent variables that are known to affect the inhibitory activity of Ag
+
 (e.g. choice of 
culture media and Ag
+
 formulation) from influencing the interpretation of results, and to 
allow data from future Ag
+
 susceptibility surveys to be directly compared with each 
other. 
The impact of Ag
+
 resistance on the continued use of Ag
+
 in the treatment of infection is 
also not clear, with recent publications noting that Ag
+
 resistance is unstable in a 
number of studies, implying that the resistance phenotype confers a metabolic cost to 
the host strain that could potentially limit its emergence and spread in a patients 
(Lansdown & Williams, 2007). Nevertheless, this hypothesis has not been confirmed 
experimentally for any Ag
+
-resistant strain. Furthermore, there is conflicting evidence 
over the role of Ag
+
 resistance in the failure of Ag
+
 therapy to treat infection. For 
example, two Ag
+
-containing dressings were able to reduce the bioburden of a chronic 
wound, irrespective of the fact that an Ag
+
-resistant E. cloacae was present (Lansdown 
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& Williams, 2007). In contrast, Ag
+
-resistant E. cloacae  was responsible for the failure 
of AgSu in preventing burn wound infections that resulted in the death of 13 patients at 
a burn treatment centre (Gayle et al., 1978), whilst an Ag
+
-resistant S. Typhimurium 
had a similar effect in patients treated with AgNO3 (McHugh et al., 1975). Given the 
popularity of Ag
+
-containing products in preventing and treating infection, and the 
likelihood that the use of such products will increase, it is apparent that a thorough 
investigation into the potential impact of Ag
+
 resistance is required, particularly to 
establish if Ag
+
 resistance will act as a barrier to the continued use of Ag
+
 therapy. Such 
an investigation should include studies to examine the potential for Ag
+
 resistance to 
arise by endogenous and exogenous mechanisms and determine the propensity for such 
phenotypes to spread, persist and cause infection in patients. In addition, elucidating the 
molecular basis of Ag
+
 resistance phenotypes could identify potential targets for the 
rational design of inhibitors against the resistance mehcanism, allowing for the 
continued use of Ag
+
 against resistant strains. The remainder of this chapter will explore 
what is currently known about these aspects and highlight where additional studies are 
required. 
1.2.6.1. Exogenous Ag+ resistance 
Four plasmids have been identified that confer Ag
+
 resistance (Table 1.5); of these, 
pMG101 is the only one to have been characterised at the molecular level. Analysis of 
pMG101 revealed a 14.2 kb region harbouring the Ag
+
 resistance determinant (Gupta et 
al., 1999). Subsequent DNA sequence determination revealed that this determinant 
contained nine open reading frames in a divergently-transcribed operon, which has been 
named the sil operon (Figure 1.2) (Gupta et al., 1999). With the exception of the protein 
encoded by ORF105, the putative functions of the proteins encoded by this operon have 
been hypothesised (Figure 1.2) (Gupta et al., 1999; Silver, 2003).  
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Figure 1.2. Proposed role of the Sil proteins in Ag
+
 resistance of Gram-negative 
bacteria. SilE binds Ag
+
, preventing its entry into the cell. SilP is a P-type ATPase that 
transports Ag
+
 from the cell into the periplasm. Ag
+
 is then exported from the cell by 
the efflux pump SilCBA in a process chaperoned by SilF. SilRS, a two-component 
system, mediates transcription of the sil genes. Adapted from Gupta et al., (1999) and 
Silver, (2003) 
 
1.2.6.1.1. SilE 
The silE gene encodes a periplasmic metal-binding protein (Gupta et al., 1999). Binding 
studies of SilE with heavy metal ions (Cd
2+
, Cu
2+
, Ag
+
) have revealed that SilE 
specifically binds Ag
+
 (Gupta et al., 1999). SilE can bind up to 5 Ag
+
 ions, with each 
ion co-ordinated by two histidine residues (Gupta et al., 1999). It is likely that SilE acts 
to sequester Ag
+
 as it enters the cytoplasm, thus preventing Ag
+
 from reaching its 
antibacterial target(s).  
    
   
  silE silS silR silC silF silB silA silP ORF105 
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1.2.6.1.2. SilRS 
The protein products of silS and silR are believed to encode a sensor kinase and a 
cognate response regulator, respectively, to form a two-component sensor-response 
system. This is based on amino-acid sequence identity with PcoRS (~42% average 
identity), a two-component regulator of copper resistance, and CzcRS, a system 
regulating cobalt, zinc and cadmium resistance (~40% average identity) (Gupta et al., 
1999). Although the structure and function of SilRS has not been characterised in vitro, 
or in vivo, it is believed that this system acts as a positive regulator for the expression of 
the entire sil operon if Ag
+
 is present (Gupta et al., 1999). Following sensing of a 
substrate (presumably Ag
+
), SilS subsequently phosphorylates SilR and changes its 
structure to enable it to bind DNA (likely the intergenic region between silC and silR, as 
this is where the sil operon diverges) and recruits RNA polymerase for transcription of 
downstream genes (Silver, 2003). 
1.2.6.1.3 SilCBA 
Transcribed divergently from silERS, the product of silCBA is hypothesised to be a 
cation anti-porter of the resistance nodulation division (RND) superfamily (Gupta et al., 
1999). SilA is the inner membrane component of this system and shares partial 
sequence identity with AcrB from E. coli (Gupta et al., 1999). The structure of AcrB 
has been solved and forms a trimer in the inner membrane, transporting a wide spectrum 
of antibiotics from the intracellular milieu into the periplasm (Nikaido, 2009; Silver, 
2003). It is believed that SilA performs the same action, with the exception that it 
transports Ag
+
 instead. An outer membrane porin, SilC, is fused to SilA by the adaptor 
protein SilB. This tripartite system transports Ag
+
 either from the cytoplasm, or the 
periplasm, to the outside of the cell (Gupta et al., 1999). The structure of CusCBA, a 
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known Cu
+
- and Ag
+
-efflux pump in E. coli has recently been solved and was found to 
transport Ag
+
/Cu
+
 via a methionine shuttle (Su et al., 2011). As CusCBA and SilCBA 
share ~60% sequence identity, it is likely that SilCBA transports Ag
+
 from the cell in a 
similar manner.  
1.2.6.1.4. SilF 
The function of SilF remained undefined in the initial characterisation of the Sil system 
(Gupta et al., 1999). However, later work revealed similarities between SilF and CusF 
(amino acid identity of ~50%), the latter a known periplasmic Ag
+
- and Cu
+
-binding 
protein of E. coli (Silver, 2003, Silver et al., 2006). CusF binds a single Ag
+
/Cu
+
 
resulting from co-ordination with histidine, methionine and tryptophan residues (Xue et 
al., 2008). These residues are conserved in SilF (Xue et al., 2008), thus it is likely that 
SilF also binds Ag
+
 in this manner, and contributes to Ag
+
 resistance by sequestering 
Ag
+
 entering the periplasm (as with SilE) (Silver et al., 2006), although this has not 
been established experimentally. 
1.2.6.1.5. SilP 
SilP is a putative member of the P-type ATPase family of heavy metal efflux pumps 
(Gupta et al., 1999). This has been deduced based on amino acid sequence similarities 
between SilP and cadmium, copper and zinc ATPases (Gupta et al., 1999). SilP does 
differ from other P-type ATPases in that it possesses an N-terminal polyhistidine region, 
which replaces a usually conserved cysteine-X-X-cysteine motif. It is believed that this 
substitution confers specificity of SilP for Ag
+
 (Silver et al., 2006). P-type ATPases are 
known to efflux metal ions from the cytoplasm into the periplasm (Solioz & Vulpe, 
1996) and it is likely that SilP has the same mechanism to transport Ag
+
. As with other 
Sil system components, this remains to be confirmed. 
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Even though the putative functions of Sil system components have been assigned, the 
relative contribution made by each component to the Ag
+
 resistance phenotype has not 
been determined. This would be of benefit as it may reveal that certain Sil components 
are essential to the resistance phenotype, and might represent a promising target for 
developing inhibitors of Ag
+
 resistance. In addition, the fitness cost imposed on strains 
harbouring a known exogenous Ag
+
-resistance determinant (i.e. pMG101, pKK1, 
pUPI199, pJT1) has not been established, thus the potential for these determinants to 
survive and spread in a clinical setting (e.g. a hospital ward) is unclear. 
Unlike in Gram-negative bacteria, there is no evidence of Ag
+
 resistance arising by 
exogenous mechanisms in Gram-positive bacteria.  
1.2.6.2. Endogenous Ag+ resistance 
Although endogenous Ag
+
 resistance does not arise in S. aureus by a single mutational 
event (Maple et al., 1992), continuous exposure of S. aureus, E. coli and K. pneumoniae 
to sub-inhibitory concentrations of Ag
+
 in the laboratory resulted in the selection of 
isolates with a reduced susceptibility to Ag
+
, presumably as a consequence of multiple 
mutational events (Kaur et al., 1987; Gupta et al., 1992; Li et al., 1997). In S. aureus, an 
isolate resistant to 70 g/ml AgNO3 could be selected (compared with the parental 
strain, for which AgNO3 had an MIC of 8 g/ml) (Kaur et al., 1987), whereas a 
K. pneumoniae isolate resistant to 150 g/ml AgNO3 (MIC against parental strain: 
15 g AgNO3/ml) was selected by Gupta et al. (1992). Although both of these studies 
revealed that the virulence of resistant isolates was reduced compared with their 
respective parental strain, the time taken for resistance to emerge, the fitness cost, or the 
molecular basis of the resistance phenotype were not established. As discussed earlier, 
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each of these aspects are important in understanding the relevance of such strains from 
the perspective of the continued clinical use of Ag
+
.  
In contrast to Ag
+
-resistant S. aureus and K. pneumoniae, the mechanisms of 
endogenous Ag
+
 resistance in E. coli have been explored in relative detail. The MIC of 
AgNO3 against strains of Ag
+
-resistant E. coli was >1024 g/ml (AgNO3 MIC of 
parental strain: 8 g/ml) (Li et al., 1997). Such strains were deficient in OmpF, or both 
OmpF and OmpC outer membrane porins (although it was not established if porin loss 
was essential for the maintenance of the resistance phenotype), and could efflux Ag
+
 
from the cell by an energy-dependent mechanism (Li et al., 1997). A later study 
provided evidence to suggest that Ag
+
 efflux was mediated by overexpression of the 
CusCBA efflux pump (described in section1.2.6.1.3), as the expression of a component 
of this pump (CusB) and another protein encoded by the same operon (CusF) were 
found to be up-regulated in resistant strains, and a missense mutation was identified in 
cusS, which encodes the sensor kinase that regulates expression of this operon (Lok et 
al., 2008). However, the genetic changes necessary to confer endogenous Ag
+
 resistance 
in E. coli have yet to be elucidated, and, as with endogenous Ag
+
 resistance in S. aureus 
and K. pneumoniae, key experiments vital to understanding the threat this phenotype 
poses to the clinical utility of antibacterial Ag
+
 have not been performed (e.g. fitness 
studies and establishing the time taken for resistance to arise). 
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1.3. Introduction to the research in this study; aims and objectives 
The antibacterial properties of the silver cation have been exploited for centuries, and 
with the rising prevalence of bacterial pathogens that are resistant to multiple classes of 
antibiotics, the use of Ag
+
 as an alternative for the treatment of infectious disease is 
increasing (Atiyeh et al., 2007). In addition, Ag
+
 is now frequently incorporated into 
consumer products, such as deodorants, clothing and work surfaces, as a biocide (Silver, 
2003). There are concerns that such prolific use of Ag
+
 will select for the emergence of 
Ag
+
 resistance, which may limit the utility of Ag
+
 in treating infectious disease (Chopra, 
2007). However, the current prevalence of Ag
+
 resistance amongst bacterial pathogens 
is unclear. In addition, the ease in which Ag
+
 resistance can arise, persist and spread in 
an environment where Ag
+
 is employed therapeutically, or the mechanisms employed 
by bacteria to resist Ag
+
 are either not currently known, or are poorly understood. One 
aim of the research presented in this thesis was to address these issues, by establishing a 
standardised methodology for testing bacterial susceptibility to Ag
+
, and using it to 
establish the frequency of Ag
+
 resistance in a large and geographically diverse range of 
clinical bacterial isolates. Using established techniques, the potential for endogenous 
Ag
+
 to emerge in a number of relevant pathogens was explored and the fitness costs 
associated with any arising Ag
+
 resistance phenotype determined. The genetic basis and 
mechanism of Ag
+
 resistance resulting from endogenous and exogenous means was also 
explored.    
Although a number of potential antibacterial targets of Ag
+ 
have been identified, the 
exact mechanism by which Ag
+
 exerts an antibacterial effect has not been elucidated. 
Furthermore, there is conflicting evidence in the scientific literature regarding the 
killing kinetics of Ag
+
. The second aim of the work presented in this thesis was to 
provide further insight into both of these aspects of Ag
+
, by using assays that are 
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routinely employed in the pre-clinical evaluation of antibiotic drug candidates (O'Neill 
& Chopra, 2004). 
Sections of the work included in Chapters 3-5 have been published. A list of these 
publications is presented in Appendix 3. 
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Chapter two: Materials and Methods 
2.1 Bacterial strains and plasmids 
All strains used in this study (Tables 2.1-2.2) were stored in 8% (v/v) glycerol at -80
o
C. 
Table 2.1. Laboratory strains used in this study 
Strain Description/Application Reference/Sou
rce 
Staphylococcus
 aureus 
strains: 
  
SH1000 Derivative of strain 8325-4, containing functional rsbU  (Horsburgh et 
al., 2002) 
RN4220 Restriction-deficient cloning host (Kreiswirth et 
al., 1983) 
KS100 SH1000 deficient in catalase- KatA (katA::Tn917) (Cosgrove et 
al., 2007) 
MHKM SH1000 deficient in superoxide dismutase - SodM (sodM::tetL) (Karavolos et 
al., 2003) 
MHKA SH1000 deficient in superoxide dismutase - SodA 
(sodA::Tn917) 
(Karavolos et 
al., 2003) 
MHKAM SH1000 deficient in superoxide dismutases – SodA and SodM 
(sodA::Tn917 sodM::tetL ) 
(Karavolos et 
al., 2003) 
KCO43 SH1000 deficient in alkyl hydroperoxide reductase- AhpC and 
superoxide dismutase- SodA (ahpC::tet sodA::Tn917) 
(Cosgrove et 
al., 2007) 
SH1000 SH1000 containing pJIM2246 with lacZ insert under control of 
staphylococcal promoter cap1A  
(O'Neill et al., 
2004) 
CB1618 Daptomycin-resistant derivative of S. aureus MW2 Friedman et al., 
2006) 
NR111 Nisin/daptomycin-resistant derivative of S.aureus SH1000 Blake et al., 
2011) 
Bacillus 
subtilis strains: 
  
1S34 Parental strain of reporter constructs (Urban et al., 
2007) 
1S34 (pS63) RNA biosynthesis inhibition reporter (Urban et al., 
2007) 
1S34 (pS72) Protein biosynthesis inhibition reporter (Urban et al., 
2007) 
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Table 2.1 (continued) 
1S34 (pS77) DNA biosynthesis inhibition reporter (Urban et al., 
2007) 
1S34 (pS107) Cell envelope biosynthesis inhibition reporter (Urban et al., 
2007) 
1S34 (pNS14) Fatty acid biosynthesis inhibition reporter (Urban et al., 
2007) 
Enterococcus hirae 
strains: 
  
9790 Source of copper-efflux pump CopB ATCC 
Pseudomonas              
aeruginosa strains 
  
PAO1  ATCC (number 
47085) 
Enterobacter cloacae  
strains 
  
13047 Harbours Sil system ATCC 
Citrobacter freundii 
strains 
  
8090 Harbours Cus system ATCC 
Escherichia coli 
strains: 
  
DH5 fhuA2 lac(del)U169 phoA glnV44 Φ80' 
lacZ(del)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
Life 
Technologies 
BW25113 Derivative of E. coli K12 strain BD792 (lacIq 
rrnBT14 ΔlacZWJ16 hsdR514 ΔaraBADAH33 
ΔrhaBADLD78) and parental strain of Keio collection 
(Datsenko & 
Wanner, 2000; 
Baba et al., 
2006) 
BW25113-ompR Derivative of BW25113 deficient in OmpR 
(ompR::neoR) 
(Baba et al., 
2006) 
BW25113-ompF Derivative of BW25113 deficient in OmpF 
(ompF::neoR) 
(Baba et al., 
2006) 
BW25113-ompA Derivative of BW25113 deficient in OmpA 
(ompA::neoR) 
(Baba et al., 
2006) 
BW25113-cusC Derivative of BW25113 deficient in CusC 
(cusC::neoR) 
(Baba et al., 
2006) 
BW25113-cusF Derivative of BW25113 deficient in CusF 
(cusF::neoR) 
(Baba et al., 
2006) 
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Table 2.1 (continued) 
BW25113-cusB Derivative of BW25113 deficient in CusB (cusB::neoR) (Baba et al., 
2006) 
BW25113-cusA Derivative of BW25113 deficient in CusA (cusA::neoR) (Baba et al., 
2006) 
50110 E. coli J53 harbouring silver-resistance plasmid pMG101 NCTC 
DY441 E. coli harbouring cat-sacB allelic replacement cassette Donald Court, 
National Cancer 
Institute, USA 
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Table 2.2. Clinical isolates used in this study 
Strain Description Reference/Source 
Staphylococcus aureus 
strains: 
  
29213, 25923 Staphylococcus aureus 
subsp. aureus Rosenbach 
ATCC 
G1- G100, O1-O100, 
Y1-Y100, W1-100,  
C1-C47, K1-K23, 
KT1-KT11 (n= 483) 
Clinical isolates (isolated 
between 1997-2001) 
Department of Microbiology, 
Leeds General Infirmary (O'Neill 
et al., 2002) 
IC1-IC54 (n=54) Clinical isolates from patients 
with burns (isolated in 2010): 
Department of Microbiology, 
Chelsea and Westminster 
Hospital, UK 
A2-A84 (n=77) Fusidic acid-resistant clinical 
isolates (isolated in 1999) 
Departments of Dermatology and 
Microbiology, Harrogate district 
Hospital, UK (Ravenscroft et al., 
2000) 
N1-N100 (n=95) Clinical isolates (isolated in 
2010) 
Department of Microbiology, 
Freeman Hospital, Newcastle, 
UK 
SN 1-65 (n=65) Clinical isolates from patients 
with diabetic ulcers (isolated in 
2010) 
Smith and Nephew, York, UK 
F1-F70 (n=70) Clinical MRSA isolates  
(isolated in 2007) 
(Larsen et al., 2008) 
Coagulase-negative 
staphylococci strains: 
  
SN 66-80 (n=14) Clinical isolates from patients 
with diabetic ulcers (isolated in 
2010) 
Smith and Nephew, York, UK 
IT1-IT29 (n=29) Clinical isolates (isolated in 
2010) 
Department of Experimental 
Medicine and Biochemical 
Sciences, University of Perugia, 
Italy 
GRL05001- GRL05020 
(n=20) 
Meticillin-susceptible (n=10) 
and methicilin-resistant (n=10)  
S. epidermidis (isolated in 2006) 
G.R. Micro Limited 
L1-L27 (n=27) Clinical isolates (isolated 
between 1997-2001) 
Department of Microbiology, 
Leeds General Infirmary  
IC55 and 56 (n=2) S. epidermidis (isolated in 2010) Department of Microbiology, 
Chelsea and Westminster 
Hospital, UK 
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Table 2.2. (continued) 
 
S. lugdenensis (n=8) Clinical isolates (isolated in 
2005) 
(O'Neill et al., 2007) 
CL1 and CL2 (n=2) S. pseudintermedius isolates 
(isolated in 2004) 
(Guardabassi et al., 2004) 
7292,11041-11046, 
11048 and 15306 (n=9) 
Various coagulase-negative 
staphylococci 
NCTC 
CA1-39 (n=39) Various coagulase-negative 
staphylococci (isolated in 2010) 
London Health Sciences Centre, 
Victoria Hospital, Ontario, 
Canada 
RST 1-10 (n=10) Staphylococcus rostri isolates 
(isolated in 2010) 
Vincent Perreten, University of 
Berne, Berne, Switzerland 
Klebsiella pneumoniae 
strains: 
  
KP1-3 (n=3) Clinical isolates (isolated in 
2011) 
Department of Microbiology, 
Leeds General Infirmary 
Shigella  sonnei strains:   
SS1 Clinical isolate (isolated in 
2011) 
Department of Microbiology, 
Leeds General Infirmary 
Escherichia coli strains:   
EC18 Clinical isolate deficient in 
OmpC/F (isolated in 2010) 
Health Protection Agency 
Antibiotic Resistance Monitoring 
& Reference Laboratory, 
Colindale, (Beceiro et al., 2011) 
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Table 2.3. Plasmids used in this study 
Plasmid Description Reference/Source 
pSIM8 Contains temperature inducible  exo--for DNA 
recombineering. Confers ampicillin resistance (blaZ) 
(Datta et al., 
2006) 
pSIM18 Contains temperature inducible  exo-- for DNA 
recombineering. Confers hygromycin resistance (hph) 
(Datta et al., 
2006) 
pCP20 Encodes yeast FLP recombinase for excision of FRT-flanked 
resistance cassettes. Confers ampicillin and chloramphenicol 
resistance (blaZ, cat) 
(Cherepanov & 
Wackernagel, 
1995; Datsenko & 
Wanner, 2000) 
pKD4 Contains FRT-neoR-FRT cassette (Datsenko & 
Wanner, 2000) 
 
2.2 Antibacterial agents and chemicals 
Unless otherwise stated, all antibacterial agents and chemicals were from 
Sigma-Aldrich (Poole, UK). Vancomycin, cetyltrimethylammonium bromide (CTAB), 
nisin and triclosan were from Duchefa Biochemie (Haarlem, Netherlands), BDH 
Laboratory Supplies (Poole, UK) NBS Biologicals Ltd. (Huntingdon, UK) and LG Life 
Sciences (South Korea) respectively. Daptomycin and XF-73 were gifts from Cubist 
Pharmaceuticals (Lexington, MA, USA) and Destiny Pharmaceuticals (Brighton, UK) 
respectively. Stock solutions were prepared by dissolving the compound in an 
appropriate solvent (see Table 2.4) before dilution in sterile distilled water.  
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Table 2.4. Antibacterial agents used in this study 
Antibiotic Solvent  
Silver nitrate H2O 
Erythromycin H2O 
Fusidic acid 50% EtOH 
Vancomycin H2O 
Tetracycline H2O 
Triclosan 50% EtOH 
Rifampicin 50% DMSO 
Ciprofloxacin 20mM HCl 
CTAB H2O 
Daptomycin H2O 
Nisin 20mM HCl 
Mupirocin 50% EtOH 
Ampicillin H2O 
Chloramphenicol 50% EtOH 
Penicillin G (benzyl penicillin) H2O 
Gentamicin H2O 
Kanamycin H2O 
XF-73 H2O 
Hygromycin H2O 
 
 
2.3. Bacteriological media and culture conditions 
All bacteriological media were purchased from Oxoid Ltd (Basingstoke, UK) and 
prepared according to the manufacturer‘s instructions. Aerobic culture and 
determination of antibacterial susceptibilities of the S. aureus, coagulase-negative 
staphylococci, and Gram-negative strains were routinely carried out with cultures grown 
using Mueller-Hinton agar (MHA) and broth (MHB). For maintenance of constructs, 
strains were grown on MHB and MHA under appropriate antibiotic selection. Plate 
cultures were grown aerobically at 37
o
C for 18 hours, with the exception of strains 
harbouring pSIM8, pSIM18 or pCP20, which were grown at 30
o
C due to the 
temperature-sensitive origin of replication present on these plamids. Liquid cultures 
were incubated under the same conditions in a rotary shaker at 300 rpm. Experiments 
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under anaerobic conditions utilised MHB that was de-oxygenated for at least 16 hours 
in an anaerobic cabinet. For studies with daptomycin, MHB was supplemented with 
Ca
2+
 (in the form of CaCl2.6H2O) to a final concentration of 50 g/ml. Silver nitrate 
(AgNO3) was used as a source of Ag
+
, unless otherwise stated. 
2.4. General microbiology techniques 
2.4.1. Determination of susceptibilities to antibacterial agents 
MICs of antibacterial agents were routinely determined by 2-fold serial dilution in 
MHB according to the CLSI broth microdilution method (Wayne, 2012). However, 
susceptibility of clinical staphylococcal isolates to Ag
+
 was determined using the CLSI 
agar dilution method. Preliminary studies also utilised the BSAC standardised broth 
microdilution and agar dilution methods of antimicrobial susceptibility testing, as 
described elsewhere (Andrews, 2001). Biofilm MICs (bMICs) and minimum biofilm 
eradication concentrations (MBECs) were determined in MHB using the Calgary 
Biofilm Device as described previously (Miller et al., 2005). 
2.4.2. Time-kill analysis 
Time-kill assays were carried out as described previously (Oliva et al., 2003), with 
modifications. Briefly, a 1:100 dilution of overnight culture of either S. aureus SH1000, 
MHKAM or KCO43 in MHB was grown to an OD600 of 0.2 units and then exposed to 
antibacterial compounds at 4X MIC. Sample volumes of culture were taken at time 
points over a 24-hour period, diluted in phosphate buffered saline and spread onto 
MHA. Viable counts were determined following an overnight incubation at 37
o
C and 
the number of colony forming units (CFU)/ml calculated. Variations of this method 
were also carried out as described below. 
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Time-kill assays under anaerobic conditions were carried out using S. aureus SH1000 as 
described above, with the exception that all work was undertaken in an 
MG1000 anaerobic workstation (Don Whitley Scientific, Shipley, UK) with MHB and 
PBS that had been de-oxygenated for at least 16 h.  
Time-kill assays in HEPES glucose buffer were carried out under aerobic conditions as 
described above, with the exception that once cultures reached an OD600 of 0.2 units, 
cells were harvested by centrifugation, washed twice and resuspended in an equal 
volume of 5 mM HEPES and 5 mM glucose buffer (pH 7.2) before challenge with 
antibacterial agents at 4X MIC. 
2.5. Resistance studies 
2.5.1. Selection of spontaneous antibacterial-resistant mutants 
Spontaneous antibacterial-resistant mutants were selected by plating sample volumes of 
overnight culture of the strain of interest onto MHA containing 4X MIC of antibacterial 
agent. Plates were then incubated for 48 hours at 37
o
C. If colonial growth was observed, 
colonies were selected at random and MICs determined to confirm that they did indeed 
show reduced susceptibility compared with the parental strain. The frequency of 
spontaneous mutation (mutation frequency) was calculated as the number of resistant 
mutants per number of viable bacteria. 
2.5.2. Selection of endogenous Ag
+
 resistance 
2.5.2.1. Repeated exposure method 
Resistance selection was carried out as an adaptation of a method described previously 
(Miller et al., 2008). Briefly, overnight cultures in MHB were exposed to 100 g 
AgNO3/ml for six hours. Following exposure, cells were harvested by centrifugation at 
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5000 x g and washed twice in sterile deionised water before being resuspended in an 
equal volume of MHB. Sample volumes (90 l) of the washed culture were then 
transferred into fresh, drug-free MHB and the cycle repeated for 42 days. The 
AgNO3 MIC was determined every five cycles from a sample of culture. 
2.5.2.2. Continuous exposure method 
Bacrteria were continuously exposed to AgNO3 in a manner analogous to the method 
described by Friedman et al. for selecting for daptomycin resistance (Friedman et al., 
2006). On day one a microdilution broth MIC was performed for cultures as described 
in section 2.4.1., using three doubling dilution series of AgNO3. This extended gradient 
provided the following silver nitrate concentrations (g/ml):  
128   96   80   64   48   40   32   24   20   16   12   10   8   6   5   4   3   2.5   2   1.5   1.25 
Following incubation and determination of the MIC, the well that contained the highest 
concentration of AgNO3 that permitted growth was diluted 1:100 in MHB and used as 
the inoculum for the next MIC assay. This process was repeated for a maximum of 
42 days.  
2.5.3. Determination of bacterial fitness 
2.5.3.1. Growth rate determination 
Growth rates of cells in the presence of AgNO3 were carried out in microtitre plates. 
Briefly, overnight cultures of test strains were diluted 1:100 in MHB and sample 
volumes (180 l) transferred to the wells of a 96-well plate containing 20 l of 
AgNO3 at 20 g/ml (final concentration of AgNO3: 2 g/ml). Plates were then 
transferred to a Fluostar Optima plate reader (BMG-Labtech Ltd, Aylesbury, UK) 
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pre-warmed to 37
o
C and incubated for 18 h with shaking (200 rpm) for 30 sec every 
5 min. During incubation OD600 readings were taken for each well every 10 min. 
2.5.3.2. Determination of competitive fitness 
Sample volumes (9 l and 90 l respectively) of overnight cultures of Ag+-resistant and 
parental strains (in MHB) were combined and used to inoculate 9 ml of MHB. A sample 
volume of culture was diluted and 100 l volumes of appropriate dilutions were plated 
onto both MHB and MHB containing 64 g AgNO3/ml. Sample volumes (100 l) of 
parental cultures were also plated onto MHB containing 64 g AgNO3/ml to determine 
the number of spontaneous mutants to Ag
+
 resistance. The remaining mixed culture was 
incubated for 24 h and the plating procedure described above was repeated. All plates 
were incubated overnight at 37
o
C with aeration and the number of colonies counted. 
Relative fitness was then calculated using the following equation: 
                 
  (
  (  )
  ( )
)
  (
  (  )
  ( )
)
 
Where Nr(0) and Nr(24) represent the population density of the resistant strain at 
time 0 h or 24 h respectively, following subtraction of the number of spontaneous 
mutants to Ag
+
 resistance. Ns(0) and Ns(24) represent the population density of the 
parental strain at time 0 or 24 hr respectively (O‘Neill, et al., 2001) 
2.5.6. Assessment of porin expression in E. coli outer membranes 
Outer membrane proteins were extracted and purified according to methods previously 
described (Stapleton et al., 1999). Overnight cultures of E. coli BW25113, 
BW25113 ompR and BW25113 AgR grown in LBB were diluted 1:100 in 200 ml 
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LBB and grown at 37
o
C with aeration and shaking (200 rpm) to an OD600 of 0.8 units. 
At this point cells were collected by centrifugation (5000 x g, 15 min, 4
o
C), 
resuspended in 9 ml PBS containing 100 g lysozyme/ml, and incubated on ice for 
20 min. Cells were then sonicated in an MSE Soniprep 150 sonicator (MSE scientific 
instruments, Crawley, UK) for 5 min on ice. Sonication consisted of cycles of 30 sec 
bursts at amplitude of 20 microns followed by 30 sec rest periods. Membranes were 
collected by first centrifuging at 5000 x g for 15 min to remove cell debris and unlysed 
cells, then subjecting the supernatant to a second centrifugation (18,000 x g, 90 min, 
4
o
C) to collect the membranes, which were resuspended in 10 ml of Tris buffer (50 mM, 
pH 7.6). Cytoplasmic membranes were solubilised by adding sodium lauryl-sarcosinate 
to a final concentration of 1.7% (w/v) and incubating without shaking at room 
temperature for 20 min. This was followed with a further centrifugation step (18,000 x 
g, 90 min, 4
o
C) to pellet the outer membranes. The pellet was resuspended in 50 ml of 
sterile H2O and porin expression assessed by SDS-PAGE, as described in section 2.5.7. 
2.5.7. SDS-PAGE 
Sample volumes (10 l) of protein suspension diluted 1:1 with loading buffer 
(Sambrook, 2001) were incubated at 95
o
C for 5 min prior to separation by SDS-PAGE. 
Samples were run on a pre-cast 4-20% gradient polyacylamide gel (Expedeon Ltd, 
Harston, Cambridgeshire, UK) according to guidelines provided by the manufacturer. 
Gels were stained overnight in Comassie blue stain and de-stained for 4 h in 50% (v/v) 
methanol and 10% (v/v) acetic acid, with the de-stain replaced every hour. 
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2.6. Mode of action studies 
2.6.1. BacLight
™
 assay of membrane integrity 
Bacterial membrane integrity following exposure to antibacterial agents was assessed 
using the Live/Dead BacLight™ bacterial viability kit (Life Technologies, Paisley, UK) 
as described previously (Hilliard et al., 1999). Briefly, S. aureus SH1000 was grown in 
MHB to an OD600 of 0.5 units, and volumes of culture (500 l) were washed twice and 
resuspended in 900 l of H2O. Volumes (100 l) of antibacterial compounds at a 
concentration of 40x MIC were then added and samples mixed for 10 minutes at 37
o
C. 
Following incubation, samples were washed twice and resuspended in 1 ml of H2O. In a 
dark room, 50 l of each sample were added to the wells of a blacked out 96-well 
microtitre plate containing 150 l of BacLight™ reagent (consisting of propidium 
iodide and SYTO 9 stock solutions diluted 300-fold in H2O) and incubated in the dark 
at room temperature for 15 min. Fluorescence was measured in a Fluostar Optima plate 
reader with excitation set at 485 nm and emission at 645 nm (propidium iodide 
fluorescence) or 530 nm (SYTO 9 fluorescence). Fluorescence values were normalised 
against drug-free controls and percentage membrane integrity was then expressed as the 
ratio of SYTO 9:Propidium iodide fluorescence relative to cultures treated with 
0.5% (w/v) SDS.  
Bacterial membrane integrity following exposure to antibacterial agents under anaerobic 
conditions was carried out as described above with the exception that all work was 
carried out in an MG1000 anaerobic workstation using MHB and sterile H2O that had 
been de-oxygenated for at least 16 h. 
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2.6.2. Membrane potential 
Bacterial membrane potential following exposure to AgNO3 and comparator agents was 
measured over a 3 h time course using the fluorescent dye 
3,3‘-dipropylthiadicarbocyanine iodide (DiSC3(5)) (Life Technologies, Paisley, UK) 
according to methods described previously (Hobbs et al., 2008), with adaptations. 
Overnight cultures of S. aureus SH1000 in MHB were diluted 1:100 into 20 ml of MHB 
and incubated at 37
o
C with aeration to an OD600 of 0.2 units. Cells were then pelleted by 
centrifugation (5000 x g, 15 min, 37
o
C), washed twice and resuspended in 20 ml of 
5 mM HEPES, 5 mM glucose buffer (pH 7.0) containing 100 mM KCl and 2 M 
DiSC3(5) reagent. Cultures were then incubated as described above for an additional 
30 min in the dark before addition of test compounds to a final concentration of 4X 
MIC. Cultures continued to be incubated for 120 min with samples taken at 0, 10, 20, 
30, 40, 50, 60, 90 and 120 min. 
Samples removed at time-points were centrifuged at 13,000 x g for 30 sec and the 
supernatant (containing extracellular dye) transferred into an equal volume of DMSO.  
Cell pellets were re-suspended in DMSO and incubated at room temperature for 10 min 
to release intracellular dye prior to the addition of an equal volume of 5 mM HEPES, 
5 mM glucose buffer (pH 7.2). The fluorescence of both extracellular and intracellular 
samples was measured in a Perkin Elmer LS 45 luminescence spectrometer with 
excitation set at 622 nm and emission at 670 nm. The membrane potential at each time 
point was then calculated using the Nernst equation (see below) and then expressed as a 
percentage of the time 0 value. 
                     (
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Where R is the gas constant (8.3144621), T is the temperature in degrees Kelvin, F is 
the Faraday constant and If and Ef are the intracellular fluorescence and extracellular 
fluorescence respectively. 
2.6.3. Construction of liposomes 
Carboxyfluorescein-filled liposomes were constructed as described previously (StGelais 
et al., 2007), with modifications. Stock solutions (10 mg/ml in chloroform) of 
L--phosphatidic acid (PA), L--phosphatidylcholine and lissamine 
rhodamine B-labelled L--phosphatidylethanolamine (RPE) were mixed in a 
49:49:2 ratio to a final volume of 100 l in a glass test tube. All lipids were purchased 
from Avanti polar lipids (Alabaster, Alabama, USA). All chloroform was removed by 
first drying the lipids under a stream of argon then placing the tubes under vacuum for 
2 h prior to adding 1 ml of CF buffer (50 mM carboxyfluorescein, 10 mM NaCl, 10 mM 
HEPES, 134 mMNaOH, pH 7.4) and incubating overnight at 30
o
C with shaking 
(200 rpm). Liposomes were produced by extrusion through a 0.4 m filter in an Avanti 
mini-extruder with glass syringes and purified by ultracentrifugation (100,000 x g, 
20 min) and washing three times in assay buffer (1 mM HEPES, 107 mM NaCl, 
pH 7.4). Liposomes were resuspended in 500 l of assay buffer and the liposome 
concentration calculated by measuring rhodamine absorbance at OD570. To create 
―staphylococcal‖ liposomes, this method was repeated, but the lipids described above 
were substituted for 1,2-dioleoyl-sn-phosphatidylglycerol (PG), cardiolipin (CL) and 
RPE in a 59:39:2 ratio (Epand, et al., 2007). Liposomes of E. coli membrane 
phospholipid were created using E. coli polar lipid extract (consisting 67% [w/w] 
phosphatidylenanolamine, 23.2% [w/w] PG and 9.8 % [w/w] CL) mixed with RPE in a 
48:2 ratio. 
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2.6.4. Liposome damage assay 
To the wells of a blacked-out 96-well plate, 50 mM of liposomes were mixed with the 
antibacterial agent to be tested at 4x MIC and incubated in the dark at 37
o
C for 2 h. 
Fluorescence measurements were then taken in a Fluostar Optima plate reader with 
excitation at 485 nm and emission at 520 nm. Fluorescence values were normalised to 
drug-free controls and the percentage liposome integrity expressed as the fluorescence 
intensity relative to that of liposomes treated with 0.1% (w/v) Triton X-100. 
2.6.5. -galactosidase leakage 
Assessment of -galactosidase leakage from S. aureus was carried out as described 
previously (O'Neill et al., 2004), with the exception that the assays were performed 
using strain SH1000. Briefly, cultures of SH1000 were grown in MHB to an OD600 of 
0.6 units before the addition of AgNO3 and comparator compounds at a final 
concentration of 4X MIC. Following a 10 min incubation at 37 
o
C, cells were removed 
by centrifugation and 4-methylumbelliferyl--D-galactoside was added to samples 
(180 l) of culture supernatant (final concentration 1 mg/ml) prior to incubation for 2 h 
at 25 
o
C. Sample fluorescence was measured (excitation 365 nm, emission 460 nm) in a 
Fluostar Optima plate reader plate reader and values converted into fluorophore 
(4-methylumbelliferone) concentration using a calibration curve consisting of known 
fluorophore concentrations. 
2.6.6. Bacillus subtilis reporters 
Five B. subtilis antibiotic biosensors containing specific promoters that are induced by 
inhibition of DNA, RNA, fatty acid, cell wall and protein biosynthesis were utilised as 
described previously (Urban et al., 2007), with modifications. Strains were grown in 
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LBB to an OD600 of 0.2 units, then samples (90 l) of culture were treated with 
AgNO3 or an appropriate control antibiotic in a 96 well plate and incubated at 37
o
C for 
1-3 h (depending on the construct). Volumes (60 l) of 0.8M luciferin in 0.1M citrate 
buffer (pH 5.0) were then added and the luminescence of the sample recorded by a 
Fluostar Optima plate reader. Luminescence values were compared relative to a 
non-induced control and a >2-fold increase in luminescence was considered a positive 
result.   
2.6.7. Macromolecular synthesis assays 
The inhibition of DNA, RNA, protein and peptidoglycan synthesis by AgNO3 and 
control compounds was monitored by determining the incorporation of radiolabelled 
precursors [methyl-
3
H] thymidine (DNA), [5, 6-
3
H] uridine (RNA), L-[G-
3
H] glutamine 
(protein) and [1-
14
C] glycine (peptidoglycan), as described previously (Cherrington et 
al., 1990). All radiolabelled compounds were purchased from Perkin-Elmer 
(Cambridge, UK). Overnight cultures of SH1000 in MHB were diluted 1:100 in 9 ml 
MHB and incubated at 37
o
C with aeration and shaking (200 rpm) to an OD600 of 
0.2 units. Isotopes were added at a final concentration of 1 Ci/ml for 3H compounds 
and 0.1 Ci/ml for 14C-glycine 10 min prior to addition of antibacterial agent at a final 
concentration of 4X MIC. Following a further 10 min incubation, 500 l of culture was 
added to 4.5 ml of 10 % (w/v) ice-cold trichloroacetic acid (TCA) and incubated on ice 
for 40 min to precipitate macromolecules. Samples were then processed as previously 
described (Wilson et al., 1995) and radioactivity measured using a TriCarb 2100TR 
liquid scintillation counter (Packard Bioscience Ltd, Berkshire, UK).  
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2.6.8. Enzyme specificity assays 
2.6.8.1. RNA polymerase 
The ability of Ag
+
 and comparator compounds (at 4X MIC) to inhibit E. coli 
RNA polymerase (RNAP) was determined by measuring transcription using SYBR 
green as described previously (Mariner et al., 2010). Briefly, test compounds (or 
compound diluents) were mixed with 0.2 U of E. coli core RNAP (Epicentre, Madison, 
Wisconsin, USA) and incubated at 37
o
C for 10 min prior to the addition of Kool
TM
 
NC-45
TM
 Universal RNA polymerase template (Epicentre) and rNTPs to a final 
concentration of 125 ng/ml and 0.5 mM respectively. Following incubation at 37
o
C for 
2 h, the reaction was stopped by the addition of EDTA to a final concentration of 
20 mM EDTA (pH 8) and the amount of transcript produced was measured by adding 
0.07% (v/v) SYBR-Green I (Life Technologies) and determining fluorescence intensity 
at 520 nm, using an excitation wavelength of 497 nm. Fluorescence readings were 
determined using an EnVision 2103 Multilabel Reader (Perkin-Elmer). Percentage 
inhibition of RNAP by test compounds was calculated as the fluorescence intensity 
relative to reactions treated with compound diluents, following normalisation to 
template-free controls.  
2.6.8.2. Malate dehydrogenase  
The ability of Ag
+
 and comparator agents (at 4X MIC) to inhibit the conversion of 
oxaloacetic acid + -NADH to L-malic acid and -NAD by malate dehydrogenase was 
determined spectrophotometrically as described previously (Seidler et al., 2003). 
Briefly, test compound was added to a cuvette containing 50 mM KPO4 buffer 
(pH 7.35), followed by addition of malate dehydrogenase (final concentration 
0.002 M), NADH (Boehringer Mannheim; final concentration 0.2 mM) and 
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oxaloacetic acid (final concentration 0.2 mM). The contents of the cuvette were mixed 
and OD340 readings were taken every 30 sec for 6.5 min in a SPECTRAmax 
PLUS
384 
Microplate Spectrophotometer (Molecular Devices Ltd, Sunnyvale, California, 
USA). Readings were plotted on a scatter graph in Microsoft Excel software and the 
rate of reaction calculated as the gradient of a trendline fitted to the data. Percentage 
inhibition was calculated using the following equation: 
 
                          ((
     
     
)     ) 
Where Rc= Rate of reaction when exposed to antibacterial agent, Rb= Rate of reaction 
with no malate dehydrogenase present and Rd=Rate of reaction when exposed to 
diluent only. 
2.6.8.3. Chymotrypsin 
The ability of Ag
+
 and comparator agents (at 4X MIC) to inhibit the conversion of the 
substrate Suc-AAPF-pNA to 4-nitroaniline by chymotrypsin was determined 
spectrophotometrically as described previously (Seidler et al., 2003). Briefly, test 
compound was added to a cuvette containing 50 mM KPO4 buffer (pH7.35), followed 
by addition of chymotrypsin (final concentration 0.05 M) and Suc-AAPF-pNA (final 
concentration 0.15 mM). The contents of the cuvette were mixed and OD410 readings 
were taken every 30 sec for 6.5 min in a SPECTRAmax PLUS
384 
Microplate 
Spectrophotometer (Molecular Devices). Readings were plotted on a scatter graph in 
Microsoft Excel software and the rate of reaction calculated as the gradient of a 
trendline fitted to the data. Percentage inhibition was calculated using the equation 
described in section 2.6.8.2. 
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2.6.8.4. -galactosidase 
The effect of Ag
+
 and comparator compounds (at 4X MIC) to inhibit the conversion of 
4-methylumbelliferyl-β-D-galactopyranoside to 4-methylumbelliferone by 
-galacotsidase was determined by fluorescence intensity. Test compound was added to 
the wells of a blacked-out 96-well plate containing AB buffer (100mM NaCl, 60mM 
K2PO4 and 40mM KH2PO4), followed by the addition of 1 U E. coli -galactosidase and 
4-methylumbelliferyl-β-D-galactopyranoside to a final concentration of 1 g/ml. 
Reactions were incubated for 90 min at 25
o
C and the reaction stopped by addition of 
Na2CO3 to a final concentration of 0.2 M. Fluorescence intensity was measured in a 
Fluostar Optima plate reader at 460 nm, using an excitation wavelength of 365 nm. 
Percentage inhibition of -galactosidase by test compounds was calculated as the 
fluorescence intensity relative to reactions treated with compound diluents, following 
subtraction of background fluorescence from each sample.  
2.6.9. Transcriptome analysis 
Overnight cultures of S. aureus SH1000 were diluted 1:100 into 27 ml of MHB and 
incubated at 37
o
C with aeration and shaking to an OD600 of 0.2 units. At this point 3 ml 
of AgNO3 was added at a concentration that would inhibit growth of cultures by 25% 
(relative to a drug-free controls, into which 3 ml of sterile H2O was added) over a 
40 min period (Freiberg, et al., 2005). Following incubation, 10 ml volumes were 
transferred into 50 ml falcon tubes containing 20 ml of RNA protect bacterial reagent 
(Qiagen, Manchester, UK), vortexed for 10 sec, and then incubated without shaking at 
room temperature for 10 min. Following centrifugation of samples (at 5000 x g) and 
removal of supernatant, cell pellets were washed twice in TE buffer (10 mM tris 
(hydroxymethyl) aminomethane, 1 mM ethelynediaminetetra-acetic acid [pH 8.0]), 
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re-suspended in TE buffer containing 200 g RNAse-free lysostaphin/ml, and then 
incubated at 37
o
C for 90 min with gentle mixing every 15 min. RNAse-free 
Proteinase K was then added to a final concentration of 40 g/ml and the cell 
suspension incubated at room temperature for a further 10 min. Total RNA was 
extracted from cell suspensions using an RNAeasy midi kit (Qiagen) according to 
manufacturer‘s instructions, and eluted in 500 l of nuclease-free H2O. 
Determination of RNA quality, synthesis and hybridisation of cDNA to microarrays and 
subsequent analysis (i.e. fluorescence measurements and normalisation) was performed 
by Roche Nimblegen (Madison, Wisconsin, USA). Microarray probe sequences were 
derived from the chromosomal DNA sequence of S. aureus 8325 and fluorescence 
values were normalised using quantile normalisation.  
Results from microarray experiments were subsequently analysed using ArrayStar 
4 software (DNAstar, Madison, Wisconsin, USA) and a ≥2-fold difference in gene 
expression between control and test samples (at a 99% confidence limit)  was 
considered significant. 
2.6.10. Screening of a near-saturation transposon library of S. aureus 
A library of S. aureus SH1000 comprising ~20,500 transposants was screened for Ag
+
 
hypersusceptibility according to a method described previously (Blake & O'Neill, 
2013). The concentration of AgNO3 selected for screening transposants was determined 
as the concentration that inhibited the growth of 1-2 library strains per 96-well plate, 
without inhibiting growth of the parental strain under identical conditions. 
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2.7. Molecular biology techniques 
2.7.1. Isolation of plasmid DNA 
Plasmid DNA from E. coli was isolated from 3 ml of overnight culture in LBB using 
the QIAprep miniprep kit from Qiagen according to manufacturer‘s instructions. 
Plasmid DNA extraction from S. aureus followed the method above with the exception 
that 100 g lysostaphin/ml was added to cells following their resuspension in buffer 
P1 and cells were incubated at 37
o
C for 30 min prior to continuation of the 
manufacturer‘s protocol. In cases where high concentrations of plasmid were required, 
multiple minipreps were performed and the eluted plasmid DNA was concentrated by 
ethanol precipitation according to the method described previously (Sambrook, 2001). 
Plasmid DNA was stored at -20
o
C  
2.7.2. Isolation of chromosomal DNA 
Chromosomal DNA from Gram-negative species and S. aureus was isolated using the 
bacterial genomic DNA purification kit from Edge biosystems (Maryland, VA, USA) 
following the manufacturer‘s instructions, with the exception that for S. aureus cultures 
100 g lysostaphin/ml was added to cells following their resuspension in spheroplast 
buffer. Cells were then incubated for 30 minutes at 37
o
C prior to continuation of the 
manufacturer‘s protocol. All chromosomal DNA was stored at -20oC 
2.7.3. Polymerase chain reaction  
Oligonucleotide primers for PCR were designed using Oligo software (Molecular 
Biology Insights inc., West Cascade, Colorado, USA) or primer 3 (Untergasser, et al., 
2012) and ordered from Eurofins MWG operon (Ebersberg, Germany). PCR was 
carried out using a Techne TC-3000 thermal cycler (Bibby Scientific Ltd, Staffordshire, 
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UK) using Phusion high-fidelity DNA polymerase (New England Biolabs, Ipswich, 
Massachusetts, USA) in 25 l volume reactions. PCR reactions consisted of 5 l 
5x Phusion HF buffer, 0.5 l 10 mM dNTPs (Promega– consisting 2.5 mM of each 
dNTP), 1.25 l of each primer (stock concentration 100 pmol/l), 1 l of template DNA 
(approx. 50-100 ng) and 15.75 l of nuclease-free H2O. Thermal cycling conditions 
consisted of initial denaturation at 98
o
C for 1 min followed by 30 cycles of denaturation 
at 98
o
C for 10 sec, annealing for 30 sec and extension at 72
o
C for 30 sec/kb and a final 
extension cycle at 72
o
C for 7 minutes. Reactions were then held at 4
o
C until required. 
The annealing temperature was optimised for each reaction and was based on the 
melting temperature (Tm) for each primer used. Primer Tm was calculated using 
Phusion Tm calculator at 
https://www.neb.com/tools-and-resources/interactive-tools/tm-calculator (last accessed 
29/06/2013) 
2.7.4. Determination of DNA concentration 
DNA was quantified spectrophotometrically at 260 nm using a P300 nanophotometer 
(Implen, Munich, Germany). The purity of the DNA obtained was determined by 
measuring the ratios of wavelengths 260 nm/280nm and 260nm/230nm (Sambrook, 
2001) 
2.7.5. Colony PCR 
Colonies were picked into 20 l of nuclease-free H2O and 3 l of this suspension was 
transferred onto an index plate of LBA containing an appropriate selection antibiotic. 
Colony PCR was performed using GoTaq PCR mastermix (Promega). Reactions 
consisted of 1.5 l of cell suspension, 12.5 l of GoTaq mastermix, 1.25 l of each 
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primer (100 pmol/l stock concentration) and 8.5 l of nuclease-free water. 
Thermocycler cycling conditions consisted of initial denaturation at 95
o
C for 10 min, 
followed by 30 cycles of denaturation at 95
o
C for 30 sec, annealing at 50
o
C for 30 sec 
and extension at 72
o
C for 1 min/kb. This was followed by a final extension at 72
o
C for 
7 min. Reactions were held at 4
o
C until required.  
2.7.6. Agarose gel electrophoresis and DNA fragment purification 
Gels comprised of 0.8% (w/v) agarose in TAE buffer containing SYBR safe DNA stain 
(Life Technologies). Prior to loading, samples were mixed with 6x loading dye 
(Promega) in a 6:1 ratio. Samples of DNA from colony PCR already contained loading 
buffer and so no additional buffer was added. Electrophoresis was performed in TAE 
buffer at 90 V for 30 min. DNA fragments required for further applications were 
excised from gels and purified using the MinElute gel extraction kit from Qiagen 
according to manufacturer‘s instructions. 
2.7.7. DNA sequence determination (Sanger) 
The nucleotide sequences of PCR products and plasmid constructs were determined by 
Beckman Coulter Genomics (Takeley, Essex, UK) with appropriate oligonucleotide 
primers. Results were analysed using Sequencher software by GeneCodes (Ann Arbor, 
Michigan, USA). 
2.7.8. Next generation sequence determination 
Samples (1 g) of total (i.e. chromosomal and plasmid) DNA from E. coli 
J53 pMG101 and purified plasmid pMG101 were sent to the Leeds Clinical Molecular 
Genetics centre (St. James‘ Hosptial, University of Leeds) and nucleotide sequences 
determined using the Illumina sequencing-by-synthesis method (2x250 paired-end 
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reactions) on a MiSeq platform. De novo assembly of the J53 chromosome and 
pMG101 was performed using CLC genomics workbench, version 6 (CLC Bio, 
Cambridge, Massachusetts, USA).    
2.7.9. Quantitative PCR (qPCR) 
Total RNA was extracted from cultures using Trizol reagent (Life Technologies), 
following manufacturer‘s instructions and was resuspended in nuclease-free H2O. RNA 
concentration was determined by measuring absorbance at 260 nm using a 
P300 nanophotometer and quality of samples were assessed by visual inspection of 
bands corresponding to the 16S and 23S rRNA subunits following gel electrophoresis. 
First-strand cDNA synthesis was performed using Omniscript RT kit (Qiagen) with 
oligo-dT(15) primers and RNAse inhibitor (Promega) at final concentrations of 1 M 
and 10 U respectively. qPCR was carried out in an MxPro Mx3005P thermal cycler 
(Agilent, Wokingham, UK) using Quantifast SYBR Green PCR kit (Qiagen) in 25 l 
reactions containing 100 ng of cDNA using oligonucleotide primers specific to the gene 
of interest or towards 16S cDNA, which acted as an internal control. Thermocycler 
conditions consisted of an initial denaturation step at 95
o
C for 5 min, followed by 
35 cycles of denaturation (95
o
C, 10 sec) and a combined annealing/extension step 
(60
o
C, 30 sec).  SYBR green fluorescence was measured at the end of each 
annealing/extension step. Relative expression from the gene of interest was calculated 
using the Ct method, with the abundance of 16S cDNA used as the normalising 
control. Calculations were performed using MxPro Mx3005P software.  
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2.7.10. Lambda red recombineering 
Genes of interest were modified using recombineering (recombination-based genetic 
engineering) methods, as described previously (Sawitzke et al., 2007). First, plasmid 
pSIM9 or pSIM18 (containing the lambda red system) were transformed into the strain 
of interest using the method described in section 2.7.13, with the exception that strains 
were recovered at 30
o
C to prevent loss of plasmid. Overnight cultures of transformants 
were diluted 1:100 in 30 ml of LBB and incubated at 30
o
C with shaking to an OD600 of 
0.5 units. Lambda red functions were then induced by incubating cultures at 42
o
C for 
15 min. Lamda red-induced cells were then made electrocompetent by washing 3 times 
in ice-cold H2O and resuspending in a final volume of 200 l H2O. Sample volumes 
(50 l) of cells were then mixed with 100-200 ng of modification cassette (see below) 
in a 0.1 cm-gap electroporation cuvette and pulsed in a Genepulser XCell electroporator 
(Biorad Ltd, Hemel Hempstead, Hertfordshire, UK)  at 1.35 kV, 600  and 10 FD. 
Following electroporation, 1 ml of LB was added to the cuvette. The contents of the 
cuvette were transferred to a 50 ml Falcon tube and incubated for 2 h at 30
o
C with 
aeration and shaking (200 rpm). Cells were plated onto LBA containing 30 g 
kanamycin/ml (FRT-neoR-FRT cassette), 10 g chloramphenicol/ml (cat-sacB 
cassette), or 6% (w/v) sucrose (allelic replacement cassette) and incubated overnight at 
30
o
C. Colonies were screened for the presence of gene modification by PCR 
amplification and sequence determination using appropriate oligonucleotide primers. 
Strains were cured of pSIM plasmids by of overnight culture at 37
o
C and checking for 
loss of resistance to the plasmid selection antibiotic. 
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2.7.10.1. Construction of disruption cassette 
To disrupt a gene of interest, bipartite oligonucleotide primers were designed. Each 
primer consisted of 50 bases homologous to the regions flanking the gene of interest on 
the chromosome and an additional 20 bases, which primed to the FRT-neoR-FRT 
cassette on plasmid pKD4. Following amplification of FRT-neoR-FRT, the PCR 
product was gel purified as described in section 2.7.6 and introduced into 
lambda red-induced cells by electroporation. 
2.7.10.2. Removal of disruption cassette 
To remove the disruption cassette (and thus leave a markerless deletion), strains were 
transformed with plasmid pCP20 (containing FLP recombinase) as described in section 
2.7.13, with the exception that strains were recovered at 30
o
C to prevent loss of 
plasmid. Following transformation, strains were incubated in LBB overnight at 30
o
C 
with aeration and shaking, then checked for the loss of disruption cassette by looking 
for absence of growth on LBA containing 30 g kanamycin/ml. Strains were cured of 
pCP20 by 3 cycles of overnight culture at 37
o
C and checking for loss of 
pCP20-mediated ampicillin resistance.  
2.7.10.3. Allelic replacement  
Genes containing mutations of interest were transferred into a recipient strain by 
cat-sacB counterselection, as previously described (Thomason et al., 2007). Bipartite 
primers were designed as in 2.7.10.1 with the exception that the amplification target 
was cat-sacB from strain DY441, or the replacement allele from the strain of interest. 
Following correct recombination of the cat-sacB cassette into the recipient strain, 
sucrose hypersensitivity was confirmed by subculture onto LBA containing 6% (w/v) 
sucrose. Recombineering functions were again induced in the recipient strain prior to 
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transformation with the allelic replacement cassette, which in positive recombinants 
replaces the cat-sacB cassette and restores sucrose resistance.  
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Chapter three: Development of standardised methodology to assess  
the antibacterial activity of Ag+, and its use in examining the 
prevalence of Ag+ resistance amongst the staphylococci 
Abstract 
The growing prevalence of antibiotic resistance in bacteria has led to an increased 
interest in exploiting the antibacterial properties of Ag
+
. However, there are several 
poorly understood aspects of Ag
+
, including its activity against bacteria in both 
planktonic and biofilm growth states, the prevalence of Ag
+
 resistance amongst bacteria 
isolated from patients, and the propensity for Ag
+
 resistance to arise. This chapter 
sought to investigate these issues by using methodologies routinely used in the 
assessment of antibiotics. The CLSI standard method for assessing bacterial 
susceptibility to antibiotics was found to be suitable for use with Ag
+
 in the form of 
AgNO3. The time-kill method used for assessing antibiotic kill-kinetics revealed that at 
4X MIC, Ag
+
 was bactericidal against S. aureus in buffered solution, but bacteriostatic 
in growth medium. Ag
+ 
was unable to eradicate S. aureus biofilms. There was no 
evidence of Ag
+
 resistance amongst a large collection of staphylococcal hospital isolates 
(n=1006), and continuous exposure of S. aureus to sub-inhibitory concentrations of Ag
+
 
for 42 days failed to select for endogenous Ag
+
 resistance. The universal susceptibility 
of staphylococci to Ag
+
 and the inability to select for Ag
+
 resistance in S. aureus 
suggests that Ag
+
 remains a viable option for the prevention and treatment of 
staphylococcal infections. 
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3.1. Introduction 
3.1.1 Aspects of the antibacterial activity of Ag
+
 are unclear  
When bacterial infection is suspected in a patient, empirical antibacterial therapy is 
usually initiated, and samples (e.g. swabs, blood cultures, etc.) may be taken so that the 
infecting organism can be identified and the susceptibility of the organism to a range of 
antibacterial agents can be determined (Mandell et al., 2009). This informs the clinician 
if the empirical therapy is likely to prove effective in treating the infection, and if not, 
enables selection of an antibacterial agent that provides the best clinical outcome for 
their patient. To assess bacterial susceptibility to antibiotics, clinical laboratories 
typically follow a standardised method, such as the disk-diffusion or minimum 
inhibitory concentration (MIC) methods published by the Clinical Laboratory Standards 
Institute (CLSI) and the British Society for Antibacterial Chemotherapy (BSAC) 
(Andrews, 2001, Wayne, 2012). This standardisation allows for susceptibility data to be 
compared between clinical laboratories, providing an additional advantage in that the 
spread of antibiotic-resistant bacteria can be followed on a national and international 
scale. These data can then be utilised to provide guidance to clinicians, and prevent an 
antibiotic being used against infections where it is likely to be ineffective.  
In contrast to the situation with antibiotics, when a patient presents with an infection 
that may benefit from treatment with an Ag
+
-containing product (e.g. a burn or chronic 
wound), determining the susceptibility of isolates to Ag
+
 does not routinely take place. 
(Warriner & Burrell, 2005; Ip et al., 2006a). A major reason for this appears to be that 
there is currently no standardised method for determining bacterial susceptibility to 
Ag
+
; therefore, of the limited number of Ag
+
 susceptibility surveys that have been 
published, each have used methodologies that differ in the use of culture media, 
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Ag
+ 
formulations, bacterial inoculum densities, and incubation conditions. As a 
consequence results between studies differ and are therefore not directly comparable 
(Carr et al., 1973; Vasishta et al., 1989; Maple et al., 1992; Hamilton-Miller et al., 
1993; Ug & Ceylan, 2003). Ultimately, the lack of routine Ag
+
 susceptibility testing 
means that the current prevalence of Ag
+
 resistance amongst common wound pathogens 
is unclear. This omission in testing could considerably impact the morbidity or mortality 
of patients treated with Ag
+
-containing products if they are infected with an 
Ag
+
-resistant isolate. It is therefore apparent that if the use of Ag
+
-containing products 
for the treatment of bacterial infection is to continue, the issues described above should 
be rectified and a standardised method for assessing and interpreting bacterial 
susceptibility to Ag
+
 should be introduced.  
As with determining bacterial susceptibility to Ag
+
, there is currently no standardised 
method for assessing the killing kinetics of Ag
+
-containing compounds; therefore the 
killing (bactericidal) activity of Ag
+
 is also unclear. Indeed, the lack of a standardised 
methodology has led to reports that Ag
+
 is bactericidal (i.e. capable of reducing 
bacterial cell viability by ≥3-log10 cfu/ml over 24 h exposure) in some studies 
(Matsumura et al., 2003), and bacteriostatic (<3-log10 reduction) in others (Gordon et 
al., 2010). Burns and chronic wounds are typically poorly vascularised, resulting in a 
limited presence of immune system components at the site of infection once it occurs 
(Warriner & Burrell, 2005). As a consequence it would be beneficial for Ag
+
-containing 
compounds to be bactericidal, as treatment would then not be as reliant upon the 
patient‘s immune response to clear the infection (as would be the case if using a 
bacteriostatic agent).  
In addition to establishing the killing activity of Ag
+
 against bacteria growing in a 
planktonic (free-living) state, it would also be of use to determine the ability of Ag
+
 to 
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eradicate biofilm cultures of bacteria. Biofilms are sessile communities of bacteria 
encased in a matrix of extracellular polymeric substances (EPS) consisting of proteins, 
polysaccharides and DNA (Costerton et al., 1999). In addition to forming on plastics, 
abiotic surfaces coated in plasma, and environments exposed to high levels of 
hydrodynamic shear (Costerton et al., 1999), it is becoming increasingly apparent that 
chronic wound infections contain bacteria in a biofilm state (James et al., 2008). Once 
formed, biofilms are highly recalcitrant to clearance by the host immune system and 
antibacterial chemotherapy, a phenomenon attributable to several key properties of the 
biofilm. For example, EPS can act as a permeability barrier to immune system effectors, 
and can bind aminoglycosides by charge interactions, in both cases preventing them 
reaching their microbial target (Shigeta et al., 1997; Costerton et al., 1999). 
Furthermore, high populations of non-growing and ‗persister‘ cells are encountered 
within a biofilm (Eng et al., 1991; Kint et al., 2012), which, as a consequence of their 
attenuated metabolic activity, are tolerant to the killing activities of agents such as the 
-lactams and fluoroquinolones (Eng et al., 1991; Kint et al., 2012). A number of 
studies have demonstrated that Ag
+
 can inhibit biofilm formation, or prevent the further 
proliferation of an existing biofilm (De Prijck et al., 2007; Stobie et al., 2008). 
However, as biofilms are recalcitrant to clearance by the host immune system, the 
simple inhibition of biofilm growth by Ag
+
 would be insufficient to achieve clinical 
cure, as upon cessation of Ag
+
 therapy, the biofilm would once again proliferate (Jensen 
et al., 2010). Against biofilms of P. aeruginosa it was suggested that silver 
sulphadiazine at concentrations ≥ 5 g/ml could cause complete eradication (Bjarnsholt 
et al., 2007). This study used a P. aeruginosa strain constitutively expressing GFP to 
identify ―live‖ cells and the stain propidium iodide to identify ―dead‖ cells when 
visualised by confocal microscopy. However, it is unclear if metabolically inert cells of 
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P. aeruginosa within a biofilm would express GFP, or if propidium iodide could 
successfully penetrate the entirety of a biofilm, thus it is not apparent from this study if 
complete biofilm eradication can be achieved with Ag
+
, which necessitates further 
studies using an appropriate testing methodology. 
3.1.2. The propensity for bacterial Ag
+
 resistance to arise is unknown 
As discussed above, the lack of a standardised method for evaluating bacterial 
susceptibility to Ag
+
 has prevented the prevalence of bacterial Ag
+
 resistance amongst 
clinical isolates from being established. In addition, the propensity for bacterial Ag
+
 
resistance to arise and spread is not known. Endogenous (mutational) resistance to Ag
+
 
has reportedly been selected in the laboratory by continuous exposure of E. coli and 
S. aureus to sub-inhibitory Ag
+
, with the MIC of AgNO3 increasing from 4 and 8 g/ml 
against parental strains of E. coli and S. aureus, respectively, to >256 and 70 g/ml 
against resistant strains (Li et al., 1997; Kaur et al., 1987). However, in neither study 
was the time taken for resistance to arise reported, a factor which is important to 
establish the rapidity with which endogenous Ag
+
 resistance might arise in a patient 
treated with Ag
+
. Exogenous (horizontally-acquired) Ag
+
 resistance has been found in 
strains of Salmonella Typhimurium and Enterobacter cloacae  isolated from patients 
(McHugh et al., 1975; Lansdown & Williams, 2007); however, the propensity for this 
mechanism to spread has not been established, and it is not known if exogenous 
Ag
+
 resistance currently exists, or can arise in Gram-positive bacteria commonly 
isolated from wounds, such as S. aureus. Furthermore, in all cases of Ag
+
 resistance 
discovered thus far, the metabolic (fitness) cost associated with the resistance phenotype 
has not been assessed. All this information is vital to provide an indication for an 
Ag
+
 resistance phenotype to emerge, persist and spread in any given environment.  
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3.1.3. Use of the staphylococci as a model genus for this study 
Members of the genus Staphylococcus are Gram-positive, catalase-positive cocci that 
are facultative anaerobes, and can be transient or permanent commensals of the 
microbiota on the skin and mucous membranes of a variety of mammals, including 
humans (Mandell et al., 2009).  Staphylococcus epidermidis is the predominant species 
isolated from humans; however other species, such as S. aureus, S. capitis and 
S. hominis are also frequently isolated. Although all these species can cause 
opportunistic infection in the human host, S. aureus is the most pathogenic, as a 
consequence of harbouring an array of virulence factors that enable it to cause 
infections ranging from the relatively benign (e.g. boils and impetigo) to the severe and 
life-threatening (e.g. abscesses, endocarditis, pneumonia and bacteraemia) (Mandell et 
al., 2009). Of interest to this study, however, is that members of the genus 
Staphylococcus (S. aureus in particular) can frequently colonise and cause wound 
infections that are resistant to antibiotics (Rezaei et al., 2011; Anderson & Kaye, 2009). 
Staphylococcus therefore represents a genus of bacteria against which Ag
+
 would need 
to display antibacterial activity in order to retain clinical utility. For the same reason, it 
would also be important to ascertain the susceptibility of clinical isolates of this genus 
to Ag
+
, and establish the propensity for Ag
+
 resistance to emerge, persist and spread by 
endogenous and exogenous mechanisms. As a consequence staphylococci were used as 
model organisms in the studies presented in this chapter. 
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3.2 Objectives 
The objectives of the work presented in this chapter were: 
 to develop a standardised methodology for assessing bacterial susceptibility to 
Ag
+
  
 to establish the bactericidal activity of Ag+ against planktonic and biofilm 
cultures of S. aureus 
 to elucidate the prevalence of Ag+ resistance amongst patient isolates of 
staphylococci using a standardised methodology 
 to establish the propensity for Ag+ resistance to emerge in S. aureus   
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3.3 Results and discussion 
3.3.1. Antibacterial activity of Ag
+
 
3.3.1.1 Validation of methodology for Ag
+
 susceptibility testing 
In testing of bacterial susceptibility to antibiotics, clinicians and researchers typically 
follow the agar dilution or broth microdilution methods described by BSAC or CLSI 
(Andrews, 2001, Wayne, 2012). These methodologies are almost identical, although 
BSAC recommends the use of Iso-Sensitest (IS) media, whilst CLSI recommends 
Mueller-Hinton (MH) media. Although originally developed as a medium for growing 
Neisseria spp. (Mueller & Hinton, 1941), MH medium was found to be suitable for 
performing antibacterial susceptibility testing, as it contains low concentrations of 
thymine and thymidine (which are antagonists of sulphonamides and trimethoprim) and 
includes sufficient Mg
2+
 and Ca
2+
 to maintain the activity of aminoglycosides and 
tetracyclines, respectively (Bauer et al., 1966, Wayne, 2012). Nevertheless, there have 
been reports of batch-to-batch variability with MH medium, leading to variations in its 
performance (Barry & Effinger, 1974). Although this has been rectified by the CLSI 
with the standardisation of MH composition (CLSI standard M6-A), IS has been 
adopted by some groups, due to it being a semi-defined media that enables better 
standardisation of composition between commercial suppliers (Andrews, 2001).  
If either CLSI or BSAC methodologies are suitable for use in determining bacterial 
susceptibility to Ag
+
, then they could be quickly adopted by microbiology reference 
centres, given that these methods are already in use to monitor antibiotic resistance. 
Therefore, AgNO3 MICs were determined against S. aureus strains SH1000, MRSA252, 
ATCC 29213 and ATCC 25923 and E. coli strains BW25113 and J53-pMG101 (an 
Ag
+
-resistant strain), using both agar dilution and broth microdilution methods in IS or 
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MH media according to CLSI/BSAC guidelines. As a comparison, bacterial 
susceptibility to Ag
+
 was also determined in Luria-Bertani (LB) broth and agar, due to 
its use in previous studies on the antibacterial activity and mode of action of Ag
+
 (Li et 
al., 1997; Gupta et al., 1999; Feng et al., 2000) (Table 3.1). Silver nitrate (AgNO3) was 
chosen as the source of Ag
+
 for this study and the remaining studies throughout this 
thesis, as unlike most other antibacterial Ag
+
 formulations (i.e. silver sulphadiazine, 
silver nanoparticles) it can be readily dissolved in water and culture media.  
Table 3.1. Determination of bacterial susceptibility to Ag
+
 on various culture 
media using agar dilution or broth microdilution  
Strain AgNO3 MIC (g/ml) 
 ISA ISB LBA LBB MHA MHB 
SH1000 32 32 8 8 16 16 
MRSA252 32 32 8 4 16 8 
ATCC 29213 32 16 8 8 8 8 
ATCC 25923 32 32 4 4 16 8 
BW25113 8 8 4 4 4 4 
J53-pMG101 >256 >256 >256 >256 >256 >256 
ISA/ISB: Iso-Sensitest agar/broth; LBA/LBB: Luria-Bertani agar/broth; MHA/MHB: 
Mueller-Hinton agar/broth. 
 
IS media inhibited Ag
+
 activity to a greater extent than MH and LB media as 
demonstrated by the higher MIC values obtained. This difference in Ag
+
 activity is 
likely due to differing amounts of inhibitory components in each culture medium. LB 
media utilises a pancreatic digest of casein (i.e. tryptone) as a source of nitrogen and 
amino acids for bacterial metabolism, whereas IS and MH media utilise an acid 
hydrosylate of casein (Atlas, 2010). Pancreatic digests lead to an incomplete breakdown 
of casein compared with acid hydrolysis, thus in tryptone (and therefore LB), there may 
be fewer exposed amino acid side-chains capable of binding and inactivating Ag
+
 (such 
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as thiol groups), meaning there is more active Ag
+
 present to inhibit bacterial growth. 
Although IS and MH media both contain casein hydrosylate, IS media is supplemented 
with additional cysteine (Atlas, 2010), which is likely responsible for the reduced 
activity observed. As MH medium is standardised (unlike LB) and inhibited Ag
+
 
activity to a lesser extent than IS (thus providing greater sensitivity when comparing 
Ag
+
 susceptibility between isolates), the CLSI method for antibiotic susceptibility 
testing (using MH medium) was employed for all remaining studies investigating the 
antibacterial activity of Ag
+
.  
3.3.1.2. Bactericidal activity of Ag
+ 
against S. aureus 
As with determining bacterial susceptibility to Ag
+
, there is currently no standardised 
method for assessing the killing kinetics of Ag
+
-containing compounds, which prevents 
direct comparison of results between studies. In establishing the bactericidal activity of 
antibiotics, the ‗time-kill‘ method is routinely used; in this method exponential-phase 
bacterial cultures of a defined density (usually 5x10
8 
cfu/ml) are exposed to a test 
compound at 4X MIC (Oliva et al., 2003). At regular time points, the number of viable 
bacteria remaining within a culture are determined and subsequently used to establish 
the kill-kinetics of the test compound (Oliva et al., 2003). To establish if this method 
would give reproducible results with Ag
+
, exponential-phase cultures of S. aureus 
SH1000 were exposed to AgNO3 and comparator compounds at 4X MIC, and viable 
cell counts determined every 30 min for 6 hours (Figure 3.1). Bacterial cultures were 
suspended in MHB, to maintain consistency with the media used in susceptibility 
testing. 
Against S. aureus cultures in MHB, Ag
+
 exhibited only weak killing activity, causing a 
<1 log10 drop in cell viability over the time course. This result was reproducible and was 
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found to be comparable to that obtained for fusidic acid, a bacteriostatic antibiotic 
frequently used in the treatment of topical staphylococcal infections (Brown & Thomas, 
2002). After 24 h exposure to AgNO3, a 2.2 ± 0.09 log10-drop in cell viability was 
observed and would therefore define Ag
+
 as a bacteriostatic compound. Cultures 
exposed to daptomycin or nisin underwent a >7-log10-drop in cell viability after 24 h, 
defining these compounds as bactericidal, which is in agreement with previous studies 
(Hobbs et al., 2008). 
Prior studies that have assessed the bactericidal activity of Ag
+
 have produced 
conflicting data, with some studies indicating that AgNO3 is bacteriostatic, and others 
suggesting that it is bactericidal (Matsumura et al., 2003; Gordon et al., 2010). As 
components of culture media (i.e. protein and sodium chloride) affect the inhibitory 
activity of Ag
+
 (Liau et al., 1997; Gupta et al., 1998), it seems likely that a similar effect 
will be observed when evaluating the killing activity of Ag
+
. To assess this, the above 
experiment was repeated, with the exception that S. aureus SH1000 cultures were 
re-suspended in HEPES-glucose buffer (which lacks culture media components) (Figure 
3.1). Whilst only a slight increase in bactericidal activity was observed for comparator 
agents nisin and daptomycin relative to that seen against cultures in MHB, Ag
+
 was 
rapidly bactericidal in buffer, with a >7 log10-drop in cell viability observed after 10 min 
exposure.  
The fact that culture media components have a dramatic impact on the killing activity of 
Ag
+ 
not only provides further indication of the need of a standardised method to assess 
the antibacterial activity of Ag
+
 products, but also raises questions as to the activity of 
Ag
+
 when it is employed therapeutically in wounds. Both acute and chronic wounds can 
secrete fluid (exudate) with a high protein and salt content that could bind (and therefore 
inhibit the antibacterial activity of) Ag
+
 released from Ag
+
-containing products 
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(Cutting, 2003). However, although there have been numerous studies into the 
bactericidal activity of silver preparations in vitro, none appear to have taken into 
account the high protein content of the wound environment. In consequence, these 
studies could be over-estimating the true bactericidal activity of these dressings in vivo. 
It is therefore apparent that future studies should seek to employ a method of assessing 
the bactericidal activity of Ag
+
-containing products in an environment more analogous 
to that found in wounds to address this issue.  
  
 
 
         8
4 
   
Figure 3.1: Effects of AgNO3 and comparator agents on the viability of exponential cultures of S. aureus SH1000 over a 6 h period in 
MHB (a) and over a 2 h period in cultures re-suspended in 5mM HEPES-glucose buffer (b). Values shown are the means of three replicates 
from three independent experiments. Error bars represent the standard deviation from the mean. 
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3.3.1.3. Activity of Ag
+ 
against biofilm cultures of S. aureus  
Bacteria growing as a biofilm can cause persistent infections that are highly refractory 
to antibacterial therapy and may present in environments where Ag
+
 is used, such as in 
chronic wounds (James et al., 2008). Therefore the ability of Ag
+
 to inhibit and 
eradicate biofilms of SH1000 and MRSA252 grown on the Calgary biofilm device was 
assessed, as determined by the biofilm MIC (bMIC) and minimum biofilm eradication 
concentration (MBEC) methods, respectively (Ceri et al., 1999) (Table 3.2). These 
methods have previously been utilised for the rapid screening of compounds for 
anti-biofilm activity (Ceri et al., 1999; Ooi et al., 2010). At a concentration of 16 g/ml, 
AgNO3 could prevent shedding of planktonic cells from established biofilms in vitro 
(Table 3.2). This may indicate that, in vivo, Ag
+
 could prevent further biofilm growth 
and dissemination to other sites. However, as this bMIC is equivalent to the MIC of 
Ag
+
, it seems likely that Ag
+
 inhibits the growth of planktonic cells following their 
release from the biofilm and has no direct effect on the viability of the biofilm itself. 
Indeed, Ag
+
 was unable to eradicate established biofilms (MBEC >256 g/ml) (Table 
3.2). This may be a consequence of Ag
+
 binding to negatively charged extracellular 
polymeric substances within the biofilm, thereby preventing Ag
+
 from reaching cells in 
sufficient concentration to exert an antibacterial effect (Chaw et al., 2005). 
With the exception of XF-73, all control compounds were also unable to eradicate 
biofilm cultures at the concentrations tested (MBEC= >256 g/ml, or >64 g/ml for 
nisin) (Table 3.2), which is in agreement with previous studies (Ooi et al., 2010). In 
contrast, XF-73, as previously reported (Ooi et al., 2010), displayed potent activity 
against both SH1000 and MRSA252 biofilms, with an MBEC of 2 g/ml (Table 3.2). 
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Table 3.2: Activity of AgNO3 and comparator compounds against biofilms  
Compound bMIC (g/ml) MBEC (g/ml) 
 SH1000 MRSA252 SH1000 MRSA252 
Silver nitrate 16 16 >256 >256 
Vancomycin 2 1 >256 >256 
Tetracycline 0.5 1 >256 >256 
XF-73 1 2 2 2 
Fusidic acid 0.25 0.125 >256 >256 
Daptomycin 2 2 >256 >256 
Nisin 16 16 >64 >64 
bMIC: biofilm minimum inhibitory concentration; MBEC: Minimum biofilm 
eradication concentration. Results are representative of at least three independent 
experiments 
 
As Ag
+
-containing dressings typically release Ag
+
 at concentrations ranging from 
70-100 g/ml (Warriner & Burrell, 2005), the results obtained from this study would 
suggest that such dressings would be unsuitable for the treatment of chronic wounds 
with a biofilm component. Indeed, during the course of this study, a separate 
investigation revealed that a range of commercial Ag
+
-containing dressings were unable 
completely to eradicate biofilms of S. aureus, P. aeuriginosa or E. coli grown in a 
chronic wound model (Kostenko et al., 2010). However, given this result, it is unclear 
what could be used in place of Ag
+
 to treat chronic wound infections with a biofilm 
component. As demonstrated in this and in prior studies, antibiotics currently in clinical 
use are also ineffective at eradicating biofilms. There is evidence to suggest that 
biocides such as hydrogen peroxide, N-propanol and a commercial mixture of propanol, 
ethanol and chlorhexidine can eradicate biofilms of S. epidermidis (Presterl et al., 
2007); however, these compounds are also known to reduce the healing of wounds 
drastically. The novel porphyrin compound, XF-73 was found to be able to eradicate 
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biofilms at a concentration close to its MIC and would therefore be of benefit in treating 
biofilm-associated infections. This compound is currently in stage-one clinical trials as 
a topical antibacterial agent (I. Chopra, personal communication). Nevertheless, this 
study highlights the urgent need to develop new compounds with anti-biofilm activity 
for use in antibacterial chemotherapy. 
 3.3.2. Staphylococcal resistance to Ag
+
 
3.3.2.1. Survey of staphylococcal isolates for Ag
+
 resistance 
In order to provide a comprehensive assessment of current Ag
+
 susceptibility amongst 
the staphylococci, a large collection of isolates obtained from a range of locations 
should be surveyed (Chopra, 2007). To fulfil these criteria, a collection of 
1006 staphylococcal isolates was assembled for this study, primarily consisting of 
isolates obtained from patients in a number of hospitals from the UK, Denmark, Italy, 
France and Canada. Of the 1006 isolates, 876 were S. aureus (including 
meticillin-resistant and vancomycin-intermediate strains) and 130 were 
coagulase-negative staphylococci (CoNS), representing 18 different species/subspecies 
(Table 3.3). At least 230 isolates in the collection came from patients with burns and 
diabetic foot ulcers in clinics where therapeutic Ag
+
 was known to be in use at the time 
of isolation. Silver nitrate MICs were determined against each isolate using the CLSI 
agar dilution method (i.e. using MH medium).  
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Table 3.3. Staphylococcal species present in culture collection 
Species Number of isolates 
S. aureus 876  (comprising 706 MSSA, 166 MRSA 
and 4 VISA isolates) 
S. epidermidis 38 
S. rostri 10 
S. lugdenensis 8 
S. haemolyticus 7 
S. intermedius 7 
S. saprophyticus 7 
S. sciuri 6 
S. simulans 6 
S. xylosus 6 
S. caprae 5 
S. hominis 5 
S. schleiferi 5 
S. capitis 4 
S. cohnii (subspecies cohnii) 4 
S. cohnii (subspecies urealyticum) 3 
S. hominis (subspecies novobiosepticum) 3 
S. pseudintermedius 3 
S. warneri 3 
 
All isolates from the collection were found to be susceptible to AgNO3 at concentrations 
between 8 and 16 g/ml, with the exception of a single isolate of S. intermedius for 
which AgNO3 had an MIC of 4 g/ml. As there are no breakpoints for Ag
+
, the 
AgNO3 MIC that corresponds to clinically significant Ag
+
 resistance in staphylococci is 
unknown (Chopra, 2007). However, as the AgNO3 MICs obtained against isolates in 
this study are equal to that of SH1000, a laboratory strain of S. aureus, and are 
significantly lower than that obtained for a known Ag
+
-resistant strain (J53-pMG101) it 
can be assumed that all isolates in this study would be susceptible to therapeutic 
concentrations of Ag
+
. The universal susceptibility of staphylococci to Ag
+
, as 
suggested by this study, would indicate that Ag
+
 resistance is unlikely to act as a barrier 
to the continued use of Ag
+
 as an alternative for the treatment of topical staphylococcal 
skin infections, including those that are resistant to commonly used topical antibiotics. 
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However, surveillance of bacterial susceptibility to Ag
+
 needs to continue, particularly 
in clinical settings where Ag
+
 is frequently used. As the method described in this study 
produced consistent, reproducible results, it could be utilised by clinicians to determine 
susceptibilities of wound isolates to Ag
+
. Indeed, as this method is based on CLSI 
guidelines that clinical laboratories routinely follow for antibiotic susceptibility testing, 
it would be straightforward for this method to be included in their testing regimens. By 
employing this method, clinicians could be alerted to emergence of Ag
+
 resistance and 
consequently change their prescribing practise accordingly. 
3.3.2.2. Evaluating the propensity for Ag
+
 resistance to emerge in S. aureus via 
endogenous mechanisms  
This study has demonstrated that staphylococci isolated from hospital patients appear 
universally susceptible to Ag
+
. However, the increasing exploitation of Ag
+
 for its 
antibacterial properties will likely provide sufficient selection pressure for the 
emergence of Ag
+
-resistant staphylococci at some point in the future (Chopra, 2007). It 
would therefore be of benefit to ascertain the ease with which Ag
+
 resistance can 
emerge in a laboratory setting, as this could be used to inform clinicians and appropriate 
regulatory bodies of the potential risks in using therapeutic Ag
+
 without appropriate 
stewardship. Although a previous study revealed that endogenous resistance to Ag
+
 
could be selected in S. aureus, the time taken for resistance to arise, the mechanism of 
resistance, or the fitness cost associated with the resistance phenotype was not assessed 
(Kaur et al., 1987). The present study therefore sought to select endogenous 
Ag
+
 resistance in S. aureus, and characterise the mechanism and fitness cost associated 
with any Ag
+
-resistance phenotype that arises. 
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To select for endogenous Ag
+
 resistance, S. aureus strains SH1000 and MRSA 252 (a 
strain representative of the EMRSA-16 lineage endemic to hospitals in the UK), were 
continuously exposed to sub-inhibitory concentrations of Ag
+
 in the form of repeated 
microdilution broth MICs, using an extended concentration gradient of AgNO3. The 
extended range of AgNO3 concentrations would in principle allow for incremental 
increases in Ag
+
 resistance to occur, and has been previously used to select for 
endogenous resistance to daptomycin, a lipopeptide antibiotic reserved for treating 
infections caused by multidrug-resistant S. aureus and vancomycin-resistant enterococci 
(VRE) (Friedman et al., 2006). Continuous Ag
+
 exposure was carried out for six weeks 
(42 days), as this is the typical amount of time in which a patient with a burn or chronic 
wound is treated with an Ag
+
-containing product (Dr Chris Roberts, Smith and Nephew, 
personal communication). Parallel experiments were also performed using daptomycin 
instead of AgNO3 (Figure 3.2). 
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Figure 3.2: Susceptibility of S. aureus SH1000 and MRSA252 continuously passaged in sub-inhibitory concentrations of AgNO3 (a) or 
daptomycin (b). 
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After 42 days of continuous exposure to Ag
+
, selection of S. aureus strains with reduced 
susceptibility to Ag
+
 did not occur. This result appears to contrast with that obtained by 
Kaur et al. (1987); however as this prior study did not reveal the length of selection 
necessary for the emergence of Ag
+
 resistance, it is possible that the length of selection 
used in the present study was insufficient to select an Ag
+
 resistance phenotype. 
Alternatively, the strain of S. aureus used by Kaur et al. may have possessed genetic 
factors that predisposed it to developing Ag
+
-resistance. Nevertheless, the inability to 
select for Ag
+
-resistance in S. aureus strains over such a prolonged period indicates that 
the emergence of Ag
+
 resistant S. aureus by endogenous mechanisms in a clinical 
setting is likely to be rare.  
In contrast to Ag
+
 resistance, continuous exposure of strains to daptomycin resulted in 
rapid selection of isolates with a reduced daptomycin susceptibility. Daptomycin had an 
MIC of 3 and 2.25 g/ml against isolates of MRSA252 and SH1000 respectively 
following continuous exposure for four days, which is in both cases above the resistance 
breakpoint considered by the CLSI for clinically-relevant daptomycin resistance 
(≥2 g/ml) (Wayne, 2012). After further exposure (20 days), isolates were selected to 
which daptomycin had an MIC of >10 g/ml.  
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3.4 Conclusions  
This study has demonstrated that the susceptibility of bacterial isolates to Ag
+
 can be 
determined by the CLSI agar dilution method used for antibiotic susceptibility testing. 
By employing this method, it was determined that staphylococci isolated from hospital 
patients are universally susceptible to Ag
+
. Given the substantial sample size and 
geographical diversity of isolates used in this study, the results obtained indicate that the 
prevalence of staphylococcal Ag
+
 resistance in the clinical environment is minimal or 
non-existent. In addition, the inability to select endogenous Ag
+
 resistance in S. aureus 
over a period of 6-weeks would suggest that the propensity for staphylococcal Ag
+
 
resistance to arise in the future is limited. These results would therefore indicate that 
Ag
+
-containing compounds remain a promising alternative for the treatment of topical 
staphylococcal infections that are resistant to commonly used antibacterials. 
Nevertheless, although the probability of staphylococcal Ag
+
 resistance emerging is 
low, clinicians would be advised to utilise the standardised method presented in this 
study to monitor Ag
+
 susceptibility amongst clinical isolates and contain the spread of 
Ag
+
 resistance if it emerges.  
While the above results favour the continued use of Ag
+
, staphylococcal biofilms were 
found to be refractory to eradication by Ag
+
 at concentrations higher than that found in 
commercially available Ag
+
 dressings. In addition, Ag
+
 was shown to be bacteriostatic 
against planktonic cultures of S. aureus at 4X MIC. This would suggest that the utility 
of Ag
+
 is likely to be limited for treating wound infections that are poorly vascularised 
(where the host immune response would be compromised), or contain bacteria in a 
biofilm mode of growth. As there is little information as to the true efficacy of 
Ag
+
-containing dressings in the treatment of chronic wound infections (Bergin & 
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Wraight, 2006; Vermeulen et al., 2007), it is clear that further in vivo studies are 
required to justify the continued use of Ag
+
 in this manner. 
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Chapter four: Antibacterial mode of action of Ag+ 
Abstract 
The mechanism by which Ag
+
 exerts its antibacterial effect is unclear. Although Ag
+
 
can bind to a range of cellular macromolecules, the link between such binding and any 
subsequent impact on cell viability has yet to be established. Furthermore, Ag
+
 exposure 
has also been proposed to induce the formation of reactive oxygen species that are 
known to cause oxidative damage to intracellular components and may therefore also 
contribute to the antibacterial mode of action of Ag
+
. Using mode of action studies 
frequently used in the pre-clinical evaluation of new antibacterial agents these aspects 
were explored in S. aureus.  
Exposure of S. aureus to Ag
+
 at 4X MIC resulted in a rapid (10 min) and simultaneous 
inhibition of the the incorporation of radiolabelled precursors into DNA, RNA, protein 
and peptidoglycan, which is a hallmark of a nonspecific antibacterial effect typically 
associated with membrane damage. Membrane damage was confirmed by the 
BacLight™, K+-leakage and DiSC3(5) assays. Against carboxyfluorescein-filled 
liposomes with a phospholipid content analogous to that of S. aureus membranes, Ag
+
 
caused no overt damage, suggesting Ag
+
 does not cause membrane damage by 
interfering with the phospholipid bi-layer. DNA microarray analysis of Ag
+
-exposed 
cultures revealed a substantial number of genes encoding membrane proteins were up 
regulated, together with genes encoding anaerobic mechanisms of energy utilisation. 
Taken together, these results suggest that Ag
+
-mediated membrane damage arises from 
Ag
+
 binding to and disrupting the structure of integral membrane proteins, which is 
sufficient to permit leakage of intracellular components. 
96 
 
 
Exposure of S. aureus to Ag
+
 resulted in the generation of ROS, as evidenced by 
increased activity of Ag
+
 against strains lacking ROS-protection mechanisms. The 
source of ROS is likely from Ag
+
 damage to the electron transport chain components as 
evidenced by the up-regulation of genes involved in anaerobic mechanisms of energy 
generation. However, as the killing and membrane-damaging activity of Ag
+
 were not 
perturbed under anaerobic conditions, the generation of ROS does not appear to 
contribute directly to the antibacterial MOA of Ag
+
. 
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4.1. Introduction 
Silver has been used for centuries to treat infection (Klasen, 2000a). Its broad spectrum 
of activity and relatively minimal toxicity make it an ideal topical antibacterial agent. 
However, the mechanism by which the silver cation (Ag
+
) exerts an antibacterial effect 
is poorly understood. Given the clinical success of Ag
+
, defining its antibacterial 
mode-of-action (MOA) would be beneficial as these properties could, for example, help 
identify compounds that may have synergistic activity when used in combination with 
Ag
+
, allow for the development of Ag
+
-containing compounds with improved activity or 
reduced toxicity to enable systemic usage, or be used to guide the rational design of 
future antibacterial agents.  
As described in Chapter 1, a myriad of cellular targets are purportedly affected by Ag
+
, 
including DNA, enzymatic processes and the cell membrane. However, the ability of 
Ag
+
 to inhibit enzymatic processes in vitro does not necessarily imply that this 
contributes to the antibacterial MOA of Ag
+
 in vivo. Furthermore, studies that have 
reported effects of Ag
+
 on DNA have utilised prolonged (≥4 h) incubation times, and 
the possibility that Ag
+
-mediated DNA damage is secondary to other effects of Ag
+
 
cannot therefore be excluded (Feng et al., 2000). An imaging study using TEM revealed 
that Ag
+
 exposure resulted in detachment of the cell membrane from the cell wall and 
prompted the formation of structural defects within the bacterial membrane, which is 
indicative of membrane damage (Jung et al., 2008). However, this study again exposed 
strains to Ag
+
 for a prolonged period (>2 h); thus this effect may too be secondary to the 
primary action of Ag
+
. Nevertheless, Lok et al. (2006) demonstrated that against E. coli, 
Ag
+
 caused a rapid (5 min) loss of membrane potential and leakage of K
+
 and ATP from 
cells (Lok et al., 2006), which would seem to suggest a role for the membrane in the 
antibacterial MOA of Ag
+
 that warrants further investigation.  
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In addition, Ag
+
-mediated inhibition of components of the electron transport chain (such 
as NADH dehydrogenase) is known to stall electron transfer and generate favourable 
conditions for O2
-
 generation (Bragg & Rainnie, 1974, Messner & Imlay, 1999), and 
subsequent production of the toxic hydroxyl radical (HO
.
) via the Fenton reaction 
(Gordon et al., 2010). However, it is unclear to what extent HO
.
 contributes to the 
antibacterial activity of Ag
+
, as methods previously used to detect HO
. 
were recently 
shown to be unreliable (Keren et al., 2013). Furthermore, results from studies 
demonstrating the antibacterial activity of Ag
+
 under anaerobic conditions (where HO
.
 
would not be generated), are contradictory, with one study indicating that the 
antibacterial activity of Ag
+
 is perturbed under anaerobic conditions (Park et al., 2009), 
and another finding no difference in Ag
+
 activity between aerobic and anaerobic 
environments (Xiu et al., 2011). It is therefore clear that further studies are required to 
define the role of HO
.
 (and ROS in general) in the antibacterial MOA of Ag
+
.  
 4.2. Objectives 
The objectives of the work presented in this chapter were 
 to investigate the antibacterial MOA of Ag+ against S. aureus, using assays 
routinely employed as part of the pre-clinical evaluation of new antibacterial 
drugs.  
 to determine if S. aureus generates ROS upon exposure to Ag+ and to establish 
if sufficient ROS are generated to overcome intrinsic protection mechanisms 
and contribute to the antibacterial activity of Ag
+
.   
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4.3. Results and Discussion 
Monitoring the ability of an antibacterial compound to inhibit biosynthesis of cellular 
macromolecules can provide insights into its mode of action (O'Neill & Chopra, 2004). 
As most antibacterial agents inhibit DNA, RNA, protein or peptidoglycan biosynthesis, 
prior studies have measured the rate at which radiolabelled precursors are integrated 
into these macromolecules (Oliva et al., 2001; Oliva et al., 2004; Hobbs et al., 2008; 
Ooi et al., 2009). By comparing the rate of incorporation between drug-exposed and 
drug-free cultures, inhibition of macromolecular synthesis can be detected and 
quantified. Thus, the ability of AgNO3 to inhibit incorporation of radiolabelled 
precursors into DNA, RNA, protein and peptidoglycan was assessed and compared with 
the activity of antibacterial agents known specifically to inhibit these biosynthetic 
pathways (ciprofloxacin, rifampicin, tetracycline and vancomycin, respectively) 
(Figure 4.1). In contrast to the control compounds, AgNO3 caused substantial and 
comparable inhibition of all four biosynthetic pathways after 10 min. This non-specific 
inhibition is indicative of disruption to energy producing metabolic pathways, or 
membrane damage sufficient to cause leakage of intracellular components essential for 
cell viability. Indeed, this inhibition profile has been described before for the 
membrane-damaging agents XF-73, daptomycin and clofazimine (Oliva et al., 2004; 
Hobbs et al., 2008; Ooi et al., 2009). 
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Figure 4.1. Inhibitory activity of AgNO3 and comparator compounds against incorporation of 
radiolabelled precursors into protein (A), DNA (B), RNA (C) and peptidoglycan (D). Error bars represent 
the standard deviation from at least three independent replicates 
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To further explore the antibacterial target of Ag
+
, five B. subtilis whole-cell biosensors 
each containing a luciferase reporter gene fused to promoters induced by inhibiton of 
fatty acid, protein, DNA, RNA and cell envelope biosynthesis were employed. These 
constructs have previously been shown to be of benefit in mode of action studies of 
novel antibacterial compounds such as ferrimycin A1, 8-hydroxyquinoline and juglone 
(Urban et al., 2007; Mariner et al., 2011).
 
Through gene expression profiling, inhibitors 
of fatty acid, protein, DNA, RNA and cell-envelope biosynthesis were shown to induce 
the genes fabHB, yheI, yorB, yvgS and ypuA respectively (Urban et al., 2007). While 
fabHB is known to encode an acyl carrier protein synthase, the function of the other 
genes remains unknown. The promoters of these genes were fused to a luciferase gene 
by Urban et al., allowing for induction of expression to be quantified by luminescence 
(Urban et al., 2007).  
Cultures of each biosensor were exposed to a range of concentrations of AgNO3 and 
control agents and the luminescence of each sample recorded following an incubation 
period (Table 4.1). Exposure of the biosensor strains to their positive control agents 
resulted in a greater than two-fold increase in luminescence at concentrations of 
0.5 g/ml (vancomycin), 0.1 g/ml (triclosan), 0.02 g/ml (ciprofloxacin), 0.001 g/ml 
(rifampicin) and 0.02 g/ml (fusidic acid). Exposure of the strains to AgNO3 failed to 
elicit a significant increase in luminescence. The inability of AgNO3 to induce any of 
the biosensors again suggests that Ag
+
 likely has a non-specific antibacterial MOA such 
as membrane damage. This is reinforced by a previous study showing that compounds 
known to perturb the bacterial cell membrane (valinomycin, CTAB and chlorhexidine) 
also fail to induce any of the B. subtilis biosensors (Mariner et al., 2011). Although 
AgNO3 failed to induce any of the biosensor strains, care must be taken in interpreting 
results from studies utilising inducible reporters when exposed to an antibacterial agent 
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with an unknown MOA. The compound may directly inhibit production of the reporter 
molecule (or the reaction catalysed by the reporter molecule), or quench the output of 
the reporter. To confirm that this did not occur with AgNO3, cultures of the DNA 
biosensor were exposed to 0.02 g ciprofloxacin/ml (i.e. the concentration that 
produced maximal induction). Immediately prior to addition of luciferin,  volumes of 
AgNO3 stock solution were added to cultures to achieve final concentrations in the 
range of 0.125 to 64 g/ml and luminescence values obtained to calculate fold increase 
in induction (data not shown). At concentrations up to 16 g/ml, AgNO3 had no effect 
on the output of the DNA reporter, with levels of induction comparable to that seen with 
cultures exposed to ciprofloxacin alone. However, at concentrations greater than 
16 g/ml, a substantial reduction in output could be observed (>50%), suggesting that at 
these concentrations AgNO3 directly inhibits the reaction mediated by luciferase. 
Nevertheless, given that induction of the B. subtilis biosensors is typically seen at 
concentrations at or below the MIC of the compound tested (Urban et al., 2007; Mariner 
et al., 2011) and the MIC of AgNO3 against B. subtilis (8 g/ml) is below the 
concentration at which an inhibitory effect is seen against luciferase, the results 
obtained in this study truly represent the inability of AgNO3 to induce any of the 
biosensors, indicating that the MOA of Ag
+
 is distinct from the specific inhibition of the 
pathways these biosensors detect. 
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Table 4.1. Relative expression of B. subtilis biosensors by AgNO3 and control 
compounds  
Antibacterial 
agent 
Maximal induction ratio of B. subtilis biosensors (±SD) 
Cell-envelope Protein DNA RNA Fatty-acid 
Silver nitrate 1.1 (±0.1) 1.0 (±0.1) 1.3   (±0.1) 1.1 (±0.4) 0.9 (±0.2) 
Vancomycin 3.6 (±0.4) 0.6 (±0.1) 0.9 (±0.2) 0.5 (±0.1) 1.0 (±0.01) 
Fusidic acid 0.1 (±0.2) 3.1 (±0.1) 0.8 (±0.02) 1.1 (±0.2) 0.8 (±0.1) 
Rifampicin 0.3 (±0.1) 1.6 (±0.1) 1.0 (±0.1) 2.7 (±0.2) 0.4 (±0.1) 
Ciprofloxacin 1.6 (±0.2) 1.0 (±0.2) 62.5 (±12.1) 0.9 (±0.1) 1.0 (±0.2) 
Triclosan 0.9 (±0.2) 0.9 (±0.2) 1.6 (±0.4) 0.8 (±0.04) 5.0 (±0.1) 
The maximal induction ratio represents the maximum reporter signal of the biosensor when 
exposed to a test compound as a ratio of the signal from drug-free biosensor cultures. Results 
represent means and standard deviations arising from at least three independent experiments. 
Values in bold are above the published threshold for induction and represent induction of the 
reporter. 
 
4.3.1. Activity of Ag
+
 against the S. aureus membrane 
The non-specific inhibition of biosynthetic processes by AgNO3 could be the result of 
damage to the cell membrane and consequent loss of intracellular components. Multiple 
assays have been developed to assess the effect of antibacterial agents on the bacterial 
membrane; for example, following exposure to an antibacterial agent for 10 min, the 
BacLight™ assay can be used to evaluate % membrane integrity relative to drug-free 
(100 % integrity) and SDS-treated (0 % integrity) controls based on the uptake of 
membrane-permeable and membrane-impermeable dyes (SYTO-9 and propidium 
iodide), respectively (O'Neill et al., 2004). The kinetics of membrane damage can be 
determined by measuring the leakage of small ions (such as K
+
), and the fluorescent 
reporter DiSC3(5) can be used to establish the effect of a compound on bacterial 
membrane potential (Hobbs et al., 2008; Ooi et al., 2009). As each assay provides a 
different insight into the effect of a compound on the bacterial membrane, all three 
assays were used to determine if membrane damage contributes to the MOA of Ag
+
. 
However, as the BacLight™ and DiSC3(5) assays both rely upon the measuring the 
fluorescence of a fluorophore, confirmation was first required that AgNO3 did not 
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fluoresce at the excitation wavelengths used in these assays, or quench the fluorescence 
of any of the fluorophores, as this would lead to an incorrect interpretation of the 
results. Thus, the emission spectra for a solution of Ag
+
 at 4X MIC was determined 
between 400 and 700 nm using excitation wavelengths equivalent to those used in each 
assay (485 and 622nm for  BacLight™ and DiSC3(5) respectively). No significant 
fluorescence emission could be detected at either of the excitation wavelengths used 
(data not shown). Furthermore, Ag
+
 did not quench the fluorescence of DiSC3(5), 
SYTO-9, or propidium iodide (data not shown), suggesting that both BacLight™ and 
DiSC3(5) assays are suitable for use with AgNO3.   
Following exposure of S. aureus SH1000 to AgNO3 and comparator antibiotics at 
4X MIC, membrane integrity decreased by 97%, as measured by the BacLight™ assay 
(Table 4.2). This decrease was comparable to that seen with bacteria exposed to nisin 
(99 %), clofazimine, XF-70, XF-73 and CTAB (all 100 %); compounds that are known 
to damage the bacterial membrane (Ruhr & Sahl, 1985, O'Neill et al., 2004; Oliva et al., 
2004; Hobbs et al., 2008; Ooi et al., 2009). The membrane potential (as measured by 
DiSC3(5) fluorescence) was also affected in cells exposed to Ag
+
, with a >50% decrease 
observed over 1 h (Figure 4.2b). The kinetics of membrane damage following 
Ag
+
 exposure was further explored by measuring the leakage of intracellular K
+
 from 
S. aureus SH1000 over 2 h (Figure 4.2a). In less than 10 min, >90 % of intracellular K
+
 
was lost from cells exposed to Ag
+
; again, this effect was comparable with that 
observed for bacteria exposed to nisin. The rapid and substantial loss of bacterial 
membrane integrity following Ag
+
 exposure strongly suggests that the antibacterial 
activity of Ag
+
 results directly from damage to the cell membrane.  
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Table 4.2. Effect of AgNO3 and comparator compounds on S. aureus 
SH1000 membrane integrity as determined by BacLight
TM
 assay 
Compound % Membrane integrity after 10 min 
(±SD) 
AgNO3 2.9 (0.3) 
Nisin 0.8 (0.3) 
CTAB 0 (0) 
Clofazimine 0 (0) 
XF-70 0 (0) 
XF-73 0 (0) 
Tetracycline 98.9 (2.2) 
Rifampicin 97.1 (3.6) 
Vancomycin 93.9 (2.7) 
Ciprofloxacin 88.5 (5.7) 
Results represent means and standard deviations from at least three independent experiments. 
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Figure 4.2. Effect of AgNO3 and comparator compounds on intracellular K
+
-levels (A) and membrane potential (B) of S. aureus SH1000. 
Error bars represent the standard deviation from at least three independent replicates. Data for Figure 4.3(A) were collected by L. Oyama, 
University of Leeds. 
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Cells treated with certain membrane-damaging compounds (for example nisin and 
CTAB) eventually undergo lysis as a consequence of damage to the membrane (O'Neill 
et al., 2004). As Ag
+
 exposure caused membrane damage, the ability for Ag
+
 to prompt 
cell lysis was examined. S. aureus SH1000 cells re-suspended in 5mM HEPES, 
5mM glucose buffer (pH 7.2) were exposed to AgNO3 at 4X MIC and monitored for 
lysis over a period of 2 h by optical density measurements (Figure 4.3). Results were 
compared with that of nisin-exposed cultures. Over 2 h, the optical density of cultures 
exposed to nisin decreased by approximately 37%, indicating that lysis was occurring. 
There was no change in the optical density of cultures exposed to AgNO3, suggesting 
that under these conditions Ag
+
 did not cause lysis. To confirm the absence of lysis and 
to detect any changes in the morphology of cells exposed to Ag
+
, cells were visualised 
using scanning electron microscopy (SEM) following exposure to Ag
+
 or nisin for 5 and 
120 min. Cells visualised after 120 min exposure to nisin showed evidence of lysis, but 
no lysis or other changes in cell morphology were seen for cells treated with 
AgNO3 (Figure 4.3). 
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Figure 4.3. Effects of Ag
+
 and nisin on the integrity of S. aureus SH1000 re-suspended in HEPES/glucose buffer as determined by optical 
density measurements at 600nm and SEM. Values shown are the means of three replicates from three independent experiments. Broken lines 
point to scanning electron micrographs of cells taken from cultures at indicated time-points. Error bars represent standard deviations from the 
mean. Electron micrographs were taken by L. Oyama, Univeristy of Leeds. 
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Although Ag
+
 can cause membrane damage that is sufficient to permit leakage of K
+
 
and allow for ingress of propidium iodide (molecular mass of 668 Da), the inability of 
Ag
+
 to prompt cell lysis indicates that the extent of membrane damage caused by Ag
+
 is 
unclear. To provide further insight into the extent of Ag
+
-mediated membrane damage, 
the ability of larger molecules to leak out of the cell was assessed following Ag
+
 
exposure. Previously, the 464 kDa protein -galactosidase has been used for this 
purpose, as it can catalyze the cleavage of 4-methylumbelliferyl-β-D-galactoside into the 
fluorophore 4-methylumbelliferone, thus allowing for its detection and quantitation 
(O'Neill et al., 2004) in the extracellular milieu. Against S. aureus SH1000 
(SH1000 constitutively expressing -galactosidase), AgNO3 caused no apparent leakage 
of -galactosidase when used at concentrations of 4X MIC, suggesting that the extent of 
membrane damage was insufficient to permit leakage of this molecule (Table 4.3). This 
is in contrast with exposure to nisin and CTAB which in both cases resulted in >3-fold 
increase in -galactosidase release from cells, in agreement with a previous study 
(O'Neill et al., 2004). However, as discussed above, a compound with an unknown 
MOA may directly inhibit the catalytic activity of a reporter molecule. Unfortunately, 
this occurred with -galactosidase exposed to Ag+, as exposure to concentrations of 
AgNO3 greater than 1 g/ml directly inhibited the ability of -galactosidase to produce 
4-methylumbelliferone (Figure 4.4). As a consequence, it remains unclear if 
Ag
+
-mediated damage to S. aureus membrane is sufficient to permit leakage of 
-galactosidase. This result nevertheless emphasizes the necessity of appropriate control 
experiments when working with reporter molecules, to prevent incorrect interpretation 
of results obtained from such assays.  
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Table 4.3. Ability of AgNO3 and comparator agents to induce -galactosidase 
leakage in S. aureus SH1000  
Compound Relative -galactosidase release (±SD) 
AgNO3 0.4 (0.1) 
Tetracycline 1.1 (0.1) 
Vancomycin 0.9 (0.1) 
CTAB 4.0 (0.4) 
Nisin 4.4 (0.3) 
Values and standard deviations shown are the mean of three independent experiments. Values of 
≥2-fold compared with drug-free controls are considered significant for release of 
-galactosidase. 
 
 
 
 
 
Figure 4.4. Activity of -galactosidase in the presence of AgNO3 and comparator 
compounds. Values shown are the mean of at least three independent experiments. 
Error bars represent the standard deviation from the mean. 
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Ag
+
 must first pass through the cell membrane. As it has been demonstrated that Ag
+
 
causes rapid damage to cell membranes, the leakage of intracellular components will 
result in cell death irrespective of the ability Ag
+
 to bind and inhibit intracellular targets. 
Indeed, prior studies demonstrating the interaction of Ag
+
 with cellular macromolecules 
used prolonged incubation times (Feng et al., 2000; Jung et al., 2008), suggesting that 
these effects would only occur long after membrane damage. Thus, it seems likely that 
the bacterial membrane is the primary target of Ag
+
, although the subsequent binding of 
Ag
+
 to intracellular components and their consequent inhibition may accelerate bacterial 
killing.  
Various intracellular enzymes are known to be inhibited by Ag
+
, thus it seems 
reasonable to assume that the ability of Ag
+
 to bind and inhibit intracellular targets is 
non-specific. To test this hypothesis, the catalytic activities of three unrelated enzymes 
(chymotrypsin, malate dehydrogenase and RNA polymerase) were determined in the 
presence of AgNO3 and comparator agents. In each case, the half maximal inhibitory 
concentration (IC50) was determined (Table 4.4). As expected, tetracycline, vancomycin 
and ciprofloxacin demonstrated no inhibitory activity against all three enzymes at the 
concentrations tested, whereas rifampicin had an IC50 of 0.021 g/ml against 
RNA polymerase, which is consistent with its known mode of action (Konno et al., 
1973). In contrast, AgNO3 was found to be inhibitory against all three enzymes, with 
IC50 values at concentrations equivalent to ≤4 x MIC of AgNO3 against S. aureus. The 
promiscuous inhibitory activity of Ag
+
 against enzymes at biologically relevant 
concentrations would appear to suggest that Ag
+
 does not have a specific intracellular 
target. Therefore once Ag
+
 has reached the intracellular milieu, it could inhibit multiple 
biological processes simultaneously. As inhibition of certain cellular processes are 
known to result in cell death rather than cessation of growth (i.e. transcription, 
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DNA synthesis), this property of Ag
+
 may contribute to the rate of cell killing following 
disruption of the membrane. Nevertheless, as the cell membrane is the primary target of 
Ag
+
, the remainder of this study attempted to elucidate the component of the membrane 
that is targeted by Ag
+
 to elicit an antibacterial effect.   
 
Table 4.4. Inhibitory activity of AgNO3 and comparator agents against malate 
dehydrogenase, chymotrypsin and RNA polymerase 
 Compound IC50 against (g/ml)(±SD) 
Malate 
dehydrogenase 
Chymotrypsin RNA polymerase 
AgNO3 19.37 (0.09) 26.56 (0.03) 4.94 (0.052) 
Tetracycline >128 >128 >128 
Ciprofloxacin >128 >128 >128 
Rifampicin >128 >128 0.021 (0.008)  
Vancomycin >128 >128 >128 
Values and standard deviations shown are the mean of three independent experiments 
  
4.3.2. Identification of the target(s) of Ag
+
 at the S. aureus cell membrane 
The bacterial cell membrane predominantly consists of a phospholipid bilayer 
interspersed with integral membrane proteins (i.e. containing one or more domains 
inserted into, or spanning the membrane) and peripheral membrane proteins (proteins 
tethered to the membrane by a lipid tail, or via binding to an integral membrane 
protein). Unlike eukaryotes, bacterial membranes do not contain sterols (which serve to 
stabilise eukaryotic membranes), but instead contain hopanoids, which are believed to 
serve a similar purpose (Madigan et al., 2010). Damage to either the phospholipid 
bilayer or to integral membrane proteins could potentially permit leakage of 
intracellular components and cause cell death; thus, Ag
+
 presumably achieves its 
antibacterial activity via one or both of these mechanisms. To investigate the ability of 
Ag
+
 to disrupt the phospholipid component of membranes, phospholipid vesicles 
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(liposomes) encapsulating the fluorescent dye carboxyfluorescein at a self-quenching 
concentration were used. This system has been employed previously to ascertain the 
effects of agents on phospholipid bilayer integrity, as following sufficient damage to the 
bilayer, carboxyfluorescein will leak from the liposome, reaching an extracellular 
concentration that is no longer self-quenching; consequently, leakage (and therefore 
damage) can be detected and quantified by measuring carboxyfluorescein fluorescence 
(Jung et al., 2004; StGelais et al., 2007). As the phospholipid content of cell membranes 
differs between species and organisms (Epand et al., 2007), three separate liposome 
formulations were created analogous to staphylococcal, E. coli and mammalian 
membranes respectively, for which the compositions are detailed in section 2.6.3. 
Furthermore, to ensure that identical concentrations of liposomes were used in each 
experiment, 0.5 % (w/w) of rhodamine-labelled phosphatidylethanolamine was 
incorporated into each liposome preparation; the concentration of liposomes in any 
given solution could then be calculated based on rhodamine absorbance at 570 nm. 
Following exposure of liposomes to compounds for 10, 60 and 180 minutes, 
carboxyfluorescein fluorescence was measured  and % liposome integrity calculated 
relative to Triton X-100 (0% integrity) and solvent-only (100% integrity) treated 
controls (Table 4.5). Prior to carrying out this assay, it was confirmed that none of the 
compounds tested fluoresced at 520 nm when excited at 485 nm, or quenched the 
fluorescence of carboxyfluorescein (data not shown). 
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Table 4.5. Activity of AgNO3 and comparator compounds against liposomes 
analogous to the phospholipid bilayers of S. aureus, E. coli and mammalian cell 
membranes 
Compound % Liposome integrity 
S. aureus liposomes  E. coli liposomes  Mammalian 
liposomes  
10 
min 
60 
min 
180 
min 
10 
min 
60 
min 
180 
min 
10 
min 
60 
min 
180 
min 
AgNO3 101.0 
(1.22) 
99.3 
(1.57) 
104.4 
(0.73) 
96.9 
(0.82) 
102.4 
(1.33) 
98.4 
(4.51) 
93.1 
(5.01) 
98.5 
(4.14) 
99.1 
(0.52) 
CTAB 99.2 
(0.51) 
94.3 
(0.80) 
98.3 
(0.38) 
91.4 
(3.01) 
82.0 
(2.71) 
76.9 
(2.66) 
104.2 
(3.51) 
97.3 
(0.88) 
97.8 
(0.40) 
SDS 42.7 
(0.77) 
0  
(0) 
0  
(0) 
51.6 
(1.68) 
0  
(0) 
0  
(0) 
31.0 
(0.66) 
0  
(0) 
0  
(0) 
Tetracycline 90.3 
(1.41) 
92.2 
(0.53) 
88.6 
(2.72) 
102.1 
(3.22) 
98.1 
(1.17) 
99.2 
(1.37) 
93.4 
(1.66) 
95.0 
(0.11) 
99.7 
(0.29) 
Vancomycin 99.8 
(1.10) 
100.1 
(0.19) 
101.5 
(0.70) 
90.8 
(5.38) 
99.6 
(1.22) 
101.1 
(0.20) 
98.4 
(0.29) 
99.5 
(0.44) 
99.6 
(0.07) 
Gentamicin 95.2 
(0.93) 
93.3 
(1.08) 
96.7 
(0.38) 
96.8 
(3.71) 
95.5 
(0.17) 
100.5 
(0.02) 
102.8 
(1.90) 
95.2 
(2.98) 
98.6 
(0.20) 
Rifampicin 100.4 
(1.37) 
99.8 
(1.78) 
104.6 
(3.46) 
97.2 
(0.81) 
97.0 
(1.21) 
97.9 
(0.53) 
99.1 
(0.71) 
102.5 
(3.90) 
103.4 
(4.73) 
Ampicillin 102.0 
(1.08) 
100.9 
(0.88) 
98.5 
(1.99) 
95.4 
(2.24) 
97.4 
(2.01) 
100.5 
(1.58) 
91.3 
(0.56) 
98.2 
(1.00) 
99.5 
(0.29) 
XF-73 0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
0 
(0) 
0  
(0) 
Clofazimine 22.3 
(0.55) 
0  
(0) 
0  
(0) 
38.9 
(0.94) 
0  
(0) 
0  
(0) 
33.4 
(1.26) 
0  
(0) 
0  
(0) 
Daptomycin 62.5 
(0.06) 
21.7 
(0.15) 
5.21 
(0.07) 
97.3 
(2.11) 
94.5 
(1.92) 
86.3 
(3.51) 
90.4 
(0.42) 
93.3 
(0.28) 
91.5 
(0.66) 
Values and standard deviations shown are the mean of at least three independent experiments. 
Values demonstrative of a substantial loss of membrane integrity (≤70%) are highlighted in bold  
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Antibacterial agents that do not target the bacterial membrane (e.g. tetracycline, 
vancomycin, gentamicin, rifampicin and ampicillin) had no effect upon liposome 
integrity after 3 h exposure. In contrast, compounds previously shown damage bacterial 
membranes (SDS, clofazimine and XF-73) had a significant effect on the integrity of all 
three types of liposome, albeit with different kinetics of damage. In the BacLight™ 
assay, SDS is used as the 0% membrane integrity control as the damage it causes to 
bacterial membranes is extensive and rapid (O'Neill et al., 2004). However against all 
three liposome formulations, the damage mediated by SDS was not as rapid, as after 
10 min exposure liposome integrities remained at >30%. This result may suggest that 
the rapid damage to bacterial membranes by SDS is a consequence of combined effects 
against both the phospholipid bilayer and integral membrane proteins. Indeed, the 
ability of SDS to denature proteins is well established (Bhuyan, 2010). The lack of 
integral membrane proteins also appeared to affect the rapidity of damage mediated by 
clofazimine, when comparing the results obtained here against the BacLight™ data in 
Table 4.2. Unlike SDS, clofazimine is used as a systemic antibacterial agent in the 
treatment of leprosy (caused by Mycobacterium leprae) (Oliva et al., 2004); it is 
therefore unusual that clofazimine causes equivalent damage to liposomes with a 
mammalian phospholipid composition, as this would imply that clofazimine would 
demonstrate equivalent toxicity to mammalian and bacterial cells. Nevertheless, 
although clofazimine can cause fatal enteropathy in patients taking high doses over a 
prolonged period, it has successfully been used clinically for over 40 years (Parizhskaya 
et al., 2001). This would therefore indicate that either the membrane-damaging activity 
of clofazimine is not present when used in vivo, or that other components of the 
mammalian cell membrane protect the phospholipid bilayer from the activity of 
clofazimine. In either case it is apparent that mammalian liposomes should not be 
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considered as a reliable surrogate for mammalian toxicity studies, and appropriately 
validated studies should instead be utilised in evaluating the bacterial specificity of any 
new antibacterial agent. 
As with SDS and Triton X-100, CTAB is a surfactant that causes damage to bacterial 
membranes, yet it caused no significant reduction in liposome integrity after 3 h 
exposure. This would therefore suggest that it cannot directly disrupt the phospholipid 
bilayer and must damage bacterial membranes via an alternate mechanism, for example 
by denaturing integral membrane proteins, or via the induction of reactive oxygen 
species. Indeed, analysis of spontaneous mutants of E. coli displaying resistance to 
CTAB revealed mutations in soxR, which resulted in constitutive expression of the 
soxRS regulon that provides protection against O2
-
 (Nakata et al., 2010). Thus, ROS 
(particularly O2
-
) generation appears critical to the antibacterial MOA (and therefore the 
membrane-damaging activity) of CTAB.  
Daptomycin is a member of the lipopeptide family of antibacterial agents used for the 
treatment of antibiotic-resistant Gram-positive skin and skin-structure infections and 
S. aureus bacteraemia and right-sided endocarditis (Carpenter & Chambers, 2004). The 
antibacterial mode of action of daptomycin against S. aureus results from Ca
2+
-mediated 
insertion into the phospholipid bilayer of the cell membrane that causes damage 
sufficient to permit the leakage of Mg
2+
, K
+
 and ATP, leading to the de-energisation of 
cellular processes and cell death (Jung et al., 2004; Hobbs et al., 2008). At 4X MIC, 
daptomycin caused substantial damage to staphylococcal liposomes, with liposome 
integrity decreasing to 5 % after 3 h exposure. The calcium cation is believed to be 
essential for the antibacterial action of daptomycin as it allows daptomycin to interact 
with the negatively-charged head groups of the staphylococcal phospholipid bilayer 
(Jung et al., 2004). This requirement also provides an indication as to why daptomycin 
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displays selective toxicity towards bacteria, as mammalian cell membranes consist of 
neutral phospholipids, which likely prevents insertion of the Ca
2+
-daptomycin complex 
as a consequence of a reduced charge interaction. The inability of daptomycin to insert 
into mammalian membranes has been demonstrated previously (Jung et al., 2004) and 
again in this study, as no damage to liposomes with a mammalian phospholipid 
composition could be observed over 3 h exposure to daptomycin. Daptomycin was also 
unable to damage liposomes consisting of phospholipid analogous to E. coli 
membranes. Although the membranes of Gram-negative bacteria do contain negatively 
charged phospholipid, the overall proportion is substantially less than that found in 
Gram-positive bacteria (~20% vs 100% respectively) (Epand et al., 2007; Epand et al., 
2010). It therefore seems that there is an insufficient quantity of negatively-charged 
phospholipid to permit insertion of daptomycin at concentrations necessary to cause 
overt damage. Daptomycin does not display any antibacterial activity against 
Gram-negative bacteria and it was believed that this was a sole consequence of 
impermeability afforded by the outer membrane; however, the data presented here 
suggest that the target of daptomycin is not present in Gram-negative bacteria. Recent 
attempts have been made to potentiate Gram-positive-specific antibacterial agents (e.g. 
vancomycin, telavancin) for use in treating Gram-negative infections, under the 
assumption that the antibacterial target is present but is protected by intrinsic resistance 
mechanisms (such as outer membrane impermeability or efflux) (Gordon et al., 2010; 
Hornsey et al., 2012). The data presented here suggest that daptomycin would not be a 
suitable candidate for such a potentiation. This was confirmed in further experiments 
that are beyond the scope of this thesis to be presented here (Randall et al., 2013). 
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As with CTAB, Ag
+
 failed to damage any of the three types of liposomes. It was 
confirmed that this was not a consequence of Ag
+
 quenching the fluorescence of 
carboxyfluorescein, as Ag
+
 did not impact fluorescence measurements of Triton 
X-100-treated liposomes (data not shown). The inability of Ag
+
 to damage phospholipid 
bilayers implies that Ag
+
 targets another component of the cell membrane (e.g. integral 
membrane proteins), or as hypothesized above with CTAB, induces the formation of 
ROS which in turn causes oxidative damage to the membrane. There have been 
previous suggestions that the Ag
+
 may induce the formation of excessive ROS that 
could contribute to the antibacterial activity of Ag
+
 by causing oxidative damage to 
intracellular components (including the membrane), and evidence to support this has 
been provided by studies in both E. coli and S. epidermidis (Park et al., 2009; Gordon et 
al., 2010). However the extent of the contribution ROS provides to the antibacterial 
activity of Ag
+
 remains unclear. This area therefore warrants further investigation. 
4.3.3 Contribution of reactive oxygen species to the antibacterial MOA of Ag
+
  
S. aureus employs a number of mechanisms to mitigate the effect of ROS. To protect 
against O2
-
, S. aureus utilises superoxide dismutases SodA and SodM, which convert 
O2
-
 into H2O2 and O2 (Karavolos et al., 2003), whilst protection from H2O2 results from 
its conversion into H2O and O2 by catalase (encoded by katA) and H2O alone by alkyl 
hydroperoxide reductase (encoded by ahpC) (Cosgrove et al., 2007). To confirm that 
Ag
+
 can induce ROS formation in S. aureus, AgNO3 MICs were determined against 
strains deficient in one or more of the above mechanisms, as any reduction in MIC 
against these strains would be indicative of excessive ROS production (Table 4.6). 
Silver nitrate MICs did not differ between the parental strain and strains deficient in one 
ROS protection mechanism, with the exception of strain MHKA (sodA) which was 
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susceptible to AgNO3 at half the concentration required to inhibit SH1000. Strain 
KC043 (deficient in AhpC and KatA) also showed a two-fold reduction in MIC, 
whereas strain MHKAM, which lacked SodA and SodM was the most susceptible to 
AgNO3, with a four-fold decrease in the MIC compared with the parental strain. As 
strain MHKAM was the most susceptible to Ag
+
, it seems likely that O2
-
 is the primary 
ROS produced by Ag
+ 
exposure. Given that Ag
+
 is unable to produce ROS directly as 
part of a Fenton-like reaction, excess O2
-
 presumably arises from a cellular process that 
has been affected by Ag
+
. This is supported by the fact that strains deficient in SodA 
alone also demonstrate reduced susceptibility to Ag
+
, as it has been shown that SodA 
provides protection primarily against endogenous sources of O2
-
 (SodM protects from 
exogenous sources) (Karavolos et al., 2003).  
Table 4.6. Inhibitory activity of AgNO3 and comparator agents against S. aureus 
strains deficient in one or more ROS detoxification mechanisms 
Compound MIC (g/ml) 
SH1000 KS100 
(katA) 
MHKM 
(sodM) 
MHKA 
(sodA) 
MHKAM 
(sodA, 
sodM) 
KC043 
(ahpC, 
katA) 
Silver nitrate 16 16 16 8 4 8 
Rifampicin 0.016 0.016 0.016 0.016 0.016 0.016 
CTAB 2 2 2 2 2 2 
Gentamicin 0.125 0.125 0.125 0.125 0.125 0.125 
Vancomycin 2 2 2 2 2 2 
Tetracycline 0.5 0.5 0.5 0.5 0.5 0.5 
Fusidic acid 0.5 0.5 0.5 0.5 0.5 0.5 
Penicillin G 0.25 0.25 0.25 0.25 0.25 0.25 
Ciprofloxacin 4 4 4 4 1 1 
       
 
In contrast to the results observed with Ag
+
, the MIC of control antibiotics (with the 
exception of ciprofloxacin) did not differ between strains. This would suggest that ROS 
are not part of the antibacterial effect of these compounds. Against E. coli Kohanski et 
al. (2007) have suggested that the aminoglycoside, -lactam and fluoroquinolone 
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antibiotic classes prompt a common mechanism of bacterial cell death, involving the 
production of O2
-
 from hyper-stimulation of the electron transport chain and subsequent 
conversion of excessive O2
-
 into OH
. 
via the Fenton reaction (Kohanski et al., 2007; 
Kohanski et al., 2008). The same study also provided limited evidence to suggest that 
the same phenomenon could be observed in S. aureus following exposure to norfloxacin 
or vancomycin, as increased levels of OH
.
 could be detected in cells (Kohanski et al., 
2007). This ‗ROS hypothesis‘ is currently an issue of contention within the scientific 
literature, as multiple papers have refuted the findings of Kohanski et al. (Ricci et al., 
2012; Keren et al., 2013; Liu & Imlay, 2013). However these articles all utilised E. coli 
or Salmonella spp. as their model organisms, thus it is unclear if the ROS hypothesis 
remains correct for S. aureus. The results in Table 4.6 suggest that out of the 
bactericidal antibiotics tested only ciprofloxacin induced ROS formation; however, this 
experiment only measured the contribution of ROS to the inhibitory effect of a 
compound and not its bactericidal activity. Thus, to provide further insight into this 
issue, the bactericidal activity of compounds against strains deficient in peroxide- or 
O2
-
-protection mechanisms was assessed (Figure 4.5). Compared with the parental 
strain, no significant increase in killing activity could be observed for the bactericidal 
antibiotics ciprofloxacin, penicillin G, gentamicin, rifampicin, or vancomycin against 
KC043 or MHKAM. This result would therefore suggest that ROS are not responsible 
for the killing activity of bactericidal antibiotics against S. aureus and thus provide 
further evidence to refute the hypothesis suggested by Kohanski et al., (2007). Unlike 
the results obtained for bactericidal antibiotics, AgNO3 was significantly more effective 
at killing KC043 and MHKAM, with decreases in cell viability of 3.4 and 
5.5 log10 respectively over 24 h (compared with 2.51 log10 against SH1000). This result 
provides further indication that Ag
+
 can induce the formation of ROS. CTAB also 
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demonstrated greater killing activity against MHKAM, with a 7-log10 reduction in cell 
number compared with a 5.5-log10 reduction against SH1000. Earlier, it was described 
that previous studies indicate a role for ROS (particularly O2
-
) generation in the MOA 
of CTAB in E. coli. The results obtained in this study provide further evidence to the 
possibility that a similar mechanism may also occur in S. aureus.    
  
 
        1
2
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Figure 4.5. Bactericidal activity of AgNO3 and comparator compounds against S. aureus strains deficient in ROS detoxification 
mechanisms. Values are means of at least three independent experiments. Error bars represent the standard deviation from the mean.  
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Against strains lacking ROS-protection mechanisms, Ag
+
 displayed greater inhibitory 
and killing activity, which would suggest that Ag
+
 induces increased ROS formation. To 
provide further validation for this hypothesis, the inhibitory and killing activity of Ag
+
 
against S. aureus was determined in an anaerobic environment. As there will be no 
O2 available for the production of ROS, the killing activity of Ag
+
 should decrease if 
ROS contributes to Ag
+
 activity. As demonstrated in Figure 4.6, this was not the case, 
as the reduction in cell viability of SH1000 cultures exposed to AgNO3 in the presence 
or absence of O2 was comparable. This suggests that although Ag
+
 exposure generates 
increased levels of ROS, the levels produced are insufficient to affect cell viability when 
ROS protection mechanisms are intact. These results contradict the findings of Park et 
al. (2009), who found that under anaerobic conditions the cidality of Ag
+
 decreased 
against both S. aureus and E. coli (Park et al., 2009). However in their study, Park et al. 
performed killing experiments against cells suspended in phosphate buffer, instead of 
MHB used in this study. In Chapter 3 it was demonstrated that Ag
+
 is potently 
bactericidal against cultures suspended in buffer; thus, it is possible at this level of 
activity, sufficient ROS are generated to contribute to the antibacterial effect. 
Furthermore, unlike culture media, buffer may lack components that can contribute to 
mitigating the effects of ROS; for example, the manganese ion (Mn
2+
) has been shown 
to provide significant levels of protection against O2
-
 (Karavolos et al., 2003). Finally, 
Park et al. measured reduction in cell viability after 40 and 60 min exposure to Ag
+
, 
whereas in this study viable cell counts were performed only after 24 h exposure, thus 
under anaerobic conditions the kinetics of Ag
+
-mediated cell death could differ without 
affecting the loss of cell viability over a prolonged period. 
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Figure 4.6. Bactericidal activity of AgNO3 and comparator agents against S. aureus under aerobic and anaerobic conditions. Values are 
means of three independent experiments. Error bars represent the standard deviation from the mean. 
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In contrast to AgNO3, other antibacterial agents exhibited reduced bactericidal activity 
in an anaerobic environment. This may suggest that these compounds partially rely on 
ROS generation. However, under anaerobic conditions cultures of SH1000 took longer 
(5 h compared with 2.5 h under aerobic conditions) to reach the correct optical density 
for this experiment (OD600= 0.2 units). A reduced growth rate impacts the efficacy of 
killing by bactericidal agents, as most compounds require active metabolic processes to 
exert an optimal antibacterial effect (Kolter et al., 1993; Mascio et al., 2007). Indeed, 
this has been demonstrated for -lactams, rifampicin, ciprofloxacin and vancomycin 
(Mascio et al., 2007; Ooi et al., 2010). It is therefore unclear if the inability to generate 
ROS directly affects the bactericidal activity of these compounds. Aminoglycosides 
(e.g. gentamicin) require an active membrane potential to permit uptake into target cells 
(Vakulenko & Mobashery, 2003); this membrane potential cannot be generated under 
anaerobic conditions, explaining the substantial decrease in killing activity observed for 
gentamicin against SH1000. However, the antibacterial target of CTAB is the bacterial 
membrane, which is present irrespective of growth phase. Consequently, the reduced 
activity of CTAB under anaerobic conditions provides further corroboration of the 
hypothesis that the antibacterial activity of this compound is partially reliant upon the 
generation of ROS. 
Although the generation of ROS does not appear to affect the inhibitory activity of Ag
+
, 
it is still unclear if ROS impacts the kinetics of Ag
+
-mediated cell death. ROS could 
accelerate Ag
+
 killing by contributing to bacterial membrane damage, or by causing 
oxidative damage to other cellular macromolecules. To determine if ROS contributes to 
bacterial membrane damage, the effect of Ag
+
 on bacterial membrane integrity under 
anaerobic conditions was determined using the BacLight™ assay (Table 4.7). With the 
exception of CTAB, all compounds known to cause membrane damage (including Ag
+
) 
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retained this ability under anaerobic conditions with no apparent decrease in potency 
compared with that observed in an aerobic environment. 
Table 4.7. Effect of AgNO3 and comparator compounds on S. aureus 
SH1000 membrane integrity under anaerobic conditions, as determined by 
BacLight
TM
 assay 
Compound % Membrane integrity after 10 min (±SD) 
Aerobic Anaerobic 
AgNO3 2.9 (0.3) 3.5 (0.2) 
Nisin 0.8 (0.3) 0 (0) 
CTAB 0 (0) 38.9 (1.3) 
Clofazimine 0 (0) 0 (0) 
Tetracycline 98.9 (2.2) 99.0 (4.8) 
Rifampicin 97.1 (3.6) 95.4 (2.9) 
Vancomycin 93.9 (2.7) 96.6 (3.4) 
Ciprofloxacin 88.5 (5.7) 94.6 (4.0) 
Values and standard deviations shown are the mean of at least three independent experiments 
 
The decrease in the membrane-damaging activity of CTAB against S. aureus 
membranes under anaerobic conditions seems to indicate that ROS are at least partially 
responsible for the membrane-damaging properties of this compound in an aerobic 
environment. This process is likely a consequence of ROS-mediated peroxidation of 
unsaturated lipids contained in the phospholipid bilayer and/or carbonylation of integral 
membrane proteins, leading to their denaturation (Imlay, 2013). Confirmation that these 
mechanisms are involved could be achieved using previously established assays (Placer 
et al., 1966; Luo & Wehr, 2009). Nevertheless, as CTAB retains some activity against 
S. aureus membranes under anaerobic conditions it seems that this compound can also 
cause direct damage to the membrane. As CTAB does not affect the integrity of 
liposomes, this direct damage must rely upon the interaction of CTAB with integral 
membrane proteins.  
In contrast to CTAB, Ag
+
 was equally effective at damaging S. aureus membranes 
under aerobic and anaerobic conditions. This observation confirms that Ag
+
 causes 
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direct damage to the membrane and is not due to the action of ROS. As described with 
CTAB above, Ag
+
 did not damage liposomes, which implies that the phospholipid 
bilayer is not the target for Ag
+
 in bacterial membranes. Membrane damage by Ag
+
 
presumably therefore relies on the denaturation of one or more integral membrane 
proteins, which allows for the leakage of intracellular components. Although this study 
has confirmed that Ag
+
-mediated membrane damage occurs in this manner by a process 
of elimination, final confirmation of this MOA could be achieved by determining the 
ability of Ag
+
 to damage liposomes into which integral membrane proteins have been 
inserted (also known as proteoliposomes), or vesicles comprising bacterial membrane 
extract (i.e. phospholipid and protein) that are extruded in a buffer containing 
carboxyfluorescein at a self-quenching concentration. Although attempts were made to 
create both during the course of this study, numerous technical difficulties were 
encountered which resulted in vesicles that could not retain carboxyfluorescein. 
 4.3.4. Genetic techniques to identify integral membrane proteins responsible for Ag
+ 
activity 
Since Ag
+
 is non-specific in its ability to inhibit the activity of bacterial enzymes, it is 
likely that Ag
+
 can bind indiscriminately to integral membrane proteins to inhibit their 
function. However, certain integral membrane proteins may be more susceptible to 
damage by Ag
+
 (i.e. possess more functional groups that can co-ordinate Ag
+
), or be 
essential in maintaining bacterial membrane integrity. If this were the case, then 
preventing or altering the expression of such membrane proteins would likely affect the 
susceptibility of the host to Ag
+
. 
In previous studies of bacterial gene function, transposon mutagenesis has been utilised, 
to generate derivatives that contain a transposable element integrated into a random 
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location within the chromosome (Bordi et al., 2008). If transposon integration occurs 
within the coding region, or between the coding region and the promoter of an extant 
gene, then the protein product of this gene will no longer be expressed/no longer 
function (also known as insertional inactivation). If the protein product of this gene is 
involved in regulating expression of other proteins, then these too will be affected. 
Other studies have engineered transposable elements with outward-facing promoters of 
varying strengths, thus enabling expression of antisense mRNA (resulting in 
knockdown of expression of extant genes), or altering expression levels of downstream 
genes, depending on the orientation which it inserts into the chromosome (Bertram et 
al., 2005; Meredith et al., 2012). Indeed, such a system was used to aid in identifying 
the target of CDFI, a novel antibacterial agent, as an essential membrane protein 
encoded by SAV1754 in S. aureus COL (Wang et al., 2011; Meredith et al., 2012). 
Recently a near-saturation transposon library (comprising approximately 20,500 strains) 
was constructed in S. aureus SH1000 using the modified mariner transposon 
InsTet
G+
2
Cm
, which contains a chloramphenicol resistance marker to allow selection of 
transposants, and a tetracycline-inducible outward-facing promoter (Pxyl/tet) (Blake & 
O'Neill, 2013). Using this library, genes affecting the susceptibility of S. aureus to 
vancomycin, nisin and daptomycin were identified by determining the ability of each 
transposant to grow in the presence of each antibiotic at concentrations that were sub- or 
supra-inhibitory against non-mutagenised SH1000 (Blake & O'Neill, 2013). As this 
library has been previously used successfully with antibacterial agents, it was used to 
screen against Ag
+
 in an attempt to identify integral membrane proteins that are 
essential to the ability of Ag
+
 to damage the cell membrane. It was decided to screen for 
mutants that were hyper-susceptible to Ag
+
, as together with potentially identifying 
genes essential to the membrane-damaging activity of Ag
+
, other targets could be 
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identified that may lead to the rational design of compounds to potentiate the activity of 
Ag
+
.  
Prior to screening the library, the concentration of AgNO3 allowing for selection of 
transposants that were hyper-susceptible to Ag
+
 required optimization. To achieve this, 
a small collection (n=576) of transposants from the library were inoculated onto petri 
dishes containing a range of sub-inhibitory concentrations of AgNO3. The concentration 
that led to inhibition of at least one transposant per 96 transposants screened, while 
permitting growth of non-mutagenised SH1000 was found to be 12 g AgNO3/ml. 
Using this concentration, 13,056 transposants from the library were screened, from 
which 34 strains were hyper-susceptible to the concentration of AgNO3 used. Upon 
re-test, 14 strains were found to be false-positive results (i.e. could grow in the presence 
of 12 g AgNO3/ml) and were excluded from further testing. MICs of ciprofloxacin and 
rifampicin were determined against the remaining hyper-susceptible transposants to 
establish if they showed a generalised growth defect. All transposants tested were 
hyper-susceptible to both compounds, suggesting a growth defect was present and that 
hyper-susceptibility in these strains was not specific to Ag
+
. As a consequence, 
identification of the genetic locus disrupted by the transposon in each isolate was not 
carried out. Given the inability to identify putative targets of Ag
+
 within the cell 
membrane using transposon library screening, Ag
+
-mediated membrane damage likely 
arises from denaturation of multiple integral membrane proteins, or from damage 
against an integral membrane protein that is essential for cell survival. Therefore, in 
order to explore the mechanism of Ag
+
-mediated membrane damage further an 
alternative technique (DNA microarray) was employed.  
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The use of DNA microarrays to analyse bacterial transcriptomes (i.e. levels of global 
gene expression) following exposure to an antibacterial agent have been previously 
employed to provide insights into the antibacterial MOA for a variety of compounds; 
for example transcriptional analysis of S. aureus following exposure to daptomycin 
revealed a similar expression profile to cells exposed to inhibitors of peptidoglycan 
synthesis (vancomycin, oxacillin) and compounds that affect the membrane (nisin, 
CCCP), suggesting that daptomycin may have a dual mechanism of action (Muthaiyan 
et al., 2008). Furthermore, the targets of two novel antibacterial agents; moiramide B 
and a phenyl-thiazolylurea derivative were identified in B. subtilis following 
transcriptome analysis of cultures exposed to these agents (Freiberg et al., 2005). In the 
case of Ag
+
 exposure, transcriptome analysis could reveal putative protein targets for 
Ag
+
 at the membrane (which would be indicated by increased expression of genes 
encoding such proteins as the organism attempts to replace protein damaged by Ag
+
). 
Furthermore, as described with daptomycin above, the transcriptional profile of cells 
exposed to Ag
+
 could be compared with profiles arising from exposure to antibacterial 
agents with a known MOA, or from growth under different conditions (e.g. anaerobic, 
or biofilm-promoting environments) to identify any similarities that could provide 
additional insight into the effects of Ag
+
 exposure. Indeed, in the case of S. aureus, a 
database of transcriptional responses to a variety of conditions arising from published 
studies is available (the Staphylococcus aureus microarray meta-database [SAMMD], 
accessible at http://www.bioinformatics.org/sammd/ last accessed 23
rd
 July 2013), thus 
allowing for a comprehensive comparison between these conditions and Ag
+
 exposure.  
Analysis of gene expression was carried out in S. aureus SH1000 by DNA microarray. 
Previous studies into bacterial gene expression following antibiotic exposure 
recommended using a sub-inhibitory concentration of the antibacterial to be tested, as a 
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supra-inhibitory concentration may result in gene expression that is not specific to the 
antibacterial being used, but instead related to cell death (Freiberg et al., 2005; O'Neill 
et al., 2009). A number of expression studies have used a sub-inhibitory concentration 
of antibacterial agent sufficient to inhibit growth of exponential phase cultures by 25% 
(relative to drug-free controls) after 40 min exposure (Freiberg et al., 2005; O'Neill et 
al., 2009); therefore it was decided to do the same with Ag
+
 exposure. The 
concentration of AgNO3 that produced this result was found to be 1.125 g/ml. Total 
RNA was extracted from Ag
+
-exposed and control cultures (three biological replicates 
of each) and subjected to transcriptional profiling by DNA microarray. Transcriptomes 
from Ag
+
-exposed and drug-free cultures were then compared using LaserGene 
ArrayStar 4 software to identify differentially expressed genes (i.e. genes up- or 
down-regulated by at least 2-fold). This is summarised graphically in Figure 4.7.  
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Figure 4.7. Scatter plot of differentially expressed genes following exposure to 
AgNO3. Outer green lines represent the threshold (2-fold) considered significant for 
differential gene expression between AgNO3-treated and drug-free control cultures. 
Genes with a ≥2-fold change in expression are shown in white. 
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In cells exposed to Ag
+
, 526 genes were differentially regulated (339 up, 187 down) by 
at least 2-fold when compared with drug-free controls. This represents 18% of the total 
gene content of the S. aureus SH1000 genome. A description of the function for each 
gene that was differentially regulated was downloaded from the NCBI database; 
however, a substantial number (n=332) did not have an assigned function. As a 
consequence, BLASTp searches (at http://blast.ncbi.nlm.nih.gov/Blast.cgi, last accessed 
23
rd
 July 2013) were employed to identify conserved homologues with a known 
function in other bacterial species. A list of the differentially expressed genes together 
with a description of their function can be found in Appendix 1 (Table A1.1 and A1.2. 
To assist with analysis, all genes were grouped into cellular role categories using the 
J. Craig Venter Institute (JCVI) comprehensive microbial resource (CMR) database 
(http://cmr.jcvi.org/cgi-bin/CMR/CmrHomePage.cgi, last accessed 23
rd
 July 2013), 
which utilises a number of homology searches and prediction algorithms to assign each 
gene a proposed functional role within one of seventeen categories (each containing 
their own sub-categories) (Tanenbaum et al., 2010) (Figure 4.8). 
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Figure 4.8. Assignment of genes up-regulated under Ag
+
 exposure to JCVI cellular 
role categories 
 
Of the up-regulated genes with a known function (n=217), a relatively large proportion 
(37%) were associated with processes involving the cell membrane (i.e. genes grouped 
into the ―Cell envelope‖ and ―Transport and binding proteins‖ categories). This result is 
in agreement with the finding that Ag
+
 causes membrane damage, as gene up-regulation 
of membrane-associated components will likely occur as a secondary effect resulting 
from Ag
+
-mediated membrane stress, or as a consequence of direct binding (and 
inhibition) of Ag
+
 to the protein products of these genes. As the CMR database does not 
provide information on if the protein product of the gene is an integral membrane 
protein (and can thus be a direct antibacterial target of Ag
+
), putative integral membrane 
Amino acid biosynthesis (n=28)
Biosynthesis of cofactors, prosthetic
groups, and carriers (n=6)
Cell envelope (n=20)
Cellular processes (n=18)
Central intermediary metabolism (n=7)
DNA metabolism (n=3)
Energy metabolism (n=33)
Fatty acid and phospholipid metabolism
(n=4)
Mobile and extrachromosomal element
functions (n=14)
Protein fate (n=11)
Protein synthesis (n=2)
Purines, pyrimidines, nucleosides, and
nucleotides (n=4)
Regulatory functions (n=6)
Transport and binding proteins (n=61)
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proteins were identified using the program SOSUI, which uses the physicochemical 
properties of the amino acids present in a sequence to identify an integral membrane 
protein based on three parameters; the presence of -helices, and the hydrophobicity 
and amphiphilicity of any -helices detected (Hirokawa et al., 1998). This analysis is 
based on the fact that transmembrane proteins typically contain large transmembrane 
helices with a hydrophobic core, with amphiphilic residues at the ends of the helix to 
stabilise the structure (Hirokawa et al., 1998). Screening of all up-regulated genes 
following Ag
+
 challenge revealed that 93 encoded predicted integral membrane proteins 
(Table A1.3). 
Of the genes identified, there appeared to be little functional or structural similarity 
between their protein products (i.e. number of transmembrane domains, presence of 
cysteine residues) that might indicate a shared site of interaction with Ag
+
, suggesting 
that the interaction between Ag
+
 and integral membrane proteins is likely non-specific. 
Furthermore, it is unclear which of these proteins, when inhibited by Ag
+
, would be 
damaged sufficiently to perturb the bacterial membrane. This could be investigated by 
expressing each of these proteins individually and inserting them into 
carboxyfluorescein-filled proteoliposomes prior to challenge with Ag
+
 and assessment 
of proteoliposome damage. However, due to the difficulties already described in 
constructing proteoliposomes, combined with the need to express 93 functionally active 
proteins, this experiment was not performed, but could be considered for future work to 
specify the proteins responsible for the primary MOA of Ag
+
.   
Together with membrane-associated proteins, a number of genes associated with 
intracellular processes were also up-regulated following Ag
+
 exposure (such as amino 
acid and energy metabolism) (Table 4.7). It is unknown if Ag
+
 can pass through the 
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membrane and into the cytoplasm of bacteria when used at sub-inhibitory 
concentrations; however, it would seem likely that at sub-inhibitory concentrations any 
Ag
+
 present would bind to the membrane and not pass into the intracellular milieu. If 
this is the case, then genes associated with intracellular processes are likely up-regulated 
as an indirect effect of Ag
+
 exposure. Indeed, most up-regulated genes involved in 
intracellular processes can be linked to the inhibition of specific transport proteins by 
Ag
+
 (Tables 4.8-4.10). For example, a number of integral membrane proteins involved 
in the transport of free or peptide-associated amino acids were up regulated, probably as 
a consequence of direct inhibition by Ag
+
. As this would reduce the concentration of 
intracellular amino acids, up-regulation of genes involved in amino acid biosynthesis 
occurs as a homeostatic mechanism in an attmpt to restore the amino acid concentration 
to levels necessary for cellular maintenance and growth (Table 4.8). A similar affect can 
be observed with the inhibition of sugar import and the up-regulation of genes involved 
in alternative metabolic pathways, which may also include use of amino acids as an 
energy source (thus acting as an additional stimulus to up-regulation of genes involved 
in amino acid biosynthesis) (Table 4.9) and the inhibition of iron uptake and 
up-regulation of genes involved in siderophore synthesis (Table 4.10). 
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Table 4.8. Association between inhibition of amino acid transport following 
Ag
+
exposure and up-regulation of processes involved in amino acid biosynthesis 
Gene Fold Change Function 
Amino acid transport 
SAOUHSC_00168 2.1 up Peptide ABC transporter, permease protein, 
putative 
SAOUHSC_00169 3.7 up Peptide ABC transporter, permease protein, 
putative 
SAOUHSC_00932 2.4 up Oligopeptide ABC transporter, permease 
protein, putative 
SAOUHSC_01450 2.7 up Putative amino acid permease/transporter 
protein 
SAOUHSC_02967 2.3 up Arginine/ornithine antiporter, putative 
Amino acid biosynthesis 
SAOUHSC_00008 2.1 up Histidine ammonia-lyase 
SAOUHSC_00076 4.6 up Ornithine cyclodeaminase, putative 
SAOUHSC_00150 3.0 up Ornithine aminotransferase 
SAOUHSC_00340 2.9 up Trans-sulfuration enzyme family protein 
SAOUHSC_00341 3.0 up Cystathionine gamma-synthase, putative 
SAOUHSC_00435 2.1 up Glutamate synthase, large subunit, putative 
SAOUHSC_01319 2.1 up Aspartate kinase 
SAOUHSC_01367 2.0 up Anthranilate synthase component II 
SAOUHSC_01371 2.7 up Tryptophan synthase subunit beta 
SAOUHSC_01372 2.1 up Tryptophan synthase subunit alpha 
SAOUHSC_01394 2.3 up Aspartate kinase 
SAOUHSC_01451 3.3 up Threonine dehydratase 
SAOUHSC_01452 3.2 up Alanine dehydrogenase 
SAOUHSC_02281 3.5 up Dihydroxy-acid dehydratase 
SAOUHSC_02282 2.6 up Acetolactate synthase large subunit 
SAOUHSC_02284 2.5up Ketol-acid reductoisomerase 
SAOUHSC_02285 2.4 up 2-isopropylmalate synthase 
SAOUHSC_02286 2.6 up 3-isopropylmalate dehydrogenase 
SAOUHSC_02287 2.5 up Isopropylmalate isomerase large subunit 
SAOUHSC_02288 2.5 up Isopropylmalate isomerase small subunit 
SAOUHSC_02606 2.8 up Imidazolonepropionase 
SAOUHSC_02607 3.3 up Urocanate hydratase 
SAOUHSC_02965 2.4 up Carbamate kinase 
SAOUHSC_02968 3.6 up Ornithine carbamoyltransferase 
SAOUHSC_03008 3.8 up Imidazole glycerol phosphate synthase subunit 
hisF, putative 
SAOUHSC_03009 4.4 up Imidazole-4-carboxamide isomerase 
SAOUHSC_03013 3.3 up Histidinol dehydrogenase 
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Table 4.9. Association between inhibition of sugar transport following Ag
+
exposure 
and up-regulation of processes involved in sugar utilisation and alternate 
metabolic pathways 
Gene Fold Change Function 
Sugar transport 
SAOUHSC_00158 2.9 up Sucrose-specific PTS system 
component 
SAOUHSC_00177 2.9 up Maltose ABC transporter, 
permease protein, putative 
SAOUHSC_00183 4.1 up Hexose phosphate antiporter uhpt 
SAOUHSC_00209 3.0 up Glucose-specific PTS system 
component 
SAOUHSC_00216 3.2 up Galacticol-specific PTS system 
component 
SAOUHSC_00310 2.5 up Ascorbate-specific PTS system 
component 
SAOUHSC_02597 2.3 up Maltose-specific PTS system 
component 
SAOUHSC_02806 2.4 up Gluconate permease, putative 
Sugar utilisation and alternate metabolic pathways 
SAOUHSC_00088 3.7 up UDP-glucose 4-epimerase  
SAOUHSC_00113 3.2 up Bifunctional 
acetaldehyde-coa/alcohol 
dehydrogenase 
SAOUHSC_00142 4.0 up Formate dehydrogenase 
SAOUHSC_00187 2.4 up Formate acetyltransferase 
SAOUHSC_00188 3.3 up Pyruvate formate-lyase 
1 activating enzyme, putative 
SAOUHSC_00217 3.2 up Sorbitol dehydrogenase, putative 
SAOUHSC_00219 2.8 up Sorbitol dehydrogenase, putative 
SAOUHSC_00291 4.8 up Phospho-fructokinase family 
carbohydrate kinase 
SAOUHSC_00298 3.4 up N-acetylmannosamine-6-phosphat
e 2-epimerase 
SAOUHSC_00608 2.3 up Alcohol dehydrogenase 
SAOUHSC_01846 2.5 up Acetyl-coa synthetase 
SAOUHSC_01849 2.7 up Acetoin utilization protein  
SAOUHSC_02451 2.8 up PTS system, lactose-specific 
component 
SAOUHSC_02452 2.3 up Tagatose 1,6-diphosphate aldolase 
SAOUHSC_02453 2.2 up Tagatose-6-phosphate kinase 
SAOUHSC_02454 2.1 up Galactose-6-phosphate isomerase 
subunit LacB 
SAOUHSC_02455 2.5 up Galactose-6-phosphate isomerase 
subunit 
SAOUHSC_02921 3.3 up Alpha-acetolactate decarboxylase 
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Table 4.10. Association between inhibition of iron following Ag
+
 exposure and 
up-regulation of iron sequestration/transport mechanisms 
Gene Fold change Function 
Iron transport 
SAOUHSC_00071 2.2 up Permease component of 
ABC-type Fe
3+
-siderophore 
transport system 
SAOUHSC_00072 3.3 up Permease component of 
ABC-type Fe
3+ -siderophore 
transport system 
SAOUHSC_00078 3.7 up Siderophore staphylobactin 
biosynthesis protein SbnD  
SAOUHSC_00327 2.3 up Ferrous iron transport permease 
EfeU 
SAOUHSC_02864 2.6 up FeoB family ferrous iron (Fe2+) 
uptake protein 
SAOUHSC_02902 2.7 up FeoB family ferrous iron (Fe2+) 
uptake protein 
Iron sequestration mechanisms  
SAOUHSC_00077 4.5 up Siderophore staphylobactin 
biosynthesis protein SbnC 
(IucA/IucC family siderophore 
biosynthesis protein) 
SAOUHSC_00079 3.1 up Siderophore staphylobactin 
biosynthesis protein SbnE 
(IucA/IucC family siderophore 
biosynthesis protein) 
SAOUHSC_00080 2.7 up Siderophore biosynthesis protein 
SbnF (IucA/IucC family 
siderophore biosynthesis protein) 
SAOUHSC_00081 2.9 up Siderophore staphylobactin 
biosynthesis protein SbnG  
SAOUHSC_00082 2.9 up Siderophore staphylobactin 
biosynthesis protein SbnH/ 
SAOUHSC_00083 3.3 up Siderophore staphylobactin 
biosynthesis protein SbnI 
SAOUHSC_01843 2.5 up Haptoglobin-binding heme 
uptake protein HarA 
SAOUHSC_00130 4.5 up Heme-degrading 
monooxygenase IsdI 
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The inhibition of transport proteins by Ag
+
 may suggest that, at sub-inhibitory 
concentrations, Ag
+
 exposure restricts uptake of sufficient quantities of the intracellular 
substrates required for cell growth and survival. As the concentration of Ag
+
 increases, 
this effect is likely to become more pronounced until a concentration of Ag
+
 sufficient 
to cause lethal damage to the membrane is reached. In pathogenic bacteria, nutrient 
limitation typically leads to the expression of genes involved in virulence and the switch 
to an alternate method of growth (for example biofilm formation) in an attempt by the 
organism to mitigate these effects (Anderson et al., 2006). Indeed, this can be observed 
in the S. aureus transcriptome following sub-inhibitory Ag
+
 exposure, with the 
up-regulation of secreted proteases and mechanisms to protect from host immune 
responses (Table 4.11). Furthermore, components of the ica operon were found to be 
differentially regulated following Ag
+
 exposure. The ica operon encodes components 
responsible for synthesis of polysaccharide intercellular adhesin (PIA) which enables 
attachment of S. aureus to a variety of surfaces, and is the first step in biofilm formation 
(Brady et al., 2006). The propensity of S. aureus to increase the expression of virulence 
factors when exposed to sub-inhibitory Ag
+
 suggests that care should be taken when 
employing therapeutic Ag
+
 for the treatment of bacterial infection, as sub-inhibitory 
concentrations of Ag
+
 could negatively impact on patient morbidity by prompting an 
increase in bacterial virulence, or by triggering a switch to a biofilm mode of growth 
that is highly recalcitrant to eradication by Ag
+
 and other antibacterial agents (as 
described in Chapter three). 
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Table 4.11. Up-regulation of known and putative virulence factors following 
exposure to Ag
+
 
Gene Fold 
Change 
Description Reference 
SAOUHS
C_00069 
2.7 up Staphylococcal protein A (Spa). Inhibits phagocytosis (Palmqvist 
et al., 
2002) 
SAOUHS
C_00089 
4.3 up Capsular polysaccharide biosynthesis 
glycosyltransferase, putative. Extracellular capsule 
production to protect from phagocytosis  
(O'Riordan 
& Lee, 
2004) 
SAOUHS
C_00256 
2.9 up Staphyloxanthin biosynthesis protein, putative. Provides 
protection aginst external sources of oxidative stress 
such as neutrophil respiratory bursts 
(Liu et al., 
2005) 
SAOUHS
C_00259 
2.3 up Virulence protein EssA. Component of the 
ESAT-6 secretion system used to secrete virulence 
factors 
(Russell et 
al., 2011) 
SAOUHS
C_00264 
2.2 up Virulence protein EsaC. Function same as 
SAOUHSC_00259 
(Russell et 
al., 2011) 
SAOUHS
C_00292 
4.4 up Indigoidine synthase A-like protein. Indigoidine is a 
pigment implicated in pathogenicity and protection from 
oxidative stress. 
(Revercho
n et al., 
2002) 
SAOUHS
C_00383 
3.3 up Putative superantigen-like protein. Proposed to limit 
neutrophil recruitment and general modulation of 
immune response 
(Itoh et al., 
2010) 
SAOUHS
C_00384  
2.4 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00389 
5.7 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00390 
3.6 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00391 
3.6 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00393 
2.4 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00399 
3.6 up Putative superantigen-like protein. Function same as 
SAOUHSC_00383 
(Itoh et al., 
2010) 
SAOUHS
C_00674 
2.6 down Staphylococcal accessory protein X (SarX) - Negative 
regulator of agr expression  
(Manna & 
Cheung, 
2006) 
SAOUHS
C_00694 
2.3 down Transcriptional regulator MgrA. Regulator of sarX and 
norB expression 
(Manna & 
Cheung, 
2006) 
SAOUHS
C_01873 
2.4 up Cell-wall-anchored protein SasC. Proposed role in 
intercellular adhesion and biofilm accumulation 
(Schroeder 
et al., 
2009) 
SAOUHS
C_01935 
2.2 up Serine protease SplF. Secreted protease (Popowicz 
et al., 
2006) 
SAOUHS
C_01939 
2.5 up Serine protease SplC. Secreted protease (Popowicz 
et al., 
2006) 
SAOUHS
C_01941 
3.7 up Serine protease SplB. Secreted protease (Popowicz 
et al., 
2006) 
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Table 4.11 (continued) 
SAOUHS
C_01942 
4.1 up Serine protease SplA. Secreted protease (Popowicz 
et al., 
2006) 
SAOUHS
C_01954 
2.1 up Leukotoxin LukD. In combination with LukE forms 
pores in leukocyte cell membranes leading to their death 
(Gravet et 
al., 1998) 
SAOUHS
C_01955 
2.3 up Leukotoxin LukE. In combination with LukD forms 
pores in leukocyte cell membranes leading to their death 
(Gravet et 
al., 1998) 
SAOUHS
C_02971 
4.2 up Zinc metalloproteinase aureolysin, putative. Cleaves 
compliment C3 to assist in S. aureus immune evasion 
(Laarman 
et al., 
2011) 
SAOUHS
C_02998 
3.4 up Capsular polysaccharide biosynthesis protein, Cap5C. 
Function same as SAOUHSC_00089 
(O'Riordan 
& Lee, 
2004) 
SAOUHS
C_02999 
3.8 up Capsular polysaccharide biosynthesis protein Cap5B. 
Function same as SAOUHSC_00089 
(O'Riordan 
& Lee, 
2004) 
SAOUHS
C_03000 
2.7 up Capsular polysaccharide biosynthesis, CapA, putative. 
Function same as SAOUHSC_00089 
(O'Riordan 
& Lee, 
2004) 
SAOUHS
C_03001 
2.8 down Ica operon transcriptional regulator IcaR, putative. 
Negative regulator of ica operon 
(Cramton 
et al., 
1999) 
SAOUHS
C_03002 
3.4 up N-glycosyltransferase IcaA. Catalyses first step of 
polysaccharide intercellular adhesin synthesis 
(Cramton 
et al., 
1999) 
SAOUHS
C_03003 
3.0 up Intercellular adhesion protein D (IcaD). Catalyses 
second step of polysaccharide intercellular adhesin 
synthesis 
(Cramton 
et al., 
1999) 
 
Comparing transcriptomes between S. aureus exposed to Ag
+
 and S. aureus exposure to 
other antibacterial agents or environmental conditions could provide further insight into 
the cellular events occurring following Ag
+
 exposure. Using SAMMD, gene expression 
data from a variety of conditions was compared with that following Ag
+
 exposure. Most 
conditions shared little similarity in gene-expression profiles with Ag
+
 exposure; 
however, comparison between cultures exposed to Ag
+
 and those exposed to the proton 
ionophore CCCP revealed a similar profile in differentially expressed genes, 
particularly those involved in the transport of amino acids and sugars, and subsequent 
processes of amino acid synthesis and utilisation of alternative substrates for energy 
production (Muthaiyan et al., 2008). Furthermore, the expression of genes lgrAB were 
up-regulated under both conditions, as well as in cells exposed to daptomycin, another 
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membrane-damaging compound. The genes lrgAB both encode putative antiholin 
proteins that have previously been found to be overexpressed when the membrane 
potential is disrupted (Patton et al., 2006). This is to be expected for CCCP as it is a 
proton ionophore that dissipates membrane potential. It has previously been 
demonstrated that Ag
+
 exposure dissipates the membrane potential when used at 
4X MIC, however this result suggests that the membrane potential is also impacted 
when used at sub-inhibitory concentrations. The mechanism by which Ag
+
 dissipates 
the membrane potential is likely to be different from that of CCCP, in that it will bind to 
and inhibit membrane proteins involved in the efflux of protons, as opposed to CCCP, 
which forms pores in the membrane to allow effluxed protons to diffuse back into the 
cell. Although there are similarities in gene expression between Ag
+
 and CCCP-exposed 
cultures, a number of differences can also be observed. For example, exposure to CCCP 
leads to up-regulation of a number of genes involved in degradation of proteins, 
peptides and glycopeptides and protein folding and stabilisation (Muthaiyan et al., 
2008). This difference may be a consequence of the different mechanisms by which 
CCCP and Ag
+
 cause membrane damage, or, as the concentration of CCCP used in 
transcriptional analysis was above its MIC against S. aureus, the up-regulation of these 
genes may be a non-specific result of cell death. Nevertheless, other genes that are 
commonly found to be up-regulated by membrane damaging agents are not up-regulated 
following Ag
+
 exposure. The K
+
-import ATPase, encoded by kdpCBA is up-regulated in 
the presence of daptomycin, CCCP, clofazimine and the putative membrane-damaging 
agent sepracor 155342  (Muthaiyan et al., 2008; Mariner, 2011). Again, this may 
indicate a different mechanism by which Ag
+
 causes membrane damage. Indeed, unlike 
Ag
+
, both clofazimine and daptomycin cause membrane damage via disruption of the 
phospholipid bilayer, therefore this mechanism of damage may be more efficient at 
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promoting K
+
 release, leading to the up-regulation of mechanisms to mitigate such 
effects.   
The transcriptomes of Ag
+
-exposed cultures also shared similarities with cultures grown 
under anaerobic conditions. When S. aureus is exposed to anaerobic conditions, its 
transcriptome changes to reflect the reduced output of ATP from the electron transport 
chain (due to the lack of oxygen to act as a terminal electron acceptor) (Fuchs et al., 
2007). However, if a source of nitrate/nitrite is present, these can act as terminal 
electron acceptors, which allow the continued functioning of the electron transport chain 
(Fuchs et al., 2007). To facilitate this, under anaerobic conditions genes encoding 
nitrate reductases and nitrite transporters are all up-regulated (irrespective of whether a 
source of nitrate/nitrite is present) (Fuchs et al., 2007). This effect can also be observed 
in cultures exposed to Ag
+
, with the up-regulation of genes encoding nitrate reductase 
(alpha and beta subunits) (SAOUHSC_02680/02681), assimilatory nitrite reductase 
(SAOUHSC_02684), transcriptional regulator NirR (SAOUHSC_02685), nitrite 
extrusion protein (SAOUHSC_02671) and a nitrite transporter SAOUHSC_00281). If a 
source of nitrate/nitrite is unavailable then S. aureus derives energy from alternate 
sources. This can include mixed acid and butanediol fermentation and the conversion of 
the amino acids arginine, alanine, glycine,
 
and serine into formate by formate 
acetyltransferase and pyruvate-formate lyase. Formate can then be used to generate ATP 
by formate dehydrogenase (Fuchs et al., 2007). Following Ag
+
 exposure, all these 
components were found to be up-regulated (SAOUHSC_00608, 00113, 02282, 02283, 
02921, 01849 00187, 00188 and 00142). This switch to anaerobic mechanisms of 
energy generation would suggest that the electron transport chain is damaged by 
Ag
+
 exposure, thus preventing the generation of ATP by this pathway. Indeed, it has 
been shown that when the electron transport chain is disrupted under aerobic conditions, 
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expression of mixed acid and butanediol fermentation enzymes is up-regulated (Kohler 
et al., 2003; Seggewiss et al., 2006). As all of the components of the electron transport 
chain in S. aureus are membrane-associated or integral membrane proteins, it is likely 
that Ag
+
 directly inhibits one or more of these components. It has been suggested that 
the inhibition of enzymes involved in the initial steps of the electron transport chain by 
Ag
+
 would lead to electron stalling, allowing premature interaction with O2 to produce 
O2
-
 (Park et al., 2009). The results obtained in this current study seem to support this 
hypothesis. However, at sub-inhibitory concentrations of Ag
+
, it appears that damage to 
the electron transport chain is insufficient to generate ROS, as up-regulation of genes 
encoding ROS protection mechanisms (i.e. superoxide dismutases, catalase and alkyl 
hydroperoxide reductase) did not occur. 
During the course of this work, a study into the effect of Ag
+
 on gene expression in 
S. epidermidis was published (Gordon et al., 2010). As expected, a comparison of 
results between studies revealed a number of similarities in gene-expression profiles. In 
particular, genes involved in fermentative processes were up-regulated, whereas those 
encoding TCA cycle components were down regulated, suggesting that under both 
conditions damage to the electron transport chain is occurring. Furthermore, processes 
related to amino acid synthesis and the initial stages of biofilm formation were 
up-regulated, which is indicative of substrate starvation and a switch to a protective 
mode of growth to mitigate this effect. However, a number of discrepancies in gene 
expression also exist between the studies. For example, the iron transport systems of 
S. epidermidis were found to be down-regulated under Ag
+
 exposure, in contrast to the 
results obtained in this study, where equivalent systems were up-regulated. 
Furthermore, in S. epidermidis genes encoding the anti-holin enzymes LgrAB are 
down-regulated, and there was no evidence of inhibition of amino acid or sugar 
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transport proteins. Taken together, this difference may suggest that the mechanism by 
which Ag
+
 damages the S. epidermidis cell membrane differs from S. aureus, or that 
Ag
+
 relies upon an alternate antibacterial target to inhibit S. epidermidis. However, in 
their study Gordon et al. analysed the S. epidermidis transcriptome following exposure 
to a supra-inhibitory concentration of Ag
+
 (20 g AgNO3/ml) (Gordon et al., 2010). It is 
therefore probable that a number of differentially expressed genes are a consequence of 
non-specific effects relating to cell death. Alternatively, at a supra-inhibitory 
concentration of Ag
+
, damage to the bacterial membrane will be more extensive, thus 
the expression of genes encoding membrane-associated and integral membrane proteins 
may differ as a result. 
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Conclusions 
Although Ag
+
 has the potential to inhibit multiple enzymatic processes, the rapid and 
substantial loss of bacterial membrane integrity following exposure to Ag
+
 suggests that 
the primary target of Ag
+
 in S. aureus is the membrane. The observation that Ag
+
 does 
not damage phospholipid bilayers (in the form of liposomes), but causes significant 
up-regulation of a substantial number of integral membrane proteins would suggest that 
Ag
+
 causes membrane damage by non-specific binding to membrane proteins, resulting 
in damage sufficient to permit the leakage of intracellular contents, and ultimately 
leading to cell death (Figure 4.9). Following membrane damage, any remaining 
bioavailable Ag
+
 can enter the cell and bind intracellular components, causing their 
inhibition and accelerating Ag
+
-mediated killing (Figure 4.9). Most antibacterial agents 
target metabolic processes and are therefore ineffective against treating growth-arrested 
cells when these processes are inactive (Mascio et al., 2007; Ooi et al., 2010). This 
makes such compounds ineffective against treating persistent infections where 
growth-arrested cells predominate, such as in chronic wounds (Hurdle et al., 2011). As 
Ag
+
 causes membrane damage, it should retain activity against cells in such a state and 
thus emphasises an advantage of Ag
+
 over other topical antibacterial agents such as 
mupirocin and fusidic acid in the treatment of persistent wounds. However, as 
demonstrated in Chapter 3, this activity does not translate into the ability of Ag
+
 to kill 
growth-arrested cells present within a biofilm. 
In studies using E. coli and S. epidermidis, Ag
+
 has been shown to generate ROS, which 
are believed to contribute to the antibacterial MOA of Ag
+
 by causing oxidative damage 
to essential cellular components; however, the extent of the contribution provided by 
ROS was unclear. The increased inhibitory and killing activity of Ag
+
 observed against 
S. aureus strains deficient in ROS protection mechanisms indicate that Ag
+
 does induce 
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ROS formation, and transcriptional profiling of S. aureus exposed to Ag
+
 revealed that 
Ag
+
 inhibited components of the electron transport chain, which suggests a likely source 
of ROS generation (Figure 4.9). However, although ROS is generated by Ag
+
, this study 
revealed that it was at a concentration insufficient to contribute to the killing activity of 
Ag
+
 or Ag
+
-mediated membrane damage, as under anaerobic conditions the killing 
activity of Ag
+
 and the ability of Ag
+
 to damage S. aureus membranes was not affected. 
Nevertheless, as Ag
+
 induces the production of ROS, it could be combined with other 
ROS-producing compounds to potentiate the antibacterial activity of Ag
+
. Indeed, the 
combination of Ag
+
 with the ROS-producing methyl viologen (Paraquat) was found to 
be synergistic against E. coli (Park et al., 2009).  
  
 
1
4
9
 
 
Figure 4.9. Proposed antibacterial mode of action of Ag
+
 against S. aureus 
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As well as defining the antibacterial MOA of Ag
+
, insights into the antibacterial 
mechanisms of other compounds were provided by this study. The inability of 
daptomycin to disrupt bilayers comprising E. coli phospholipid provided evidence to 
suggest that the antibacterial activity of daptomycin is dependent upon the concentration 
of anionic phospholipids at the cell membrane (Randall et al., 2013). Furthermore, this 
study revealed that the anti-staphylococcal activity of CTAB is reliant upon generation 
of ROS, as its ability to damage membranes and its killing activity was significantly 
reduced under anaerobic conditions. 
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Chapter five: Resistance to Ag+ in Gram-negative bacteria: a 
dissection of endogenous and exogenous mechanisms  
Abstract 
In contrast to the situation in Gram-positive bacteria, high-level Ag
+
 resistance has been 
identified in Gram-negative bacteria and can arise by two alternate mechanisms. In 
E. coli, endogenous (mutational) Ag
+
 resistance can be selected in the laboratory by 
continuous exposure to Ag
+
. Such resistant mutants show a porin-deficient phenotype 
and can efflux Ag
+
, however the genetic changes underlying this phenotype, and the 
propensity for resistance by this mechanism to emerge, persist, and spread in an 
environment where therapeutic Ag
+
 is used remains unclear. An alternative mechanism 
of Ag
+
 resistance is conferred by the nine-component Sil-system found on the 
Salmonella Typhimurium conjugative plasmid pMG101, which is proposed to confer 
Ag
+
 resistance by a combination of Ag
+
 sequestration and efflux; however, the relative 
contribution of each component to resistance is unknown. This study found that 
endogenous Ag
+
 resistance can arise under six days of continuous exposure to 
sub-inhibitory Ag
+
, and results from a loss of function mutation in OmpR (preventing 
expression of OmpC/F), and a second mutation in the sensor kinase CusS, enabling 
constitutive expression of the Ag
+
 efflux pump CusCFBA. Using a next-generation 
sequencing approach, the sil operon on plasmid pMG101 was found to be part of a 
Tn7-like transposon that can integrate into the host chromosome. A systematic deletion 
strategy revealed that only the periplasmic binding protein SilE and efflux pump 
SilCFBA were essential for an Ag
+
 resistance phenotype. In addition, the sil operon was 
found to be a native component of strains of Enterobacter cloacae and 
Klebsiella pneumoniae; however, these species were not intrinsically resistant to Ag
+
 
unless gain-of-function mutations were selected in the sensor kinase SilS. The relative 
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ease with which endogenous Ag
+
 resistance can be selected, combined with the risk 
associated with horizontal transmission of the Sil-system, highlights the need to control 
the proliferation of Ag
+
-containing products so that the clinical utility of antibacterial 
Ag
+
 is not lost. 
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5.1. Introduction 
In Chapter 3 it was demonstrated that Ag
+
 resistance is not prevalent amongst clinical 
isolates of S. aureus, nor does resistance arise easily via endogenous mechanisms 
during continuous exposure to Ag
+
 in a laboratory environment. However, in 
Gram-negative bacteria Ag
+
 resistance is already known to exist. Under laboratory 
conditions Li et al., (1997) were able to isolate strains of E. coli resistant to an Ag
+
 
concentration >64 times that of the parental strain (Li et al., 1997). Resistant strains 
were found to be deficient in the porin OmpF alone, or in combination with OmpC, and 
demonstrated the ability to efflux Ag
+
 (Li et al., 1997). Further analysis suggested that 
Ag
+
 efflux in these strains was carried out by the Ag
+
/Cu
+
 transporter CusCFBA, as 
proteomic analysis identified components of this system (CusF and CusB) to be 
overexpressed in a resistant strain, and deletion of cusF restored Ag
+
 susceptibility to 
that of the parental strain (Lok et al., 2008). Although this study identified a mutation in 
cusS, which encodes an amino acid substitution in the sensor kinase that regulates 
CusCFBA expression, the genetic events leading to endogenous Ag
+
 resistance have not 
been explored in detail. In addition, the time taken for resistance by this mechanism to 
arise was not reported, thus the potential for emergence of this phenotype in an 
environment where Ag
+
 is used to prevent and treat infection is unclear. 
Unlike endogenous (mutational) Ag
+
 resistance described above, exogenous 
(horizontally-acquired) Ag
+
 resistance has been encountered clinically. In 1975, an 
Ag
+
-resistant strain of Salmonella enterica serovar Typhimurium caused an outbreak on 
a burns ward resulting in the death of three people (McHugh et al., 1975). The 
Ag
+
-resistance determinant was found to be located on a 14.2 kb region of the plasmid 
pMG101 and was named the Sil system (Gupta et al., 1999). The sil operon comprises 
nine open reading frames (silS, R, E, C, F, B, A, ORF105 and P), and, with the 
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exception of SilE, which was shown to be a periplasmic Ag
+
 binding protein, the 
function of the remaining components have yet to be confirmed experimentally. 
However, based on homology searches, the Sil operon is believed to confer Ag
+
 
resistance by a combination of Ag
+
 sequestration in the periplasm (via SilE and SilF 
binding) and efflux (via the RND pump homologue SilCBA and P-type ATPase 
homologue SilP). Nevertheless, the relative contribution provided by each component to 
the resistance phenotype is unknown. 
 
5.2. Objectives 
The objectives of the work presented in this chapter are as follows: 
 determine the time taken for endogenous Ag+ resistance to arise in E. coli, and 
define the genetic and phenotypic events that confer the Ag
+
resistance 
phenotype.  
 determine the relative contribution to Ag+ resistance provided by each 
component of the Sil system. 
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5.3. Results and discussion 
5.3.1. Selection and characterisation of endogenous silver resistance in E. coli 
5.3.1.1. Endogenous Ag
+
 resistance can arise in E. coli after six days of continuous 
exposure to Ag
+
, as a consequence of two mutational events 
Although it has been demonstrated that endogenous resistance to Ag
+
 can be selected in 
the laboratory, the time taken for resistance to emerge has not been reported (Li et al., 
1997). To determine if endogenous Ag
+
 resistance can arise from a single mutational 
event, overnight cultures of E. coli strain BW25113 were plated onto MHA containing 
AgNO3 at 4X MIC (16 g of AgNO3/ml). Following a 24 h incubation, no spontaneous 
mutants could be obtained (limit of detection <1 × 10−10), implying that endogenous Ag+ 
resistance in E. coli cannot arise from a single mutational event (O'Neill & Chopra, 
2004). As a consequence, strain BW25113 was subjected to continuous exposure of 
sub-inhibitory Ag
+
 in an identical manner to that described for S. aureus in Chapter 3. 
Following continuous exposure for six days, a strain resistant to >256 g/ml 
AgNO3 was selected (parental strain MIC: 4 g/ml). The ability to select for resistance 
in this manner, and over this time, was reproducible (n=3).  
Endogenous Ag
+
 resistance in E. coli results from down-regulation or loss of outer 
membrane porins, and up-regulation of Ag
+
 efflux (likely mediated by CusCFBA) (Li et 
al., 1997; Lok et al., 2008); however, the genetic changes that confer this phenotype 
have not been explored in detail. To address this, the DNA sequence of the following 
genes were determined in the Ag
+
-resistant strain: ompF, ompC, ompA (encoding the 
three major porins of E. coli), ompR, envZ (encoding regulators of porin expression), 
cusR and cusS (encoding regulators of expression of the CusCFBA efflux transporter). 
DNA sequence determination identified missense mutations G596A in ompR and G1130A 
in cusS (leading to amino acid substitutions R199H and R377H in OmpR and CusS, 
respectively). To confirm that these two mutations were necessary and sufficient for the 
156 
 
 
Ag
+
 resistance phenotype, they were introduced, alone and in combination, into the 
parental strain (E. coli BW25113) by recombineering. Individually, neither mutation 
conferred any reduction in susceptibility to Ag
+
 compared with the parental strain 
(MIC of 4 g AgNO3/ml). However, when both mutations were introduced into the 
same strain, Ag
+
 resistance (MIC >256 g of AgNO3/ml) was observed, indicating that 
high-level endogenous Ag
+
 resistance can arise as a consequence of only two mutational 
events. Furthermore, in strains carrying only one of these mutations, spontaneous 
Ag
+
-resistant mutants could be selected by plating onto agar containing AgNO3 at 
4X MIC, with mutants obtained at a frequency of 6.7 ± 1.4x10
-8 
and 9.2 ± 1.2x10
-8 
for 
strains BW25113 cusSG1130A and BW25113 ompRG596A, respectively. These 
frequencies are consistent with that of a single mutational event (O'Neill & Chopra, 
2004). Sequence determination of Ag
+
-resistant BW25113 cusSG1130A revealed 
mutations in ompR, whereas mutations in cusS were found in Ag
+
-resistant 
BW25113 ompRG596A, thus giving further indication that mutations in both ompR and 
cusS are required to confer an Ag
+
 resistance phenotype.   
By determining the sequence of ompR and cusS from multiple independent mutants, the 
diversity of mutations that contribute to Ag
+
 resistance could be determined, which may 
assist in elucidating the functional changes that occur in OmpR and CusS to bestow Ag
+
 
resistance. Therefore, ompR or cusS was sequenced from five independent Ag
+
-resistant 
mutants derived from BW25113 cusSG1130A and BW25113 ompRG596A, respectively 
(Table 5.1). These results are discussed in the following sections of this chapter. 
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Table 5.1. Mutations in ompR and cusS associated with endogenous Ag
+
 resistance 
in E. coli BW25113 
Nucleotide change Amino acid substitution 
Mutations in cusS  
A49C T17P 
T638G I213S 
C935A A312E 
C1052A A351E 
G1130A R377H 
Mutations in ompR  
A611C Q204P 
C88T Q30STOP 
G596A R199H 
 
5.3.1.2. Mutational changes in the ompR gene of Ag
+
-resistant mutants prevent the 
expression of outer membrane porins OmpC and OmpF 
The EnvZ-OmpR two-component system is responsible for sensing and regulating 
cellular changes to extracellular osmolarity (Cai & Inouye, 2002). In environments of 
low osmolarity the kinase activity of EnvZ is repressed, limiting the phosphorylation of 
its cognate response regulator OmpR, and resulting in low intracellular concentrations 
of phosphorylated OmpR (pOmpR). Under these conditions, pOmpR preferentially 
binds to regions of DNA upstream of ompF, recruits RNA polymerase and enables 
ompF transcription (Cai & Inouye, 2002). The protein product, OmpF, is an integral 
outer membrane protein with a relatively large pore diameter (1.16 nm), which thereby 
allows for an increased passive diffusion of solutes into the cell (Cowan et al., 1995). If 
the extracellular osmolarity increases, the kinase activity of EnvZ is activated, leading 
to increased phosphorylation of OmpR. At high concentrations, pOmpR can interact 
with additional regions of DNA, such as upstream of ompC (enabling its transcription) 
and an additional site upstream of the ompF promoter, altering the tertiary structure of 
DNA in this region such that RNA polymerase recruitment is prevented and ompF 
transcription cannot occur (Cai & Inouye, 2002). In combination, this has the effect of 
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reducing expression of OmpF and increasing expression of OmpC, which has a smaller 
pore diameter than OmpF (1.08 nm) and limits passive diffusion of water from the cell 
as a consequence (Basle et al., 2006).    
During the course of this study three independent mutations were identified in ompR 
that contributed to the endogenous Ag
+
 resistance phenotype. The mutation C88T 
introduces a premature stop codon into ompR, which would lead to the expression of a 
truncated protein product. Truncated OmpR, irrespective of its phosphorylation status, 
is unlikely to be able to bind DNA and mediate transcription of ompC/F; as a 
consequence, cells harbouring this mutation will be unable to express OmpC or OmpF. 
It seems likely that the mutations in ompR identified from other Ag
+
-resistant strains 
(A611C and G596A) similarly disrupt the function of OmpR. To confirm that the 
mutations identified in ompR prevented expression of OmpC/F, outer membranes were 
extracted and purified from strain BW25113 ompRG596A cusSG1130A and the parental 
strain. Analysis of porin expression using SDS-PAGE revealed that bands 
corresponding to OmpC/F were not present in strains containing these mutations 
(Figure 5.1). 
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Figure 5.1. SDS-PAGE of outer membrane proteins from BW25113 ompRG596A 
cusSG1130A and comparator strains. Lane 1, BW25113 ompRG596A cusSG1130A; Lane 
2, BW25113 ompF, Lane 3, BW25113 ompC; Lane 4, BW25113; Lane 5, 
BW25113 ompR; Lane 6, NCTC 50110. N.B. OmpC and OmpF co-migrate under 
standard SDS-PAGE conditions 
 
As the structure of the C-terminal domain of OmpR has been determined (PDB 
accession: 10DD), the amino acid substitutions encoded by A611C and G596A were 
mapped onto this structure in order to provide insight into how they may disrupt OmpR 
function (Figure 5.2). 
Marker 6 5 4 3 2 1 
46 kDa 
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Figure 5.2. Location of amino acid substitutions found in OmpR in Ag
+
-resistant 
mutants of E. coli. The residues comprising the 3 DNA-binding helix are highlighted 
blue, whereas those highlighted yellow represent the ―turn‖ (loop) region essential for 
recruitment of RNA polymerase. Residues in red are those found to be altered in 
Ag
+
-resistant strains. 
 
The residues 138 to 233 of OmpR comprise a winged helix-turn-helix (wHTH) domain 
(Kondo et al., 1997). This domain is capable of binding DNA and variations of it exist 
amongst a number of transcriptional regulators and other DNA-binding proteins (Santos 
et al., 2009). In OmpR, the 3 helix (residues 200-213) and the loop extending from 
this helix (residues 214-220) are responsible for DNA recognition and binding, whereas 
Q204P 
R199H 
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the 2 helix (residues 182-190) stabilises the OmpR-DNA interaction (Kondo et al., 
1997; Martinez-Hackert & Stock, 1997; Rhee et al., 2008). In addition to the wHTH 
domain binding DNA, the ―turn‖ region contained in this domain (residues 191-199) 
recruits RNA polymerase to the site of OmpR-DNA interaction, allowing for 
transcription of downstream genes (i.e. ompC or ompF) (Kondo et al., 1997; Pratt & 
Silhavy, 1994). The amino acid substitutions R199H and Q204P found in OmpR of 
Ag
+
-resistant E. coli are both located in the wHTH domain; with Q204P located within 
the 3 helix and R199H located within the ―turn‖ region. It therefore seems likely that 
these substitutions disrupt the ability of OmpR to bind DNA or recruit 
RNA polymerase, respectively. Disruption of either of these functions would 
presumably prevent the expression of OmpF and OmpC, thus giving the porin-deficient 
phenotype observed in Ag
+
-resistant strains.  
In contrast to the work presented here, where all Ag
+
-resistant strains harboured ompR 
mutations that prevents both OmpC and OmpF expression, a selection of Ag
+
-resistant 
isolates obtained by Li et al. (2007) lacked OmpF alone. To ascertain if strains deficient 
in OmpF require only a single additional mutational event (e.g in cusS) to confer Ag
+
 
resistance (as occurs with strains deficient in OmpR), the frequency of spontaneous 
mutation to Ag
+
 resistance was determined for BW25113 deleted for ompF or ompR. 
Whereas strains deleted for ompR yielded Ag
+
-resistant mutants at a frequency of 
7.5±1.5x10
-8, a frequency consistent with a single mutational event (O‘Neill et al., 
2004), no spontaneous Ag
+
-resistant mutants could be selected for strains deleted for 
ompF. This result would suggest that the loss of OmpF alone is insufficient for Ag
+
 
resistance. Although this result appears to contradict that obtained by Li et al. (2007), 
the duration of the resistance selection carried in their study was not disclosed, and it is 
possible that disruption of OmpF alone is sufficient to contribute to Ag
+
 resistance when 
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mutational changes in addition to those in cusS are present. Indeed, further 
characterisation of an Ag
+
-resistant strain that was deficient in OmpF revealed 
down-regulation of a number of periplasmic proteins (for example periplasmic 
maltose-binding protein and periplasmic histidine-binding protein) and an additional 
outer membrane channel (TolC), all changes that may provide additional protection 
against Ag
+
 (Lok et al., 2008).   
Porin loss is likely to contribute to an Ag
+
 resistance phenotype by limiting the diffusion 
of Ag
+
 into the periplasm to a concentration that can be successfully transported out of 
the cell before it causes damage to the cytoplasmic membrane. It therefore seems 
reasonable to suggest that the primary mechanism by which Ag
+
 traverses the outer 
membrane is through OmpC/F. Indeed, it has been established that OmpC/F 
preferentially transport cations (e.g. Ag
+
) as opposed to anions and compounds with a 
net neutral charge (Benz et al., 1985; Danelon et al., 2003). However, as OmpC/F allow 
for the diffusion of a range of important solutes into the cell (e.g. sugars, ions and amino 
acids), the loss of these porins under Ag
+
 resistance suggests that cells would be 
compromised in their ability to acquire nutrients; this would likely reduce their growth 
rate and affect their ability to compete with other organisms in an Ag
+
-free 
environment. The impact of this phenotype on the clinical significance of endogenous 
Ag
+
 resistance will be explored later in this chapter.   
5.3.1.3 Mutations in CusS lead to uncoupling of Ag
+
 sensing from expression of 
CusCFBA, resulting in constitutive expression of the latter 
The CusRS two-component system is a positive regulator of the cusCFBA operon 
(Munson et al., 2000). Upon sensing extracellular Cu
+
 or Ag
+
, the sensor kinase (CusS) 
phosphorylates its cognate response regulator (CusR), which in turn binds to a region of 
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DNA (termed the ―CusR box‖) upstream of cusCFBA and activates cusCFBA 
transcription (Munson et al., 2000). Increased expression of cusCFBA has been 
observed following both Ag
+
 and Cu
+
 challenge in transcriptional profiling experiments 
(Yamamoto & Ishihama, 2005, Gudipaty et al., 2012). The components CusCBA 
comprise an efflux pump of the resistance nodulation division (RND) family that has 
been shown to efflux both Cu
+
 and Ag
+
 (Su et al., 2011), whilst CusF is a periplasmic 
Cu
+
 and Ag
+
 binding protein that is believed to sequester ions in the periplasm and 
transport them to CusB for subsequent efflux (Xue et al., 2008). Deletion of any 
component of the Cus system results in hyper-susceptibility to Cu
+
 in anaerobic 
environments, suggesting that the primary role of the Cus system is to enable copper 
homeostasis during anaerobiosis (Munson et al., 2000). 
Given that the CusRS two-component system is a positive regulator of CusCFBA, it 
seems likely that mutations in cusS that contribute to Ag
+
 resistance do so by promoting 
gain of function in CusS, thereby increasing the expression of CusCFBA and 
consequently the rate of Ag
+
 efflux. To establish the effect of such a mutation on the 
expression of CusCFBA, qPCR was used to determine relative expression of CusC in 
the parental strain and Ag
+
-resistant strain BW25113 ompRG596A cusSG1130A, in the 
presence and absence of AgNO3 at 1 g/ml, using a previously validated 
oligonucleotide primer set (Gudipaty et al., 2012) (Figure 5.3). Whilst the parental 
strain exhibited Ag
+
-dependent expression of CusCFBA, the Ag
+
-resistant derivative 
exhibited high-level and constitutive expression of this operon even in the absence of 
Ag
+
 stimulus, suggesting that Ag
+
 sensing is uncoupled from CusCFBA expression in 
Ag
+
-resistant strains. 
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Figure 5.3 Relative expression of CusC in Ag
+
 susceptible (WT) and resistant 
(AgR) strains of BW25113 in the presence and absence of 1 g AgNO3/ml. Error 
bars represent the standard deviation from three independent experiments. 
 
Sensor kinases exist in the cell as homodimers, and regulate gene expression by altering 
the phosphorylation state of their cognate response regulator (CusR in this case) 
(Stewart, 2010). This is achieved through modulation of the relative kinase or 
phosphatase activities within the sensor kinase (Stewart, 2010). As CusRS is a positive 
regulator of CusCFBA, the concentration of phosphorylated CusR in the cytoplasm will 
be proportional to the level of CusCFBA expression. Therefore the CusS mutations 
identified in Ag
+
 resistant E. coli could enable continuous kinase activity, or inactivate 
the phosphatase properties of this protein. In either case, levels of phosphorylated CusR 
would remain high and allow for the constitutive expression of CusCFBA that has been 
observed in this study. Further insight into how the observed mutations might affect the 
function of CusS could be obtained by mapping the amino acid substitutions onto a 
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structure of CusS, in a similar manner to that carried out earlier in this study with 
OmpR. However, unlike OmpR, the structure of CusS has yet to be determined. The 
structure and functional domains of CusS were therefore predicted using the iterative 
threading assembly refinement (I-TASSER) server and the protein families (Pfam) 
database, respectively.  
The I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/ last accessed 
6
th
 August 2013) produces a predicted three-dimensional protein structure based on a 
submitted amino acid sequence. This is achieved via a four-stage process; threading, 
structural assembly, model selection and refinement, and structure-based functional 
annotation (Roy et al., 2010). To summarise, I-TASSER uses the submitted amino acid 
sequence to search protein structure databases for homologous regions of sequence for 
which there is structural data. These data are then amalgamated into a predicted 
structure, which is further refined by a comparison with structural homologues of the 
whole protein (Roy et al., 2010). In a similar manner to I-TASSER, Pfam 
(http://pfam.sanger.ac.uk/ last accessed 6
th
 August 2013) uses the submitted amino acid 
sequence to search a database for regions of sequence that share homology. Unlike 
I-TASSER, Pfam utilises a database of proteins for which a functional role has been 
determined (Punta et al., 2012). As CusS is a putative sensor kinase, it will contain an 
extra-cytoplasmic sensing domain of a unique structure (as this is required for substrate 
specificity in sensing). As I-TASSER predicts protein structure based on homology 
searches, it is likely that the sensing domain of CusS will negatively impact the 
predictive ability of I-TASSER (Roy et al., 2010). As a consequence, the sequence 
corresponding to the extracellular sensing- and membrane-spanning domains of CusS 
were identified by SOSUI (as described in Chapter 4) and omitted from the sequence 
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submitted to I-TASSER. The predicted structure for the cytoplasmic region of CusS was 
highlighted with functional domains identified by Pfam and is presented in Figure 5.4.
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Figure 5.4. Predicted structure of the cytoplasmic domain of CusS. Dimerization 
and catalytic/ATP-binding domains are shaded orange and purple respectively. The 
conserved histidine residue required for phosphorylation of CusR is shaded red and sites 
of amino acid substitutions associated with Ag
+
 resistance are shaded pink. 
 
As expected, the overall structure of CusS is similar to that of a typical sensor histidine 
kinase. The amino acid sequence from residues 209 to 237 is consistent with a HAMP 
domain that is responsible for transducing signals from the sensing domain to the 
cytoplasmic domains (Hulko et al., 2006). The region containing residues 242 to 322 is 
R377H 
A312E 
A351E 
I213S 
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a putative dimerization and histidine phosphotransfer (DHp) domain (Ferris et al., 
2012), containing a conserved histidine at position 271 that likely transfers phosphate to 
CusR. The remaining amino acid sequence (332 to 480) corresponds to a catalytic and 
ATP-binding (CA) domain which, as indicated, binds ATP and transfers a phosphate 
group to the conserved histidine residue within the DHp domain when the kinase is 
activated (Stewart, 2010). 
Inserting the amino acid changes required for Ag
+
 resistance onto the predicted structure 
of CusS reveals that the changes are distributed throughout the structure (Figure 5.4). 
The amino acid substitution I213S occurs within the proposed HAMP domain, whilst 
substitution A312E is located within the DHp domain. The remaining substitutions, 
A351E and R377H, are located in the CA domain. The kinase and phosphatase activities 
of a sensor kinase are activated by a conformational change in the cytoplasmic domains 
of the protein, which moves the conserved histidine residue in the DHp domain into the 
CA domain (Ferris et al., 2012). It is possible that the mutations observed in Ag
+
 
resistance affect the structure of CusS so that the latter conformation is locked in place, 
leading to continuous kinase activity (or blocking phosphatase activity), which in turn 
leads to maintenance of high intracellular concentrations of phosphorylated CusR and 
constitutive expression of CusCFBA as a consequence.  
5.3.1.4. All components of the CusCFBA system are essential for endogenous Ag
+
 
resistance 
As discussed above, CusCBA is a tri-partite efflux pump of the RND family, with CusC 
functioning as an outer membrane channel, CusB as a membrane fusion protein and 
CusA as the Cu
+
/Ag
+
 pump, which effluxes Cu
+
/Ag
+ 
via a methionine shuttle (Su et al., 
2011). CusF is a periplasmic protein which can bind a single Cu
+
 or Ag
+
 by methionine 
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and cation-π interactions with tryptophan (Xue et al., 2008). Using a yeast two-hybrid 
approach and chemical crosslinking, CusF has been shown to interact with CusB at a 
specific site; thus, it has been suggested that CusF acts as a chaperone to transport Ag
+
 
or Cu
+
 to CusCBA for subsequent efflux (Mealman et al., 2011). Deletion of either 
CusC, F, B, or A confers hyper-susceptibility to Cu
+
 under anaerobic conditions (Franke 
et al., 2003); however, although strains lacking CusS or CusR are hyper-susceptible to 
Ag
+
, and deletion of cusF in Ag
+
-resistant strains restores Ag
+
 susceptibility to that of 
the parental strain, it is unclear if the deletion of genes encoding any component of the 
CusCBA efflux pump in Ag
+
-resistant strains will disrupt the phenotype. Therefore, 
using a recombineering approach, markerless deletions of cusC, F, B, or A were created 
in strain BW25113 ompRG596A cusSG1130A and the subsequent effect on the Ag
+
 
resistance phenotype established by determining the AgNO3 MIC for each strain. 
Irrespective of the component that was deleted, AgNO3 MICs decreased from 
>256 g/ml to 4 g/ml, indicating that the CusCBA efflux pump, in addition to CusF, is 
essential to the Ag
+
 resistance phenotype. Furthermore, the confirmation that loss of 
Ag
+
 resistance occurs following disruption of CusF indicates that that the ability of 
CusCBA to efflux Ag
+
 is dependent upon CusF. This result may indicate that, unlike 
other pumps of the RND family, CusCBA cannot sequester its substrate directly from 
the periplasm and is reliant upon CusF for this purpose. 
In strains containing native CusS (i.e. not harbouring mutations found in Ag
+
 
resistance), Ag
+
 challenge will activate CusS and increase the level of phosphorylated 
CusR, which in turn will mediate transcription of cusCFBA (Munson et al., 2000). 
However, by the time this has happened and the expressed Cus proteins have inserted 
into the periplasm, Ag
+
 will have already caused substantial damage to the 
inner membrane. Indeed, it was demonstrated in Chapter four that Ag
+
 causes lethal 
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bacterial membrane damage after only 10 min exposure. Thus, the constitutive and 
high-level expression of CusCFBA in Ag
+
-resistant strains allows for Ag
+
-protection 
mechanisms to be present prior to challenge with Ag
+
, thereby allowing for Ag
+
 
detoxification without a time delay. Nevertheless, the continual expression of 
periplasmic proteins is likely to put a substantial metabolic strain upon the cell, which 
may impact its ability to survive when in competition with other organisms in an 
Ag
+
-free environment. 
5.3.1.5. Emergence and maintenance of endogenous Ag
+
 resistance  
This study has established that two mutational events are required for Ag
+
 resistance in 
E. coli; however, the order in which these mutations arose is unknown. As this 
information may provide insights into the evolution of this resistance phenotype, DNA 
sequence determination of ompR and cusS from strains isolated on each day of 
resistance selection was carried out to identify at which locus the first mutation arose. In 
all three independent selection experiments, mutations in ompR arose first (after 
4-5 days), with the mutation in cusS arising shortly after (day 6). As the MIC of 
AgNO3 did not change against strains harbouring ompR mutations (data not shown), it 
was hypothesised that such mutations confer a growth advantage over parental strains in 
sub-inhibitory concentrations of Ag
+
. Therefore, growth of the parental strain, 
BW25113 ompRG596A, and BW25113 ompR in the presence of 2 g AgNO3/ml was 
assessed by means of optical density measurements at 600 nm over an 18 h period 
(Figure 5.5). Under these conditions, strains harbouring mutagenised ompR had an 
increased growth rate compared with the parental strain. In addition, the ability of 
strains harbouring cusS mutations to confer a growth advantage in sub-inhibitory Ag
+
 
was also assessed; although a growth advantage could be observed, it was to a lesser 
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extent than that observed with mutagenised ompR strains (Figure 5.5). This result 
suggests that at sub-inhibitory concentrations of Ag
+
, porin loss provides a greater 
degree of protection against Ag
+
 than CusCFBA-mediated efflux. This increased level 
of protection would translate into a stronger selection pressure in favour of strains 
harbouring ompR mutations, thus allowing for this strain to predominate over the 
parental strain and other spontaneous mutants during continuous exposure to Ag
+
. As 
the population of ompR mutants increases, the probability that a spontaneous mutation 
in cusS occurs to complete an Ag
+
 resistance phenotype will also increase. 
Figure 5.5 Growth curves of BW25113 (orange diamonds), ompRG596A (blue 
squares), ompR (red triangles) and cusS (green circles) in 2 g AgNO3/ml. Results 
are representative of at least three independent experiments. 
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Although endogenous Ag
+
 resistance could be selected in E. coli by continuous 
exposure to sub-inhibitory Ag
+
, this type of selection pressure would not typically be 
encountered in a clinical setting. In the management of infection, silver formulations are 
used that employ Ag
+
 concentrations well in excess of the MIC (Yin et al., 1999). 
Therefore, in order to determine if Ag
+
 resistance could be selected under conditions 
more analogous to those that might be encountered in the clinical setting, cultures of 
E. coli BW25113 were repeatedly exposed to supra-inhibitory concentrations of 
AgNO3 (40, 80 or 100 g/ml), using a previously established method (Miller et al., 
2008). Using this method Ag
+
 resistance could not be selected over a period of 42 days. 
As this method contains periods during which cultures are allowed to recover following 
Ag
+
 exposure, it is likely that there is insufficient selection pressure to permit the 
proliferation of the OmpC/F-deficient phenotype. As hypothesised earlier, loss of 
OmpC/F expression would impact the ability of the cell to take up nutrients, which in 
turn will allow it to be out-competed by the parental strain during periods when Ag
+
 is 
absent. Indeed, the impact of porin loss on bacterial growth has been established 
previously (Adler et al., 2013), with cultures of E. coli found to grow 20% slower when 
porins are not expressed.  
Unfortunately, porin-deficient phenotypes of E. coli already exist in the clinical setting, 
as a mechanism that can confer resistance to an extended spectrum of -lactams in 
strains already expressing a -lactamase. For example porin-deficient strains containing 
an extended-spectrum or AmpC -lactamase have a reduced susceptibility to 
carbapenems, as porin loss limits the ingress of the carbapenem into the periplasm to 
concentrations that can be successfully degraded by the -lactamase 
(Martinez-Martinez, 2008; Adler et al., 2013). As a consequence, endogenous Ag
+
 
resistance could in principle arise in such clinical isolates via a single mutational event, 
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thus by-passing the apparent inability to select for ompR mutations with 
supra-inhibitory concentrations of Ag
+
. To test this, the mutation frequency to 
spontaneous Ag
+
 resistance was determined for the clinical E. coli isolate EC18, a strain 
originally detected owing to a ―false‖ ESBL phenotype resulting from a combination of 
expression of the TEM-1 -lactamase and loss of OmpC/F expression (Beceiro et al., 
2011). A mutation frequency to Ag
+
 resistance of 7.5±0.9x10
-8 
was recorded, with 
mutants resistant to >256 g AgNO3/ml. This frequency is consistent with a single 
mutational event, and would therefore seem to confirm the possibility that spontaneous 
Ag
+
 resistance could arise in porin-deficient strains of E. coli known to cause infection. 
Although the above results indicate that Ag
+
-resistant E. coli could emerge in an 
environment where high concentrations of Ag
+
 are encountered (e.g. in wound care), the 
metabolic impact (also known as the fitness cost) of porin loss combined with 
overexpression of CusCFBA may be sufficient to limit the spread and survival of this 
phenotype, due to it being out-competed by other microorganisms, and/or be unable to 
survive in nutrient-poor environments. To give an indication of the fitness cost 
associated with endogenous Ag
+
 resistance, the ability of strain BW25113 ompRG596A 
cusSG1130A to compete with the parental strain BW25113 was evaluated by pair-wise 
competition assays. A relative fitness value (W) of 0.71 (±0.02) was obtained. Although 
this value is indicative of a considerable fitness cost, strains harbouring other 
endogenous antibiotic resistance phenotypes with a similar or greater fitness burden 
have been encountered in the clinic. For example, clinical isolates of 
rifampicin-resistant S. aureus have been encountered with W values as low as 
0.49 (O'Neill et al., 2006). This would suggest that the fitness cost observed in 
endogenous Ag
+
 resistance would not necessarily act as a barrier to this resistance 
phenotype arising and persisting in a clinical setting. However, the fitness evaluation 
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used in this study was over a 24 h period and may not be representative of the Ag
+
 
resistance phenotype in competition over a longer period. Furthermore, this study does 
not take into consideration the impact of the resistance phenotype on pathogenicity or 
on the ability of the organism to evade immune response mechanisms. Expanding 
fitness studies using an animal model of infection would therefore be beneficial in 
future studies.  
E. coli is rarely encountered (relative to other bacteria) in environments where Ag
+
 is 
employed therapeutically (e.g. burn and chronic wounds) (Posluszny et al., 2011; 
Rezaei et al., 2011), thus the clinical significance of endogenous Ag
+
 resistance in 
E. coli is unclear. However, there is the possibility that endogenous Ag
+
 resistance can 
arise in other Gram-negative bacteria that have greater relevance to the continued usage 
of Ag
+
 in wound care. To identify other Gram-negative bacteria that harbour the 
Cus system (and therefore the potential for endogenous resistance to emerge), a 
BLASTp search was carried out using the amino acid sequence of CusF from E. coli 
MG1655 (a parental strain of BW25113) as the search input. Results were then refined 
by confirming the presence of the remaining Cus components. 
BLASTp searches identified an intact Cus system in a substantial number of E. coli 
strains (data not shown). In addition, intact Cus systems were identified in Shigella and 
Citrobacter spp. with an overall amino acid identity of >60%. Both of these genera have 
been previously implicated in wound infection (Gregory et al., 1974; Arens & Verbist, 
1997). Attempts were therefore made to select for Ag
+
 resistance in Citrobacter freundii 
(strain ATCC 8090) and a clinical isolate of Shigella sonnei, by continuous exposure to 
sub-inhibitory Ag
+
. Prior to selection, the presence of cusS was confirmed by PCR 
using primers specific to this gene in each organism, in order to provide a putative 
indication that the Cus system was present (data not shown). In addition to the above 
175 
 
 
strains, selection of endogenous Ag
+
 resistance was also attempted in strains of 
Pseudomonas aeruginosa (strain PA01) and Acinetobacter baumannii  (strain 
ATCC 19606). Although these species are frequently isolated from wounds and are a 
significant cause of morbidity and mortality in patients with burn wound infections 
(Rezaei et al., 2011), they lack a Cus system and therefore acted as negative controls in 
this study.  
After 42 days of continuous exposure, mutants with a reduced susceptibility to Ag
+
 
could not be isolated in any of the strains tested. Although the Cus system and 
homologues of OmpC/F are present in both C. freundi and S. sonnei, it is possible the 
loss of OmpC/F in these strains conveys too great a fitness cost to be compatible with 
survival, or that loss of OmpC/F is unable to reduce levels of Ag
+
 entering the periplasm 
to a concentration that can be negated by CusCFBA overexpression. The inability to 
select for endogenous resistance in a range of wound pathogens would suggest that 
Ag
+
-containing products still have utility in the prevention and treatment of bacterial 
infection; however, the possibility that these organisms can acquire Ag
+
-resistance 
determinants by horizontal gene transfer has yet to be explored. Indeed, in addition to 
the strains above, the Cus system was also found to be present in strains of 
Klebsiella pneumoniae and Enterobacter cloacae, however these strains were also 
found to harbour an intact Sil system. The implication of this finding will be explored 
later in this chapter. 
5.3.2. Characterisation of the Sil system: an exogenous Ag
+
-resistance determinant 
5.3.2.1 Analysis of the Ag
+
 resistance plasmid pMG101 using a next-generation 
sequence determination approach.  
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Plasmid pMG101 from S. enterica serovar Typhimurium was the original source of the 
sil operon characterised by Gupta et al. (1999). This plasmid is a member of the IncH 
incompatibility group, and together with Ag
+
 resistance was found to confer resistance 
against ampicillin, chloramphenicol, streptomycin, tetracycline and mercury (McHugh 
et al., 1975; Gupta et al., 2001). The nucleotide sequence of the region of 
pMG101 harbouring the sil operon was determined and deposited in GenBank 
(accession number AF067954).  
Given that there is limited information on the structure and function of the components 
of the Sil-system, a study related to this thesis sought to overexpress and purify each 
Sil-component for future structural studies. However during the process of cloning 
genes encoding Sil components from pMG101 onto suitable expression vectors, a 
number of nucleotide differences (i.e. substitutions, deletions and insertions) were 
noticed when comparing the sequence of sil genes obtained in this study with that on 
GenBank (data not shown). As some of these nucleotide changes affected the resultant 
amino acid sequence, a next-generation approach was employed to determine the 
nucleotide sequence of the entirety of E. coli strain NCTC 50110 (which contains 
pMG101) as this would identify all sequence errors in the sil operon. In addition, 
determining the entire genome sequence of NCTC 50110 would allow the molecular 
basis of other antibacterial resistance determinants present on pMG101 to be identified 
and could provide additional insights into the mechanisms involved in the horizontal 
transfer of the sil operon. 
Next-generation DNA sequence determination represents a substantial improvement 
over the Sanger (dye-terminator) method in terms of sample throughput (Shendure & Ji, 
2008). By running thousands of sequencing reactions simultaneously, next-generation 
technologies can determine the sequence of an entire human genome (3.2 Gb) in 
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24-72 hours (depending on the technology used) (Shendure & Ji, 2008). In comparison, 
the first attempt to determine the sequence of a human genome using the Sanger method 
took over 10 years to complete (Lander et al., 2001; Venter et al., 2001). For the present 
study, Illumina technology was used to determine the NCTC 50110 genome sequence.  
Genomic DNA from NCTC 50110 was extracted and purified, then sent to the Next 
Generation Genomics facility, University of Leeds for library preparation (i.e. 
fragmentation of DNA and cluster generation) and sequence determination on an 
Illumina MiSeq platform using a 2x250 bp paired-end method. Using this method, 
26 million fragment reads were obtained, which corresponds to 6.5 Gb of nucleotide 
sequence. To assemble these reads into the NCTC 50110 genome by de novo assembly, 
the genome assembler provided as part of the CLC Genomics Workbench software 
(version 6.0) was used. This assembler uses de Bruijn graphs to identify and merge 
regions of overlap between reads into contiguous sequences (referred to as contigs) 
(Compeau et al., 2011). Following de novo assembly, 157 contigs were obtained which 
equated to ~4.8 Mb of unique nucleotide sequence at a mean coverage of ~200x. 
Additional data regarding the quality of this assembly can be found in Table 5.2. The 
sequence of each contig was then used as the input for BLASTn searches against the 
E. coli J53 genome (NCBI accession: PRJNA180157), so that contigs corresponding to 
the E. coli chromosome could be removed. This process found 8 contigs (corresponding 
to 151,329 bases) that shared no homology with the E. coli J53 genome, with further 
homology searches revealing these contigs to share similarity with a number of 
Salmonella spp. plasmids (data not shown). It is therefore highly likely that these 
sequences correspond to pMG101. To provide a comprehensive annotation of the genes 
present on the contigs corresponding to pMG101, nucleotide sequences were submitted 
to the Rapid Annotation and Subsystem Technology (RAST) server 
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(http://rast.nmpdr.org/ last accessed 3
rd
 August 2013). Using a combination of 
algorithms, RAST first identifies regions of sequence that are likely to encode tRNA-, 
rRNA- and protein-encoding genes, then uses a derivative of BLASTx to assign a 
functional role to the gene products based on sequence homology (Aziz et al., 2008). 
The genes identified on each contig can be found in Appendix 2. 
Table 5.2. Quality measurements from de novo assembly of E. coli NCTC 
50110 genome  
Total number of reads 26,512,772 
Number of reads assembled into contigs 21,845,309 
Number of reads discarded from 
assembly
1 
4,667,463 
Total number of contigs arising from 
assembly 
157 
N50 of contigs arising from assembly
2
 103,583 
1
Reads of poor quality (e.g. containing ambiguous bases) were discarded by the assembly 
program. 
2
N50 corresponds to the minimum nucleotide length of 50% of all contigs arising from 
the assembly 
  
Of the genes identified on pMG101, a relatively large proportion (29/79) were members 
of the tra and trb operons that encode proteins necessary to facilitate conjugation (Li et 
al., 1999). Other genes involved in plasmid replication/maintenance (rep and par genes) 
(Sia et al., 1995; Venkova-Canova et al., 2003) and survival (toxin/antitoxin genes 
ccdAB, vagCD and pemIK) (Hayes, 2003) were also present, as were genes involved in 
nutrient uptake; these would likely enhance the ability of the host organism to survive in 
a range of environments. In addition, genes encoding a class D (OXA) -lactamase, 
chloramphenicol acetyltransferase, streptomycin 3''-O-adenylyltransferase and a 
tetracycline-efflux pump (TetA) were also identified. Resistance to mercury is likely 
conferred by the Mer system; given the presence of an intact mer operon on pMG101. 
The Mer system is a relatively unusual resistance mechanism by which a toxic moiety 
(in this case Hg
2+
) is actively transported into the cell for detoxification. This process is 
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mediated by the periplasmic Hg
2+
-binding protein MerP and the membrane-bound 
Hg
2+
-transporter MerT. Once inside the cell, Hg
2+
 is reduced to elemental Hg (Hg
0
) by 
the mercuric reductase MerA. Due to its volatile state, Hg
0 
is non-toxic and rapidly 
diffuses out of the cell (Mathema et al., 2011). Although it has been known since its 
discovery that pMG101 can confer resistance to a range of antibacterial agents apart 
from Ag
+
, the results of this study nevertheless re-emphasises that horizontally-acquired 
genetic elements frequently carry more than one antibacterial resistance determinant and 
therefore the use of therapeutic Ag
+
 can potentially select for exogenous resistance 
towards a range of antibacterial agents. 
Although a substantial portion of pMG101 sequence was recovered and annotated, 
genes corresponding to the sil operon could not be located. A potential reason for the 
lack of the sil operon despite this strain displaying resistance to Ag
+
 could be that the 
operon had integrated into the E. coli chromosome. Indeed, this was found to be the 
case, as a BLAST search of contigs other than those already associated with 
pMG101 using the nucleotide sequence of silE revealed that the sil operon had inserted 
into the host chromosome. Further analysis of the contig harbouring the sil operon 
revealed that it was part of a 32.2 kb integrated element. As the sil operon is only 
14.2 kb, the entirety of the contig harbouring the integrated element was annotated 
using RAST, to provide an insight into the other components that had integrated with 
the sil operon (Appendix 2). In addition to the sil operon, a region with high sequence 
similarity to pcoABCDRSE was identified. The pco operon encodes proteins that confer 
resistance to copper (in the form of Cu
+
 and Cu
2+
) via a mechanism of sequestration 
(PcoE, PcoC), oxidation to Cu
2+
 (PcoA) and/or efflux (PcoB and PcoD), in a process 
regulated by the PcoRS two-component system (Lee et al., 2002). Of primary interest 
however, was the presence on the integrated element of genes encoding proteins 
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homologous to the Tn7 transposition system. The archetypical Tn7 system contains 
5 proteins; TnsA, B, C, D and E (Peters & Craig, 2001). TnsAB form a transposase that 
recognises inverted repeat (IR) elements at either end of the transposon (termed Tn7-L 
and Tn7-R), and creates double-strand DNA breaks at these sites, thus excising the 
transposon from the donor site. TnsC binds to recipient DNA at the site of transposon 
insertion (identified by TnsD or TnsE) and, in an ATP-driven process with TnsAB, 
integrates the transposon into this site. The target site on the recipient DNA for 
transposon integration is mediated by TnsD or TnsE. TnsD recognises a specific site on 
the recipient DNA, termed the attTn7 sequence. This sequence is ubiquitous in bacterial 
species as it is found upstream of the coding sequence of glmS (encoding glutamine 
synthetase), a highly conserved gene due to its essential role. In contrast, TnsE does not 
recognise a specific sequence of DNA, but rather directs transposon integration into 
conjugative plasmids during their replication by lagging-strand DNA synthesis (Peters 
& Craig, 2001). Analysis of the Tn7 system from the integrated element containing the 
sil and pco operons revealed the presence of TnsA, B, C and D homologues, although a 
homologue of TnsE was not detected. Additionally the IR elements Tn7-L and Tn7-R 
could not be located within, or at the terminal ends of the integrated element (data not 
shown). This suggests that although Tn7-homologues are present and are likely 
responsible for transposition of this integrated element from pMG101 into the E. coli 
chromosome, the mechanism by which this occurs is likely to be different from that 
mediated by the archetypical Tn7 system. Nevertheless, the fact that the sil operon is 
contained within an apparently functional transposon suggests that exogenous Ag
+
 
resistance could easily disseminate between plasmids and bacterial species and thus 
represent a substantial threat if introduced into an environment where therapeutic Ag
+
 
was employed clinically. This implication will be explored later in this chapter. 
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Comparison of the sil operon sequence obtained from this study with that of the 
sequence originally submitted to GenBank (accession number AF067954) revealed a 
number of errors in the original sequence. To summarise, 51 nucleotide differences 
were identified, which corresponded to 10 base changes, 13 insertions and 28 deletions. 
These nucleotide differences equated to numerous changes in the amino acid sequence 
of Sil system components (Table 5.3 and Figure 5.6). In addition, the start codon of 
silF, P, and ORF105 identified by Gupta et al. was found to be incorrect, thus affecting 
the final length of these proteins (Figure 5.6). 
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Table 5.3. Errors in Sil-system components based on original GenBank submission 
(accession number AF067954).  
Sil operon component Number of changes to amino acid 
sequence 
SilE None 
SilS 14 
SilR 7 
SilC None 
SilF 1* 
SilB None 
SilA None 
ORF105 (SilG) None* 
SilP 7* 
* represents proteins of different length than originally identified due to identification of 
incorrect start codon 
 
 
Figure 5.6a Alignment of amino acid sequences for SilS, derived from the original 
sequence of pMG101 and that arising from this study 
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Figure 5.6b Alignment of amino acid sequences for SilP, derived from the original 
sequence of pMG101 and that arising from this study 
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 Figure 5.6c Alignment of amino acid sequences for SilF, derived from the original 
sequence of pMG101 and that arising from this study 
 
 Figure 5.6d Alignment of amino acid sequences for SilR, derived from the original 
sequence of pMG101 and that arising from this study 
 
 
 Figure 5.6e Alignment of amino acid sequences for SilG, derived from the original 
sequence of pMG101 and that arising from this study 
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The original DNA sequence determination of the sil operon revealed an open reading 
frame located between silA and silP that encoded a protein of unknown function 
(ORF105) (Gupta et al., 1999). Homologues of the protein product encoded by this 
ORF were identified using BLASTp with the amino acid sequence of ORF105 from this 
study. This process revealed a number of homologous proteins predicted to be capable 
of binding metals, including the protein CopG from Cupriavidus metallidurans. The 
gene encoding CopG in this organism is part of a 19-gene operon which has been shown 
to confer high-level resistance to Cu
+
 and Cu
2+
 by a combination of cytoplasmic and 
periplasmic detoxification (Monchy et al., 2006). The role of CopG has yet to be 
confirmed, however it has been hypothesised that it can sequester Cu
+
/Cu
2+
 (based on 
the presence of a CxxC metal-binding motif) and transport it for efflux via CopF, a 
P1-type ATPase (Monchy et al., 2006). Alignment of BLASTp hits revealed that the 
CxxC metal-binding motif is conserved between these proteins (Figure 5.7). Given the 
similarity of this protein to CopG, it seemed appropriate to designate it ―SilG‖ to 
maintain the nomenclature of the Sil operon, and will be referred to as such for the 
remainder of this thesis. 
 
 
186 
 
 
 
Figure 5.7. Alignments of SilG from NCTC 50110 with CopG proteins from 
various species. Conserved CxxC metal-binding motif highlighted in red.  
As the remainder of the sil operon encodes periplasmic- or membrane-bound proteins, it 
seems likely that SilG also fits one of these categories. Analysis of the amino acid 
sequence of SilG by SOSUI determined that this protein does not contain 
transmembrane domains. However, repeating this analysis using the SignalP 4.0 server 
(http://www.cbs.dtu.dk/services/SignalP/ last accessed 6
th
 August 2013) (Petersen et al., 
2011), revealed that the first 19 amino acids of SilG comprise an N-terminal signal 
peptide. In bacteria, proteins with an N-terminal signal peptide enables the translocation 
of the protein into the membrane or the periplasm (Petersen et al., 2011). As SilG does 
not appear to contain any transmembrane domains, which suggests that SilG is a 
periplasmic protein. Although the functional roles of SilG homologues are poorly 
defined, it could be that SilG acts as a periplasmic Ag
+
 chaperone to shuttle Ag
+
 
between the P1-type ATPase SilP and the RND-type efflux pump SilCBA; however 
further experiments will be required to define this role.    
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5.3.2.2. Role of Sil-system components in Ag
+
 resistance  
Although the sil operon is known to confer Ag
+
 resistance, the relative contribution 
provided to Ag
+
 resistance by each protein product produced by the sil operon is 
unclear. Therefore, using a recombineering approach, strains of NCTC 
50110 harbouring a markerless deletion of each sil gene were created. The susceptibility 
of these strains to AgNO3 were then determined. Deletion of either silC, B, A, or E led 
to a complete loss of Ag
+
 resistance, with the MIC of AgNO3 decreasing from 
>256 g/ml to 4-8 g/ml against these strains. Disruption of SilF, P, or G had no 
observable effect on the resistance phenotype. As NCTC 50110 also harbours a Cus 
operon, it may be that components of the Cus system complement the Sil system when 
SilF, P or G are deleted. Indeed, sequence alignments of CusB with SilB reveal that the 
site of CusF binding to CusB is conserved in SilB, thus suggesting that CusF could 
potentially complement SilF when it is not present, and therefore maintain the 
Ag
+
 resistance phenotype (data not shown). To examine this, the entire cus operon was 
deleted in strains lacking silF, G or P, and AgNO3 susceptibility testing repeated. 
Deletion of the Cus system had no effect on the Ag
+
 resistance phenotype when an 
intact sil operon was present. However, deletion of silF in a Cus-negative background 
reduced the MIC of AgNO3 from >256 to 8 g/ml, confirming that SilF is essential to 
Ag
+
 resistance when the Cus system is not present. In contrast, deletion of silP or silG 
individually or combined in a Cus-negative background had no effect on the 
Ag
+
 resistance phenotype, with the MIC of AgNO3 against such strains remaining at 
>256 g/ml. 
As SilP is a predicted efflux pump of the P-type ATPase family, it is anticipated to 
reside within the cytoplasmic membrane and transport substrates (e.g. Ag
+
) from the 
cytoplasm into the periplasm. However, as described in Chapter 4, the antibacterial 
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mode of action of Ag
+
 results from direct damage to the cytoplasmic membrane. Thus, 
the ability for SilP to transport Ag
+
 out of the cytoplasm is not of direct relevance to the 
Ag
+
 resistance phenotype, as any Ag
+
 in the cytoplasm will presumably have already 
passed through (and damaged) the cytoplasmic membrane. Due to the fact that SilP and 
SilG appear not to be essential for conferring Ag
+
 resistance, it would seem likely that 
the primary function of the Sil system is not related to Ag
+
 resistance. As discussed 
previously, components of Cu
+
 homeostasis systems (e.g. Cus and Pco systems) can 
bind and transport Ag
+
, due to the structural similarities between Cu
+
 and Ag
+
 
(Zimmermann et al., 2012). It is therefore plausible that the primary function of the Sil 
system is to act as a Cu
+
 homeostasis mechanism. As the sil operon is found on a 
transposable element with the pco operon (encoding a known Cu
+
/Cu
2+
 homeostasis 
system), the Sil system likely compliments the Pco system, thus allowing the host 
organism to survive in environments containing high concentrations of copper. Future 
studies could use a similar systematic deletion strategy to the one used here to 
determine how Sil-system components contribute to Cu
+
 homeostasis. 
The endogenous Ag
+
 resistance phenotype in E. coli results from reduced ingress of Ag
+
 
into the periplasm (arising from loss of OmpC/F expression) to a concentration that can 
be successfully transported out of the cell by CusCFBA. The mechanism of Ag
+
 
resistance conferred by SilCFBA and SilE appears to be comparable to that of 
endogenous Ag
+
 resistance, in that SilE reduces the concentration of active Ag
+
 in the 
periplasm (albeit by sequestration), and SilCFBA transports the remaining Ag
+
 out of 
the cell before Ag
+
 can damage the cytoplasmic membrane. Although SilE is fulfilling 
the same function as the loss of OmpC/F in Ag
+
 resistance, it is likely to do so in a 
manner that would not confer the fitness burden observed with porin loss. This is due to 
the fact that porin loss also limits the uptake of important solutes, which presumably 
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does not result from expression of SilE. However, in Sil-mediated Ag
+
 resistance it 
seems likely that SilE would soon become saturated with Ag
+
, leading to Ag
+
 
concentrations in the periplasm reaching toxic levels. It is therefore probable that SilE 
acts in a similar manner to SilF/CusF and chaperones Ag
+
 to SilCBA, either directly or 
via transfer to SilF, whereupon Ag
+
 is transported from the periplasm into the 
extracellular milieu. 
5.3.2.3. Sil-based Ag
+
 resistance in other bacterial genera 
Earlier in this study it was demonstrated that the sil operon is contained within a 
Tn7-like transposon. As a consequence, the sil operon may have spread and integrated 
into the chromosomes of a range of bacterial species. To ascertain this, a BLASTn 
search was performed using the nucleotide sequence of the entire Tn7-like transposon 
obtained from this study (i.e. the tns, sil and pco operons). Analysis of the results 
revealed that a number of Gram-negative genera contained the entire transposon, the sil 
and pco operons, or just the sil operon, including Salmonella, Klebsiella, Enterobacter, 
Serratia and Coronobacter spp. In addition, the transposon was located in a number of 
shiga toxin-positive E. coli isolated from an outbreak in 2011 (Ahmed et al., 2012). In 
the isolates containing an intact sil operon, silR, S, C, F, B and A are all incorrectly 
annotated as cus genes, which is likely to provide a false indication of the true levels of 
sil operon prevelance. To confirm that the presence of the sil operon confers Ag
+
 
resistance in these strains, AgNO3 MICs were determined for En. cloacae ATCC 
13047 and a clinical isolate of K. pneumoniae obtained from Leeds General Infirmary. 
These strains were selected as they are both members of the ESKAPE group of 
pathogens that frequently cause nosocomial infections (Boucher et al., 2009) and could 
therefore be present in burn and chronic wound infections treated with Ag
+
-containing 
products. In addition, high-level Ag
+
 resistance has previously been encountered in 
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En. cloacae isolates (Ip et al., 2006; Lansdown & Williams, 2007; Woods et al., 2009). 
Neither strain demonstrated Ag
+
 resistance, as AgNO3 had an MIC of 4 g/ml against 
both strains. However, as with the Cus system, constitutive expression of Sil 
components may be required to confer resistance in a process that requires a mutational 
event in the sequence encoding SilS. As such, the frequency of spontaneous mutation to 
Ag
+
 resistance was assessed for both strains and was found to be 1.9 ± 0.9x10
-8 
and 
3.4 ± 1.7x10
-8
, respectively for En. cloacae and K. pneumoniae. These frequencies are 
consistent with a single mutational event (O‘Neill et al., 2004). Sequence determination 
of silS in both strains revealed the presence of mutations encoding amino acid 
substitutions P213H or A102T for En. cloacae and K. pneumoniae, respectively. It seems 
likely that as with CusS, the mutational events in silS result in the constitutive 
expression of downstream components. Indeed, it has been noted that expression of Sil 
components from pMG101 is constitutive and not dependent upon the presence of Ag
+
 
(Gupta et al., 2001). In order to ascertain the diversity of mutations in silS that can 
confer Ag
+
 resistance, silS was sequenced from a further five independent Ag
+
-resistant 
mutants of En. cloacae and the subsequent mutations mapped to an 
I-TASSER-predicted structure of the cytoplasmic domain of SilS (as described above 
for CusS) (Figure 5.8). Unlike CusS, mutations in silS that confer Ag
+
 resistance all 
resulted in amino acid substitutions localised around the HAMP/signal transduction 
domain of SilS. As hypothesised earlier for CusS, it is likely that HAMP domain 
mutations in SilS allow for the active site of the CA domain to be brought into close 
vicinity of the conserved histidine present on the DHp domain. This would lead to 
continuous phosphorylation of the cognate response regulator (SilR in this case) and 
therefore constitutive expression of the sil operon. However as with CusS, further 
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structural studies will be required to confirm that this conformational change is 
occurring and that the kinase activity of SilS is affected as a consequence. 
  
 
Figure 5.8. Predicted structure of the cytoplasmic domain of SilS in En. cloacae. 
Dimerization and catalytic/ATP-binding domains are shaded orange and purple 
respectively. The conserved histidine residue required for phosphorylation of SilR is 
shaded red and sites of amino acid substitutions associated with Ag
+
 resistance are 
shaded pink. 
 
L242Q 
P213H 
H211R 
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Unlike endogenous Ag
+
 resistance, Ag
+
 resistance conferred by the Sil system does not 
require porin loss to sustain an Ag
+
 resistance phenotype. For this reason it is likely that 
Sil-based Ag
+
 resistance confers a relatively small fitness cost to the cell, as strains 
harbouring the sil operon can still utilise porins to acquire nutrients from the 
extracellular environment. To determine if this is the case, pair-wise competition assays 
were carried out for both Ag
+
-resistant En. cloacae and K. pneumoniae with their 
respective parental strains over 24 h. This resulted in relative fitness values of 
0.91 (±0.04) and 0.98 (±0.02) obtained for En. cloacae and K. pneumoniae, 
respectively. This result indicates that there is only a minimal fitness burden associated 
with Sil-based Ag
+
 resistance and thus provides evidence to suggest that SilE is used as 
an alternative to porin loss to negate the fitness cost that would be imposed by the latter 
phenotype. 
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5.4. Conclusions 
This study has identified the genetic events that underpin endogenous Ag
+
 resistance in 
E. coli. As a consequence of mutations in cusS and ompR, constitutive expression of 
CusCFBA and loss of OmpC/F expression confers an Ag
+
 resistance phenotype with a 
susceptibility to AgNO3 concentrations ≥64-times less than the parental strain. The fact 
that endogenous Ag
+
 resistance arises from disruption to two separate two-component 
systems is an unusual phenomenon, as endogenous resistance to antibacterial agents 
typically arises as a consequence of mutation or overexpression of the antibacterial 
target. The only reported cases of antibacterial resistance arising from mutations to 
two-component systems are nisin resistance in S. aureus, whereby mutations in the 
sensor kinase NsaS result in constitutive expression of VraDE and a homologue of 
VraFG that is essential for the resistance phenotype (Blake et al., 2012; Randall, CP; 
Cruz, M and O‘Neill, AJ., unpublished observations) and polymyxin B resistance in 
P. aeruginosa, which results from constitutive expression of arnBCADTEF (leading to a 
reduction in net negative charge of LPS) as a consequence of mutations in the sensor 
kinase PhoQ (Gutu et al., 2013). However, in all of these studies the mechanistic 
changes conferred by sensor kinase mutations, or the relative kinase/phosphatase 
activities have yet to be elucidated and should be the subject of future studies. 
Although endogenous Ag
+
 resistance in E. coli can arise in a short time frame (six days) 
in the laboratory, its significance from a clinical perspective is unclear. E. coli is rarely 
encountered at sites where Ag
+
 is employed therapeutically when compared with other 
bacterial species, and the endogenous Ag
+
 phenotype harbours a fitness cost which may 
affect its ability to arise and persist in patients. On the other hand, additional prolonged 
exposure to Ag
+
 may select for compensatory mutations that may partially mitigate the 
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fitness cost associated with this phenotype. Again, further studies would be required to 
assess this possibility. 
In contrast to endogenous resistance, horizontally acquired Ag
+
 resistance in the form of 
the Sil system confers no significant fitness cost and is present on a 
Tn7-like transposon, thus potentially allowing for its dissemination into a range of 
Gram-negative pathogens. However, it appears that the presence of the Sil system is not 
synonymous with Ag
+
 resistance, as this study revealed that Sil-positive strains of 
En. cloacae and K. pneumoniae remained susceptible to Ag
+
 until mutations in silS 
were selected. Previous studies have attempted to determine the prevalence of 
Ag
+
 resistance by searching for the presence of sil operon components using a genetic 
approach (Gupta et al., 2001; Silver, 2003; Loh et al., 2009). However, as the data from 
this study indicate, this could lead to an overestimation in the number of strains 
harbouring an Ag
+
 resistance phenotype. Future studies should instead focus on 
screening for phenotypic Ag
+
 resistance by determination of AgNO3 MICs, as this will 
give a true estimate of resistance prevalence. 
Although this study has demonstrated that Ag
+
 resistance can arise in some cases via a 
single mutational step, the frequency of spontaneous mutation to Ag
+
 resistance is at a 
similar level to that seen for most antibiotics. This indicates that Ag
+
-containing 
products still have potential utility for the prevention and treatment of bacterial 
infection. However, clinicians should seek to develop surveillance programs to monitor 
the emergence and spread of Ag
+
-resistant isolates to mitigate any effects of resistance 
on patient morbidity and mortality. Finally, this work has revealed that Ag
+
 efflux is 
essential for both the endogenous and exogenous Ag
+
 resistance phenotypes. This 
discovery could lead to the rational design of efflux pump inhibitors that would negate 
Ag
+
 resistance and extend the utility of Ag
+
 in treating future bacterial infection. 
195 
 
 
Chapter six: General conclusions and future work  
6.1. Bacterial resistance to Ag
+ 
The increasing trend of infections caused by bacteria resistant to one or more antibiotics 
has led to concerns that we are soon to enter a ‗post-antibiotic era‘, wherein mortality 
resulting from infectious disease will reach rates similar to that observed prior to the 
introduction of sulphanilamide and penicillin (Alanis, 2005, Falagas & Bliziotis, 2007). 
It is vital that alternative methods to treat infectious disease are explored to prevent this 
from happening. One approach is to make more substantial use of antibacterial 
compounds that are currently underexploited, such as those containing silver (Ag
+
). 
Originally introduced into modern clinical practice as a cheap alternative to antibiotics 
for preventing burn wound infection (Moyer et al., 1965), the use of antibacterial Ag
+
 
has become widespread over the past decade, with applications ranging from the 
treatment of wound infection, to its incorporation into consumer goods to prevent 
microbial contamination (Silver, 2003, Edwards-Jones, 2009). However, there are 
concerns that such extensive and unrestricted use of antibacterial Ag
+
 will select for the 
proliferation of Ag
+
 resistance amongst bacterial pathogens, thus impacting the utility of 
Ag
+
 in treating bacterial infection (Chopra, 2007). Bacterial resistance to Ag
+
 is known 
to exist (Silver, 2003), although several aspects of the molecular basis of Ag
+
 resistance 
are unclear. In addition, the current prevalence of Ag
+
-resistant pathogens is unknown, 
nor is the propensity for such isolates to arise, persist and spread in a clinical 
environment. The research presented in this thesis sought to address these issues. 
In Chapter 3, the CLSI agar dilution and broth microdilution MIC methodologies were 
found suitable for determining susceptibility to Ag
+
 (in the form of AgNO3) against a 
range of bacteria. Using this method, 1006 isolates of staphylococci collected from 
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hospitals across Europe and Canada were found to be universally susceptible to Ag
+
; 
providing strong evidence to suggest that Ag
+
 resistance amongst this genus is currently 
minimal, or non-existent. However, since a range of other bacterial species also cause 
wound infections that are typically treated with Ag
+
 (e.g. Streptococcus and 
Klebsiella spp., P aeruginosa and A. baumannii) (Rezaei et al., 2011), it would also be 
important to establish the current prevalence of Ag
+
 resistance amongst isolates of these 
species, to justify the continued use of Ag
+ 
in treating wound infection. Future studies 
should attempt to address this aspect, and should strive to utilise the standardised 
method outlined in this thesis to enable a direct comparison of susceptibility data to be 
made between such studies. 
In addition to establishing the current prevalence of Ag
+
 resistance amongst 
staphylococci, the results presented in Chapter 3 revealed that endogenous resistance 
could not be selected in two separate strains of S. aureus in vitro, following continuous 
exposure to sub-inhibitory concentrations of Ag
+
 for 42 days. The universal 
susceptibility of staphylococci to Ag
+
, and failure to select for endogenous resistance to 
Ag
+
, would suggest that Ag
+
-containing compounds remain a viable option for the 
prevention and treatment of topical staphylococcal infections.  
Unlike S. aureus, endogenous Ag
+
 resistance arose relatively quickly (6 days) in E. coli 
following continuous exposure to sub-inhibitory concentrations of Ag
+ 
(Chapter 5). This 
phenotype resulted from a missense mutation in ompR (which prevented expression of 
the porins OmpC and OmpF), and a second missense mutation in cusS (which enabled 
constitutive expression of the Ag
+
 efflux pump, CusCFBA). Using pair-wise 
competition assays, this phenotype was found to confer a significant fitness cost 
(W=0.71); however, as antibiotic-resistant strains of bacteria have been isolated from 
patients with W values less than this (O'Neill et al., 2006), it appears unlikely that the 
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fitness cost associated with endogenous Ag
+
 resistance in E. coli will act as a barrier to 
the emergence and survival of this phenotype in patients. Nevertheless, it would be 
beneficial to ascertain if selection of this phenotype could occur in vivo, using an 
appropriate animal model and a commercial Ag
+
-containing product. 
Although endogenous Ag
+
 resistance could be selected in E. coli, resistance did not 
arise in other Gram-negative bacteria (A. baumannii, P. aeruginosa, C. freundii and 
S. sonnei), after continuous exposure to Ag
+
 for 42 days. This suggests that in the 
emergence of endogenous Ag
+
 resistance in these strains would be unlikely in vivo. 
However, this result does not exclude the possibility that these strains (or others) could 
acquire an Ag
+
-resistance determinant by horizontal gene transfer. Indeed, exogenous 
Ag
+
 resistance has previously been encountered in Gram-negative bacteria (see Table 
1.5.), and may therefore represent a threat to the continued use of therapeutic Ag
+
. One 
such exogenous Ag
+
-resistance determinant is the sil operon, which was first identified 
on the S. Typhimurium plasmid pMG101 (Gupta et al., 1999). To provide further 
insight into this determinant, the whole genome sequence of E. coli strain 
NCTC 50110 (containing pMG101) was determined (Chapter 5). Analysis revealed that 
the sil operon was located on a Tn7-like transposable element that had integrated into 
the E. coli chromosome (termed Tn7sil). The archetypical Tn7 system can integrate into 
a specific site on bacterial chromosomes, termed the attTn7 sequence, in a process 
mediated by the transposition proteins TnsABCD (Peters & Craig, 2001). Non-specific 
integration of Tn7 into conjugative plasmids can also occur, resulting from TnsE 
directing TnsABC-mediated transposition of such plasmids during their replication 
(Peters & Craig, 2001). The presence of a clinically-relevant Ag
+
-resistance determinant 
on a Tn7-like transposon is therefore a cause for concern, as this determinant could 
disseminate with relative ease into a range of bacterial species; including those which 
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cause infections routinely treated with Ag
+
. However, Tn7sil does not contain TnsE and 
lacks IR elements (Tn7-L and Tn7-R) that typically flank Tn7-like transposons, thus the 
functionality of Tn7sil relative to the archetypical Tn7 system is unclear; particularly 
with respect to the ability of Tn7sil to integrate into conjugative plasmids (given the 
lack of TnsE in this system). To establish if Tn7sil can transpose from the chromosome 
onto a conjugative plasmid, NCTC 50110 could be cured of pMG1 01, then transformed 
with another conjugative plasmid. Transposition of Tn7sil onto this new plasmid could 
be confirmed by establishing if Ag
+
 resistance is transmissible to other strains by 
conjugation. 
Although the functionality of Tn7sil is unclear, a BLASTn search using the nucleotide 
sequence of Tn7sil revealed it to be present in strains of E. coli, S. Heidelberg, 
Se. marcescens and Coronobacter  sakazakii  with >99% sequence identity. This would 
seem to suggest that Tn7sil is indeed capable of disseminating Ag
+
 resistance. In 
addition, the sil operon (i.e. not contained within Tn7sil) was identified in a number of 
En. cloacae and K. pneumoniae strains. However, as demonstrated in Chapter 5, 
representative isolates of these species did not display intrinsic Ag
+
 resistance until 
missense mutations were selected in silS, which encodes the putative sensor kinase 
believed to regulate expression of the Sil system (Gupta et al., 1999). This result 
indicates that, as with CusCFBA, it is likely that the constitutive, high-level, expression 
of Sil system components is required to confer Ag
+
 resistance; this could be confirmed 
by similar qPCR experiments to those performed in Chapter 3. This study has revealed 
that the presence of sil is not synonymous with Ag
+
 resistance, thus highlighting that the 
genotypic screens for sil components used in prior studies (Silver, 2003; Percival et al., 
2008) may not reliably predict the true prevalence of phenotypic Ag
+
 resistance.  
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In summary, Ag
+
 resistance can arise with relative ease in E. coli, En. cloacae and 
K. pneumoniae in vitro, and an exogenous Ag
+
-resistance determinant has been 
identified on a transposable element that has the potential to disseminate Ag
+
 resistance 
amongst a range of Gram-negative bacteria. As Ag
+
 resistance has resulted in the failure 
of Ag
+
 therapy to prevent infection in the past (McHugh et al., 1975; Gayle et al., 
1978), it would seem prudent to restrict the use of Ag
+
 in consumer goods; the current 
prolific use of Ag
+
 in such products likely provides a selective pressure that could 
accelerate the emergence of widespread Ag
+
 resistance amongst clinically relevant 
pathogens, which in turn will limit the use of Ag
+
 in treating infectious disease. 
Inhibitors of the Ag
+
 resistance phenotype conferred by Sil- and Cus-based mechanisms 
could be of benefit in limiting the clinical impact of Ag
+
 resistance. Using 
recombineering, deletion of any component of the RND-type efflux pumps of the Cus 
(CusCBA) and Sil (SilCBA) systems resulted in a complete loss of Ag
+
 resistance 
(Chapter 5). This finding suggests that inhibitors of Ag
+
 resistance could be developed 
by identifying a compound that can bind and disrupt the function of one (or more) of 
these proteins. Inhibitors of RND-type efflux pumps (e.g. PAβN and chlorpromazine) 
have already been identified (Renau et al., 1999; Viveiros et al., 2008) and a future 
study could assess the utility of these compounds in disrupting Ag
+
 resistance. In 
addition, as the structures of CusC, B and A have been solved (Kulathila et al., 2011; Su 
et al., 2011), a SBDD approach could be used to identify putative inhibitors of these 
proteins (Simmons et al., 2010).  
Although this study has furthered our understanding of Cus- and Sil-based Ag
+
 
resistance, other exogenous Ag
+
-resistance determinants have been identified (present 
on plasmids pKK1, pJT1 and pUPI199) that are proposed to confer resistance by an 
alternative mechanism to efflux (see section 1.2.6). Unsuccessful attempts were made to 
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obtain these plasmids. Therefore the molecular basis of resistance, and the fitness cost 
associated with the maintenance of these elements, remain unclear. 
6.2. Antibacterial MOA of Ag
+
 
Another objective of the work presented in this thesis was to elucidate the antibacterial 
MOA of Ag
+
. Although a number of studies have demonstrated that Ag
+
 can bind and 
impact the integrity of DNA, proteins and the cell membrane, it is unclear if these 
effects are the cause of Ag
+
-mediated cell inhibition/death, or are secondary to the 
primary antibacterial action of Ag
+
. The results presented in Chapter 4 indicate that the 
cell membrane is the likely antibacterial target of Ag
+
, as Ag
+
 exposure resulted in a 
rapid (10 min) and substantial loss of integrity. The inability of Ag
+
 to damage 
liposomes implies that Ag
+
-mediated membrane damage likely arises from disruption of 
integral membrane proteins. Indeed, evidence from DNA microarray analysis seems to 
support this hypothesis, as the expression of a number of integral membrane proteins 
increased in cells exposed to Ag
+
. This mechanism of membrane damage could be 
confirmed in future studies by assessing the ability of Ag
+
 to damage 
carboxyfluorescein-filled vesicles comprised of reconstituted bacterial membrane (i.e. 
comprising phospholipid and protein), performed in a similar manner to the liposome 
assay described in this thesis. In addition, the effect of Ag
+
 on membrane proteins could 
be directly visualised in vivo using atomic force microscopy (AFM). Indeed, AFM has 
previously been used to image the outer membrane of live 
Magnetospirillum magnetotacticum, at a resolution sufficient to visualise porin channels 
(Yamashita et al., 2012).  
One rationale for elucidating the MOA of Ag
+
 was to enable the identification of ways 
to improve antibacterial activity of Ag
+
. In Chapter 4, it was shown that exposure of 
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S. aureus to Ag
+
 induced the formation of ROS, albeit at levels that did not impact cell 
viability. Nevertheless, if Ag
+
 could be combined with another compound that also 
induces ROS formation, their combined action might produce sufficient ROS to 
overwhelm host detoxification mechanisms and cause oxidative damage to the cell. A 
previous study has demonstrated that the combination of Ag
+
 and Paraquat (which 
generates O2
-
 via redox cycling) is synergistic against E. coli (Park et al., 2009). 
Furthermore, Ag
+
-mediated membrane damage may enable increased uptake of 
antibiotics with an intracellular target and therefore be synergistic in combination. This 
phenomenon has been described previously for known membrane-damaging 
compounds used in combination with -lactams, macrolides, tetracyclines and 
aminoglycosides (Hemaiswarya & Doble, 2009, Choi & Lee, 2012). Indeed, a 
publication arising after the completion of the work in this thesis revealed that Ag
+
 is 
synergistic with ampicillin and ofloxacin against E. coli in vitro and with gentamicin 
and vancomycin in an in vivo mouse UTI and peritoneal infection model, respectively 
(Morones-Ramirez et al., 2013). Although this latter study did not assess the long-term 
toxicity associated with using Ag
+
 in this manner, this result demonstrates a potential 
future application of Ag
+
 as a systemic antibacterial agent. This prospect provides 
further impetus to restrict the use of antibacterial Ag
+
 in consumer products, so that the 
clinical lifespan of Ag
+
 is not prematurely cut short by the rapid proliferation of Ag
+
 
resistance.   
As discussed in Chapters 1 and 3, Ag
+
 can be bound and inactivated by protein and 
halide anions. As these components are present in environments where Ag
+
 is 
employed, it is unclear how much Ag
+
 remains available to exert an antibacterial effect 
(Liau et al., 1997; Gupta et al., 1998). As a consequence the antibacterial properties of 
Ag
+
-containing products in vitro may be attenuated in environments such as the wound. 
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One way to address this problem experimentally is to develop bacterial Ag
+
 biosensors, 
which link Ag
+
 sensing to the production of a quantifiable output (e.g. the production of 
fluorescence from GFP or luminescence from luciferase). Such a system could then be 
used to give a true measure of the active Ag
+
 concentration in any given environment 
(as only free Ag
+
 would be detected by the sensor). This concept has been employed 
previously in the creation of biosensors that can detect and quantify arsenic (Diesel et 
al., 2009). To create an Ag
+
 biosensor, the CusRS two-component system could be 
exploited for the sensing of extracellular Ag
+
, as this system was shown to be a positive 
regulator of gene expression upon Ag
+
 exposure in Chapter 5. A gene encoding a 
reporter protein (e.g. GFP of luciferase) could then be fused downstream of the 
cusR-cusC intergenic region (i.e. the region that phosphorylated CusR binds and recruits 
RNA polymerase), to enable its expression following Ag
+
 stimulus.  
Collectively, this work has produced detailed insights into the MOA of Ag
+
 and the 
prevalence and mechanisms of bacterial Ag
+
 resistance. The results presented in this 
thesis, in combination with the additional studies recommended in this chapter should 
provide further insight into optimising the future use of Ag
+
 in treating infectious 
disease. 
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Appendix 1. Transcriptional profile of S. aureus SH1000 exposed to 
Ag+ 
Table A1.1. Up-regulated genes in S. aureus SH1000 in response to Ag
+
 exposure 
(sorted according to JCVI cellular role categories) 
Gene Fold 
change 
in 
express
ion 
Protein/Function JCVI 
Cellular 
Role 
SubCatego
ry 
Amino acid biosynthesis 
SAOUHSC_01367 2.0 up Anthranilate synthase component II Aromatic 
amino acid 
family 
SAOUHSC_01371 2.7 up Tryptophan synthase subunit beta  Aromatic 
amino acid 
family 
SAOUHSC_01372 2.2 up Tryptophan synthase subunit alpha, TrpA Aromatic 
amino acid 
family 
SAOUHSC_00340 2.8 up Cystathionine beta-lyase Aspartate 
family 
SAOUHSC_00341 3.0 up Cystathionine gamma-synthase  Aspartate 
family 
SAOUHSC_01319 2.1 up Aspartate kinase Aspartate 
family 
SAOUHSC_01394 2.2 up Aspartate kinase Aspartate 
family 
SAOUHSC_02770 2.0 up Diaminopimelate epimerase family protein  Aspartate 
family 
SAOUHSC_00150 2.9 up Ornithine aminotransferase Glutamate 
family 
SAOUHSC_00435 2.0 up Glutamate synthase, large subunit, putative Glutamate 
family 
SAOUHSC_02968 3.5 up Ornithine carbamoyltransferase Glutamate 
family 
SAOUHSC_02970 3.0 up Transcriptional regulator of arginine synthesis Glutamate 
family 
SAOUHSC_03008 3.7 up Imidazole glycerol phosphate synthase subunit HisF, 
putative 
Histidine 
family 
SAOUHSC_03009 4.3 up 1-(5-phosphoribosyl)-5-[(5- phosphoribosylamino)meth
ylideneamino] imidazole-4-carboxamide isomerase 
Histidine 
family 
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Table A1.1 (continued) 
SAOUHSC_03010 4.0 up Imidazole glycerol phosphate synthase subunit HisH Histidine 
family 
SAOUHSC_03011 3.4 up Imidazoleglycerol-phosphate dehydratase. HisB Histidine 
family 
SAOUHSC_03013 3.3 up Histidinol dehydrogenase Histidine 
family 
SAOUHSC_03014 3.8 up ATP phosphoribosyltransferase catalytic subunit HisG Histidine 
family 
SAOUHSC_00264 2.2 up Virulence protein EsaC (component of the 
ESAT-6 secretion system) 
Pyruvate family 
SAOUHSC_01451 3.2 up Threonine dehydratase Pyruvate family 
SAOUHSC_02281 3.5 up Dihydroxy-acid dehydratase Pyruvate family 
SAOUHSC_02282 2.5 up Acetolactate synthase large subunit Pyruvate family 
SAOUHSC_02284 2.4 up Ketol-acid reductoisomerase Pyruvate family 
SAOUHSC_02285 2.3 up 2-isopropylmalate synthase Pyruvate family 
SAOUHSC_02286 2.5 up 3-isopropylmalate dehydrogenase Pyruvate family 
SAOUHSC_02287 2.5 up Isopropylmalate isomerase large subunit Pyruvate family 
SAOUHSC_02288 2.4 up Isopropylmalate isomerase small subunit, 
LeuD 
Pyruvate family 
SAOUHSC_00075 3.7 up Cysteine synthase/cystathionine beta-synthase 
family protein 
Serine family 
 
Biosynthesis of cofactors, prosthetic groups, and carriers 
SAOUHSC_02714 2.2 up Biotin synthase Biotin 
SAOUHSC_02715 2.2 up Adenosylmethionine-8-amino-7-oxononanoate 
aminotransferase 
Biotin 
SAOUHSC_02716 2.3 up Dethiobiotin synthase, putative Biotin 
SAOUHSC_00171 2.6 up Gamma-glutamyltranspeptidase, putative Glutathione and 
analogs 
SAOUHSC_02682 2.1 up Uroporphyrin-III C-methyltransferase, SirB, 
putative 
Heme, porphyrin, 
and cobalamin 
SAOUHSC_02901 2.5 up Cobalamin (vitamin B12) biosynthesis protein Heme, porphyrin, 
and cobalamin 
 
Cell envelope 
SAOUHSC_00052 2.5 up Tandem lipoprotein Other 
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Table A1.1 (continued) 
SAOUHSC_00137 2.1 up Sulfonate/nitrate/taurine transport system 
substrate-binding protein 
Other 
SAOUHSC_01843 2.4 up Haptoglobin-binding heme uptake protein, 
HarA 
Other 
SAOUHSC_01873 2.4 up Cell-wall-anchored protein, SasC Other 
SAOUHSC_01917 2.6 up Putative lipoprotein Other 
SAOUHSC_00181 2.2 up Sugar phosphate isomerase/epimerase Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00089 4.3 up Capsular polysaccharide biosynthesis 
glycosyltransferase (sugar transferase) 
Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00091 2.4 up Hypothetical capsular biosynthesis 
protein/O-antigen polymerase 
Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_03000 2.6 up Capsular polysaccharide biosynthesis, 
capA, putative 
Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_03002 3.3 up N-glycosyltransferase PgaC Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00053 2.0 up Tandem lipoprotein Other 
SAOUHSC_00146 2.1 up Integral membrane protein Other 
SAOUHSC_00182 2.1 up Putative isoprenylcysteine carboxyl 
methyltransferase 
Other 
SAOUHSC_00200 2.3 up  Other 
SAOUHSC_00255 2.4 up Membrane protein, putative Other 
SAOUHSC_00327 2.3 up Ferrous iron transport permease EfeU Other 
SAOUHSC_02888 4.5 up Hypothetical phosphotransferase system 
IIC component 
Other 
SAOUHSC_03020 2.5 up Membrane protein of unknown function Other 
SAOUHSC_03035 2.1 up Conserved hypothetical protein of 
unknown function 
Other 
SAOUHSC_01764 2.0 up A24 type IV prepilin peptidase family 
protein 
Surface structures 
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Table A1.1 (continued) 
Cellular processes 
SAOUHSC_02932 2.5 up Choline dehydrogenase Adaptations to atypical 
conditions 
SAOUHSC_02933 2.1 up Betaine aldehyde dehydrogenase Adaptations to atypical 
conditions 
SAOUHSC_00229 2.3 up Cell wall biosynthesis protein ScdA Cell division 
SAOUHSC_00766 2.0 up Hypothetical protein DNA transformation 
SAOUHSC_01939 2.4 up Serine protease SplC Pathogenesis 
SAOUHSC_01942 4.1 up Serine protease SplA Pathogenesis 
SAOUHSC_01954 2.0 up Leukotoxin, LukD Pathogenesis 
SAOUHSC_01955 2.3 up Leukotoxin, LukE, putative Pathogenesis 
SAOUHSC_00130 4.4 up Heme-degrading monooxygenase IsdI Toxin production and 
resistance 
SAOUHSC_00383 3.3 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00384  2.4 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00386 5.0 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00389 5.6 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00390 3.6 up Superantigen-like protein 5 Toxin production and 
resistance 
SAOUHSC_00391 3.6 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00393 2.4 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_00399 3.5 up Superantigen-like protein Toxin production and 
resistance 
SAOUHSC_03023 3.4 up Calcium-dependent lactonase Drp35 Toxin production and 
resistance 
Central intermediary metabolism 
SAOUHSC_00081 2.8 up Siderophore staphylobactin biosynthesis 
protein SbnG 
Other 
SAOUHSC_02555 2.1 up Acyl-CoA dehydrogenase, C-terminal 
domain protein 
Other 
SAOUHSC_02924 5.5 up 4-aminobutyrate aminotransferase Other 
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Table A1.1 (continued) 
SAOUHSC_02958 3.1 up Alkaline phosphatase III precursor, 
putative 
Other 
SAOUHSC_02997 2.2 up Acetyltransferase, GNAT family Other 
SAOUHSC_02998 3.4 up Capsular polysaccharide biosynthesis 
protein, Cap5C 
Other 
SAOUHSC_03012 3.1 up Histidinol-phosphate aminotransferase, 
putative 
Other 
DNA metabolism 
SAOUHSC_00765 2.3 up Competence protein ComFA DNA replication, 
recombination, and 
repair 
SAOUHSC_01763 3.1 up DNA repair protein RadC DNA replication, 
recombination, and 
repair 
SAOUHSC_01933 2.2 up Type I restriction-modification system, M 
subunit 
Restriction/modification 
Energy metabolism 
SAOUHSC_00008 2.0 up Histidine ammonia-lyase, HutH Amino acids and 
amines 
SAOUHSC_00076 4.5 up Ornithine cyclodeaminase, putative Amino acids and 
amines 
SAOUHSC_01452 3.1 up Alanine dehydrogenase Amino acids and 
amines 
SAOUHSC_02606 2.8 up Imidazolonepropionase Amino acids and 
amines 
SAOUHSC_02607 3.2 up Urocanate hydratase Amino acids and 
amines 
SAOUHSC_02965 2.4 up Carbamate kinase Amino acids and 
amines 
SAOUHSC_02969 2.9 up Arginine deiminase Amino acids and 
amines 
SAOUHSC_00142 3.9 up Formate dehydrogenase Anaerobic 
SAOUHSC_00188 3.2 up Pyruvate formate-lyase 1 activating 
enzyme, putative 
Anaerobic 
SAOUHSC_02680 2.3 up Nitrate reductase, beta subunit Anaerobic 
SAOUHSC_02681 3.5 up Nitrate reductase, alpha subunit Anaerobic 
SAOUHSC_02685 4.0 up Transcriptional regulator, NirR Anaerobic 
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Table A1.1 (continued) 
SAOUHSC_02452 2.2 up Tagatose 1,6-diphosphate aldolase, LacD Biosynthesis and 
degradation of 
polysaccharides 
SAOUHSC_02453 2.2 up Tagatose-6-phosphate kinase, LacC Biosynthesis and 
degradation of 
polysaccharides 
SAOUHSC_02454 2.0 up Galactose-6-phosphate isomerase subunit 
LacB 
Biosynthesis and 
degradation of 
polysaccharides 
SAOUHSC_02455 2.5 up Galactose-6-phosphate isomerase subunit, 
LacA 
Biosynthesis and 
degradation of 
polysaccharides 
SAOUHSC_02904 2.6 up Hypothetical thioredoxin reductase Electron transport 
SAOUHSC_02911 2.7 up Conserved hypothetical protein Electron transport 
SAOUHSC_00113 3.1 up Bifunctional acetaldehyde-CoA/alcohol 
dehydrogenase 
Fermentation 
SAOUHSC_00170 2.8 up RGD-containing lipoprotein Fermentation 
SAOUHSC_00187 2.3 up Formate acetyltransferase Fermentation 
SAOUHSC_00217 3.2 up Sorbitol dehydrogenase, putative Fermentation 
SAOUHSC_00608 2.2 up Alcohol dehydrogenase Fermentation 
SAOUHSC_02921 3.2 up Alpha-acetolactate decarboxylase Fermentation 
SAOUHSC_01846 2.4 up Acetyl-CoA synthetase Other 
SAOUHSC_01849 2.6 up Acetoin utilization protein, AcuC Other 
SAOUHSC_02825 3.0 up Putative glyoxylase-family protein Other 
SAOUHSC_02894 3.2 up Putative glyoxylase-family protein Other 
SAOUHSC_00088 3.7 up UDP-glucose 4-epimerase Sugars 
SAOUHSC_00219 2.7 up Sorbitol dehydrogenase, putative Sugars 
SAOUHSC_00291 4.8 up PfkB-family carbohydrate kinase Sugars 
SAOUHSC_00298 3.4 up N-acetylmannosamine-6-phosphate 
2-epimerase 
Sugars 
SAOUHSC_02821 2.0 up Transmembrane protein SmpB Electron transport 
 
Fatty acid and phospholipid metabolism 
SAOUHSC_00196 2.4 up 3-hydroxyacyl-CoA dehydrogenase, FadB Degradation 
SAOUHSC_00197 4.1 up Acyl-CoA dehydrogenase, FadD Degradation 
SAOUHSC_00195 3.8 up Acetyl-CoA acetyltransferase, FadA Other 
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Table A1.1 (continued) 
SAOUHSC_00051 3.2 up 1-phosphatidylinositol phosphodiesterase 
precursor, putative 
Degradation 
 
Mobile and extrachromosomal element functions 
SAOUHSC_00112 2.0 up IS200 family transposase Transposon functions 
SAOUHSC_00352 2.2 up Integrase-like protein Transposon functions 
SAOUHSC_00353 2.1 up Putative integrase Transposon functions 
SAOUHSC_01390 2.8 up Truncated IS1272 transposase Transposon functions 
SAOUHSC_01410 2.4 up Putative transposase Transposon functions 
SAOUHSC_01804 2.6 up Transposase, putative Transposon functions 
SAOUHSC_01805 2.2 up Putative transposase Transposon functions 
SAOUHSC_01905 2.6 up Truncated transposase, putative Transposon functions 
SAOUHSC_01906 2.9 up Truncated transposase, putative Transposon functions 
SAOUHSC_01911 2.2 up IS200 family transposase Transposon functions 
SAOUHSC_02437 2.4 up ISSau3 transposase Transposon functions 
SAOUHSC_02438 2.4 up ISSau3 transposase Transposon functions 
SAOUHSC_02440 2.9 up ISSau3 transposase Transposon functions 
SAOUHSC_02639 2.2 up ISSau3 transposase Transposon functions 
 
Protein fate 
SAOUHSC_00326 3.1 up Dyp-type peroxidase family protein Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_02605 2.9 up Putative amino acid 
amidohydrolase/peptidase 
Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_02755 2.1 up Putative cellulase/endo-1,4-beta-glucanase Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_02915 2.3 up CocE/NonD family hydrolase/peptidase Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_02971 4.2 up Zinc metalloproteinase aureolysin Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_03025 3.3 up Pyrrolidone-carboxylate peptidase Degradation of proteins, 
peptides, and 
glycopeptides 
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Table A1.1 (continued) 
SAOUHSC_01935 2.1 up Serine protease SplF, putative Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_01941 3.6 up Serine protease SplB Degradation of proteins, 
peptides, and 
glycopeptides 
SAOUHSC_00299 3.0 up Putative membrane protein Protein and peptide 
secretion and trafficking 
SAOUHSC_01641 2.1 up Competence protein, ComGB Protein and peptide 
secretion and trafficking 
SAOUHSC_02902 2.7 up FeoB family ferrous iron (Fe
2+
) uptake 
protein 
Protein and peptide 
secretion and trafficking 
 
Protein synthesis 
SAOUHSC_00198 3.9 up Conserved hypothetical protein tRNA aminoacylation 
SAOUHSC_00237 3.1 up SAM dependent methyltransferase tRNA and rRNA base 
modification 
Purines, pyrimidines, nucleosides and nucleotides 
SAOUHSC_02941 2.8 up Anaerobic ribonucleotide reductase 
activating protein 
 2'-Deoxyribonucleotide 
metabolism 
SAOUHSC_00107 2.0 up 5' nucleotidase family protein Nucleotide and 
nucleoside 
interconversions 
SAOUHSC_00097 2.0 up Purine nucleoside phosphorylase Salvage of nucleosides 
and nucleotides 
SAOUHSC_03015 4.3 up ATP phosphoribosyltransferase regulatory 
subunit 
Salvage of nucleosides 
and nucleotides 
 
Regulatory functions 
SAOUHSC_02726 2.2 up Positive transcriptional activator, putative DNA interactions 
SAOUHSC_02809 2.5 up Gluconate operon transcriptional repressor DNA interactions 
SAOUHSC_00157 2.4 up N-acetylmuramic acid-6-phosphate 
etherase 
Other 
SAOUHSC_02826 2.6 up MarR-family transcription regulator Other 
SAOUHSC_02451 2.8 up PTS system, lactose-specific IIA 
component, LacE 
Protein interactions 
SAOUHSC_00233 5.2 up Antiholin-like protein LrgB Other 
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Table A1.1 (continued) 
Transport and binding proteins 
SAOUHSC_00136 4.1 up Sulfonate/nitrate/taurine transport system 
ATP-binding protein 
Amino acids, peptides 
and amines 
SAOUHSC_00167 2.2 up Glutathione import ATP-binding protein 
GsiA 
Amino acids, peptides 
and amines 
SAOUHSC_00176 3.4 up Maltose/maltodextrin transporter Amino acids, peptides 
and amines 
SAOUHSC_00928 2.9 up Oligopeptide ABC transporter, 
substrate-binding protein, putative 
Amino acids, peptides 
and amines 
SAOUHSC_00929 3.4 up Oligopeptide ABC transporter, 
ATP-binding protein, putative 
Amino acids, peptides 
and amines 
SAOUHSC_02283 3.0 up Acetolactate synthase 1 regulatory subunit Amino acids, peptides 
and amines 
SAOUHSC_03019 2.4 up Putative cobalt ABC transporter, 
ATP-binding protein 
Amino acids, peptides 
and amines 
SAOUHSC_00010 2.4 up Putative azaleucine resistance protein 
AzlC 
Amino acids, peptides 
and amines 
SAOUHSC_00012 2.3 up Putative azaleucine resistance protein 
AzlD 
Amino acids, peptides 
and amines 
SAOUHSC_00078 3.7 up Siderophore staphylobactin biosynthesis 
protein SbnD 
Amino acids, peptides 
and amines 
SAOUHSC_00168 2.1 up Nickel ABC transporter, permease subunit 
NikB 
Amino acids, peptides 
and amines 
SAOUHSC_00169 3.7 up Peptide ABC transporter, permease 
protein, putative 
Amino acids, peptides 
and amines 
SAOUHSC_00241 2.0 up Ribose transporter RbsU Amino acids, peptides 
and amines 
SAOUHSC_00932 2.3 up Oligopeptide ABC transporter, permease 
protein, putative 
Amino acids, peptides 
and amines 
SAOUHSC_01450 2.7 up Amino acid permease/transporter protein Amino acids, peptides 
and amines 
SAOUHSC_02967 2.2 up Arginine/ornithine antiporter, putative Amino acids, peptides 
and amines 
SAOUHSC_00104 2.4 up Phosphonate ABC transporter, 
ATP-binding protein 
Anions 
SAOUHSC_00102 2.9 up Phosphonate ABC transporter, permease 
protein PhnE 
Anions 
SAOUHSC_00103 2.8 up Phosphonate ABC transporter, permease 
PhnE 
Anions 
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Table A1.1 (continued) 
SAOUHSC_00138 4.0 up Putative ABC-type nitrate sulfonate 
taurine bicarbonate transport system 
permease component 
Anions 
SAOUHSC_00281 2.5 up FNT family formate-nitrite transporter Anions 
SAOUHSC_01387 2.7 up Phosphate ABC superfamily ATP binding 
cassette transporter PstC 
Anions 
SAOUHSC_02671 2.4 up Nitrite extrusion protein Anions 
SAOUHSC_00175 3.7 up Multiple sugar-binding transport 
ATP-binding protein, putative 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00213 2.2 up Putative phosphotransferase system 
regulator. Contains BlgG-family 
transcriptional anti-terminator 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00214 2.0 up Phosphoenolpyruvate-dependent sugar 
phosphotransferase system, EIIA 2, 
putative 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00215 3.2 up PTS system, galactitol-specific enzyme II 
B component 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00311 3.3 up PTS system, ascorbate-specific IIB 
component 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00312 3.2 up PTS family porter component IIA Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00313 2.0 up Putative phosphotransferase system 
regulator. Contains BlgG-family 
transcriptional anti-terminator 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_02708 2.2 up Gamma-hemolysin h-gamma-II subunit, 
putative 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00158 2.9 up PTS system component, sucrose specific Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00209 3.0 up PTS system, glucose-specific IIBC 
component, putative 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00216 3.2 up PTS system component Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00310 2.5 up Ascorbate-specific PTS system enzyme, 
UlaA 
Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_02597 2.3 up PTS system component, putative Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_02806 2.4 up Gluconate permease, putative Carbohydrates, organic 
alcohols, and acids 
SAOUHSC_00077 4.5 up Siderophore staphylobactin biosynthesis 
protein SbnC (IucA/IucC family 
siderophore biosynthesis protein) 
Cations and iron 
carrying compounds 
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Table A1.1 (continued) 
SAOUHSC_00079 3.1 up Siderophore staphylobactin biosynthesis 
protein SbnE (IucA/IucC family 
Siderophore biosynthesis protein) 
Cations and iron 
carrying compounds 
SAOUHSC_00080 2.6 up Siderophore biosynthesis protein SbnF 
(IucA/IucC family siderophore 
biosynthesis protein) 
Cations and iron 
carrying compounds 
SAOUHSC_02767 2.1 up Nickel ABC transporter, periplasmic 
nickel-binding protein 
Cations and iron 
carrying compounds 
SAOUHSC_00071 2.1 up Lipoprotein, SirC, putative Cations and iron 
carrying compounds 
SAOUHSC_00072 3.2 up Lipoprotein, SirB, putative Cations and iron 
carrying compounds 
SAOUHSC_00420 3.8 up NSS family amino acid:sodium (Na+) 
symporter 
Cations and iron 
carrying compounds 
SAOUHSC_02270 2.7 up Ammonium transporter Cations and iron 
carrying compounds 
SAOUHSC_02864 2.6 up Ferrous iron transport protein B Cations and iron 
carrying compounds 
SAOUHSC_00293 3.7 up Nucleoside permease NupC, putative Nucleosides, purines 
and pyrimidines 
SAOUHSC_00315 2.1 up Multidrug export protein MepA Other 
SAOUHSC_00317 3.0 up glycerol-3-phosphate transporter Other 
SAOUHSC_00423 2.0 up Methionine import ATP-binding protein 
MetN 
Unknown substrate 
SAOUHSC_02820 2.0 up ABC transporter ATP-binding protein  Unknown substrate 
SAOUHSC_00099 2.1 up MFS family transporter: 
tetracycline:cation symporter 
Unknown substrate 
SAOUHSC_00177 2.8 up Maltose ABC transporter, permease 
protein, putative 
Unknown substrate 
SAOUHSC_00183 4.1 up Sugar phosphate antiporter, UhpT Unknown substrate 
SAOUHSC_00246 3.4 up Quinolone-resistance protein NorB, 
putative 
Unknown substrate 
SAOUHSC_00294 4.3 up SSS family solute:sodium (Na+) 
symporter 
Unknown substrate 
SAOUHSC_02658 2.2 up Membrane protein, putative Unknown substrate 
SAOUHSC_02719 2.1 up ABC transporter ATP-binding protein Unknown substrate 
SAOUHSC_02797 2.1 up Major facilitator superfamily transporter Unknown substrate 
SAOUHSC_02815 2.1 up MFS family major facilitator transporter Unknown substrate 
SAOUHSC_03037 2.0 up ATP permease, VraD, putative Unknown substrate 
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Table A1.1 (continued) 
SAOUHSC_00087 5.5 up Hypothetical protein of unknown function Unknown substrate 
SAOUHSC_00108 3.4 up Putative transcription regulator Unknown substrate 
SAOUHSC_00316 2.5 up MepB - component of MepRAB multidrug 
export operon 
Unknown substrate 
Unknown/unassigned function 
SAOUHSC_00323 2.6 up Hypothetical protein of unknown function  
SAOUHSC_00387 4.2 up Hypothetical protein of unknown function  
SAOUHSC_00418 4.4 up Hypothetical protein of unknown function  
SAOUHSC_00962 2.1 up Hypothetical protein of unknown function  
SAOUHSC_00977 2.8 up Hypothetical protein of unknown function  
SAOUHSC_01300 2.1 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_01465 2.1 up Hypothetical protein of unknown function  
SAOUHSC_02596 3.1 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02655 2.0 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02769 2.7 up rRNA methyltransferase FmrO  
SAOUHSC_02805 4.3 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02893 2.7 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02896 2.4 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_00243 2.4 up NADH dehydrogenase subunit, putative  
SAOUHSC_01409 2.3 up Putative transposase  
SAOUHSC_00069 2.6 up Staphylococcal protein A, Spa  
SAOUHSC_00256 2.9 up Staphyloxanthin biosynthesis protein  
SAOUHSC_00154 4.5 up Hypothetical protein of unknown function  
SAOUHSC_00189 2.9 up Hypothetical protein of unknown function  
SAOUHSC_00194 2.6 up Hypothetical protein of unknown function  
SAOUHSC_00212 2.0 up Hypothetical protein of unknown function  
SAOUHSC_00238 3.5 up Hypothetical protein of unknown function  
SAOUHSC_00303 2.2 up Hypothetical protein of unknown function  
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SAOUHSC_00396 5.3 up Hypothetical protein of unknown function  
SAOUHSC_00609 2.3 up Hypothetical protein of unknown function  
SAOUHSC_00745 4.3 up Hypothetical protein of unknown function  
SAOUHSC_00967 3.4 up Hypothetical protein of unknown function  
SAOUHSC_01003 2.4 up Hypothetical protein of unknown function  
SAOUHSC_01212 2.2 up Hypothetical protein of unknown 
function - no known homologues 
 
SAOUHSC_01293 2.0 up Hypothetical protein of unknown function  
SAOUHSC_01298 2.3 up Hypothetical protein of unknown function  
SAOUHSC_01299 2.8 up Phage protein F-like protein  
SAOUHSC_01339 2.1 up Hypothetical protein of unknown 
function - no known homologues 
 
SAOUHSC_01765 2.8 up Hypothetical protein  
SAOUHSC_01834 2.1 up Hydrolase, haloacid dehalogenase-like 
family protein 
 
SAOUHSC_01844 2.7 up Hypothetical protein of unknown function  
SAOUHSC_01934 2.3 up Hypothetical protein of unknown function  
SAOUHSC_01937 2.3 up Hypothetical protein of unknown 
function - no known homologues 
 
SAOUHSC_02105 2.4 up Hypothetical protein of unknown function  
SAOUHSC_02252 2.6 up Conserved hypothetical protein  
SAOUHSC_02290 6.2 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02325 2.8 up Hypothetical protein of unknown function  
SAOUHSC_02326 2.9 up Hypothetical protein of unknown function  
SAOUHSC_02339 2.1 up Hypothetical protein of unknown function  
SAOUHSC_02411 3.2 up Hypothetical protein of unknown function  
SAOUHSC_02616 2.6 up Hypothetical protein of unknown function  
SAOUHSC_02634 2.3 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02657 3.0 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02693 2.4 up Hypothetical protein of unknown function  
SAOUHSC_02717 2.9 up Conserved hypothetical protein of 
unknown function 
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SAOUHSC_02720 3.3 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02746 2.9 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02817 2.4 up MFS family major facilitator transporter  
SAOUHSC_02868 2.0 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02889 5.1 up Conserved hypothetical protein of 
unknown function 
 
SAOUHSC_02890 2.7 up Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02914 2.4 up Hypothetical protein of unknown function  
SAOUHSC_02934 2.3 up Hypothetical protein of unknown function  
SAOUHSC_02939 3.6 up Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02940 3.1 up Hypothetical protein of unknown function  
SAOUHSC_00025 2.6 up 5'-nucleotidase family protein  
SAOUHSC_00036 2.3 up Metallo-beta-lactamase family protein  
SAOUHSC_00082 2.8 up Siderophore staphylobactin biosynthesis protein 
SbnH 
 
SAOUHSC_00179 2.9 up Oxidoreductase  
SAOUHSC_00180 2.1 up Oxidoreductase  
SAOUHSC_00339 2.6 up Bifunctional homocysteine 
S-methyltransferase/5,10-methylenetetrahydrofol
ate reductase protein 
 
SAOUHSC_02728 2.6 up Metallophosphoesterase  
SAOUHSC_02824 3.3 up Phospholipase/carboxylesterase family protein 
SAOUHSC_02828 2.8 up Glyoxalase 
SAOUHSC_00106 3.8 up Hypothetical protein  
SAOUHSC_00109 2.0 up Replication initiation protein, putative  
SAOUHSC_00110 2.0 up Truncated replication initiation protein, putative  
SAOUHSC_00160 2.2 up RpiR family transcriptional regulator  
SAOUHSC_00292 4.4 up Indigoidine synthase A-like protein  
SAOUHSC_00295 3.8 up N-acetylneuraminate lyase  
SAOUHSC_00296 4.1 up ROK-family protein  
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SAOUHSC_02964 2.0 up HTH-type transcriptional regulator ArcR  
SAOUHSC_03021 2.4 up Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_03022 2.5 up Conserved hypothetical protein  
SAOUHSC_02711 2.8 up Biotin biosynthesis protein BioX, putative  
SAOUHSC_02872 2.6 up Conserved hypothetical protein  
SAOUHSC_03047 4.0 up Conserved hypothetical protein  
SAOUHSC_0304
8 
4.3 up Conserved hypothetical protein  
SAOUHSC_0025
9 
2.2 up Virulence protein EssA 
SAOUHSC_0286
3 
2.2 up Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_0300
3 
2.9 up Conserved hypothetical protein  
SAOUHSC_0006
2 
3.0 up DMT superfamily drug/metabolite transporter  
SAOUHSC_0023
2 
4.0 up Murein hydrolase regulator LrgA  
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Table A1.2. Down-regulated genes in S. aureus SH1000 in response to Ag
+
 
exposure (sorted according to JCVI cellular role categories) 
Gene Fold change 
in 
expression 
Function JCVI Cellular Role 
SubCategory 
Amino acid biosynthesis 
SAOUHSC_01635 2.7 down Shikimate kinase, putative Aromatic amino 
acid family 
 
Biosynthesis of cofactors, prosthetic groups, and carriers 
SAOUHSC_01434 2.2 down Dihydrofolate reductase Folic acid 
SAOUHSC_01874 2.2 down Rhodanese domain protein Molybdopterin 
Cell envelope 
SAOUHSC_00973 2.5 down Glycosyltransferase Biosynthesis and 
degradation of 
surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00991 2.1 down Acetyltransferase/acyltransferase, putative Biosynthesis and 
degradation of 
surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_01114 2.8 down Fibrinogen-binding protein, putative Biosynthesis and 
degradation of 
surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00332 2.0 down Putative membrane protein Other 
SAOUHSC_00672 2.4 down Hypothetical protein Other 
SAOUHSC_00717 3.2 down Putative lipoprotein Other 
SAOUHSC_00754 2.1 down Putatative lipoprotein Other 
SAOUHSC_00808 2.0 down Putatative lipoprotein Other 
SAOUHSC_01131 2.1 down Putative membrane protein Other 
SAOUHSC_01627 2.5 down Lipoprotein, putative Other 
SAOUHSC_02694 2.1 down  Other 
SAOUHSC_02695 2.2 down Lipoprotein, putative Other 
 
Cellular processes 
SAOUHSC_02381 2.4 down DNA-binding protein DpsA, putative Adaptations to 
atypical conditions 
SAOUHSC_02665 3.0 down Conserved hypothetical protein Adaptations to 
atypical conditions 
SAOUHSC_00585 2.2 down Putative membrane protein Cell adhesion 
SAOUHSC_00591 2.1 down Putative membrane protein Cell adhesion 
SAOUHSC_00598 2.4 down Hypothetical protein of unknown function Cell adhesion 
SAOUHSC_00602 2.0 down Hypothetical protein of unknown function Cell adhesion 
SAOUHSC_00835 2.6 down Glutaredoxin, putative Detoxification 
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Central intermediary metabolism 
SAOUHSC_02565 2.1 down Urease accessory protein UreD Nitrogen 
metabolism 
SAOUHSC_01882 2.0 down Lysophospholipase, putative Other 
DNA metabolism    
SAOUHSC_01342 2.0 down Exonuclease SbcCD, C subunit  DNA replication, 
recombination and 
repair 
SAOUHSC_00840 2.7 down TOPRIM domain topiosmerase/primase Other 
Energy metabolism 
SAOUHSC_00834 2.1 down Thioredoxin Electron transport 
SAOUHSC_00841 2.1 down Thioredoxin Electron transport 
SAOUHSC_01100 2.0 down Thioredoxin Electron transport 
 
Fatty acid and phospholipid metabolism 
SAOUHSC_01201 2.3 down Acyl carrier protein, AcpP Biosynthesis 
SAOUHSC_01260 2.7 down CDP-diacylglycerol--glycerol-3-phosphate 
3-phosphatidyltransferase 
Biosynthesis 
SAOUHSC_02163 6.2 down Truncated beta-hemolysin Degradation 
 
Mobile and extrachromosomal element functions 
SAOUHSC_00624 2.7 down Phage recombinase/integrase Prophage functions 
SAOUHSC_00830 2.3 down Acetyltransferase, GNAT family Prophage functions 
SAOUHSC_02038 2.2 down HK97 family phage protein Prophage functions 
SAOUHSC_01928 2.4 down Transposase family protein, putative Transposon 
functions 
SAOUHSC_02061 2.1 down Phi PVL orf 50-like protein Transposon 
functions 
SAOUHSC_02211 2.1 down Phi PVL orf 50-like protein Transposon 
functions 
 
Protein fate 
SAOUHSC_01162 2.0 down Lipoprotein signal peptidase, putative Protein and peptide 
secretion and 
trafficking 
SAOUHSC_02255 2.5 down Co-chaperonin GroES Protein folding and 
stabilization 
 
Protein synthesis 
SAOUHSC_00521 2.2 down 50S ribosomal protein L7/L12 Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01191 2.5 down 50S ribosomal protein L28, RpmB Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01208 0.430642 30S ribosomal protein S16 Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01211 2.3 down 50S ribosomal protein L19, RplS Ribosomal proteins: 
synthesis and 
modification 
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SAOUHSC_01651 2.3 down 50S ribosomal protein L33 Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01678 2.3 down 30S ribosomal protein S21 Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01784 2.7 down 50S ribosomal protein L20 Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_02361 2.1 down 50S ribosomal protein L31 type B Ribosomal proteins: 
synthesis and 
modification 
SAOUHSC_01625 2.2 down Elongation factor P Translation factors 
 
Regulatory functions 
SAOUHSC_00070 3.8 down Staphylococcal accessory regulator-like protein, 
SarS 
DNA interactions 
SAOUHSC_00620 3.1 down Staphylococcal accessory regulator T, putative DNA interactions 
SAOUHSC_00673 2.4 down AraC/XylS-family transcriptional regulator DNA interactions 
SAOUHSC_01685 2.8 down Heat-inducible transcription repressor HrcA DNA interactions 
SAOUHSC_01850 2.2 down Catabolite control protein A, CcpA DNA interactions 
SAOUHSC_02155 9.2 down GntR family transcriptional regulator DNA interactions 
SAOUHSC_02566 3.6 down Staphylococcal accessory regulator R, SarR DNA interactions 
SAOUHSC_00674 2.5 down HTH-type transcriptional regulator SarX Other 
SAOUHSC_00694 2.2 down HTH-type transcriptional regulator 
MgrA - regulator of SarX and NorB 
Other 
SAOUHSC_01361 2.3 down Transcriptional regulator, putative Other 
SAOUHSC_01362 2.9 down 4-oxalocrotonate tautomerase, putative Other 
SAOUHSC_01997 2.7 down Ferric uptake regulator-like protein, putative Other 
SAOUHSC_02669 2.2 down HTH-type transcriptional regulator SarZ Other 
SAOUHSC_00540 2.0 down Deoxynucleoside kinase/deoxypurine kinase, 
putative 
Protein interactions 
SAOUHSC_01419 2.7 down Hypothetical protein Protein interactions 
 
Transcription 
SAOUHSC_01247 2.2 down Ribosome-binding factor A RNA processing 
SAOUHSC_00767 3.5 down Ribosomal subunit interface protein, putative Transcription factors 
 
Transport and binding proteins 
SAOUHSC_00892 2.2 down Putative S1 RNA binding domain/general stress 
protein 13 
Amino acids, 
peptides and amines 
SAOUHSC_02151 7.3 down Putative membrane protein Amino acids, 
peptides and amines 
SAOUHSC_00626 3.3 down Putative monovalent cation/H+ antiporter subunit 
B 
Cations and iron 
carrying compounds 
 
Unknown function/unassigned function 
SAOUHSC_00028 2.3 down Hypothetical protein of unknown function  
SAOUHSC_00029 3.0 down Hypothetical protein of unknown function  
SAOUHSC_00280 2. down Putative membrane protein 
SAOUHSC_00331 2.3 down Hypothetical protein  
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SAOUHSC_00465 2.1 down Hypothetical protein of unknown function  
SAOUHSC_00537 2.3 down Hypothetical protein of unknown function  
SAOUHSC_00589 2.4 down Hypothetical protein of unknown function - no 
known homologues 
 
SAOUHSC_00627 2.8 down Putative monovalent cation/H+ antiporter subunit 
C 
 
SAOUHSC_00663 3.2 down Acetyltransferase, GNAT family  
SAOUHSC_00678 2.7 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00680 3.6 down LysR family transcriptional regulator 
SAOUHSC_00697 2.2 down Hypothetical protein  
SAOUHSC_00702 2.2 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00704 2.8 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00734 2.4 down 5'(3')-deoxyribonucleotidase (DNA/RNA synth) 
SAOUHSC_00736 3.1 down Diacylglycerol kinase  
SAOUHSC_00753 2.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00770 2.2 down Hypothetical protein of unknown function  
SAOUHSC_00819 2.5 down Cold shock protein CspC  
SAOUHSC_00824 2.0 down Putative membrane protein 
SAOUHSC_00825 3.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00826 4.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00837 2.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00862 2.2 down Hypothetical protein  
SAOUHSC_00919 2.0 down Putative membrane protein 
SAOUHSC_00938 2.0 down Dithiol-disulfide isomerase/thioredoxin superfamily-protein, putative 
SAOUHSC_00971 4.0 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_00972 2.2 down Hypothetical protein of unknown function  
SAOUHSC_00975 2.7 down DoxX family protein  
SAOUHSC_00996 2.1 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01024 5.0 down Hypothetical protein of unknown function  
SAOUHSC_01036 2.1 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01037 3.3 down Hypothetical protein of unknown function  
SAOUHSC_01051 2.0 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01060 2.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01062 2.1 down Hypothetical protein  
SAOUHSC_01072 2.1 down   
SAOUHSC_01096 2.2 down Cell division protein ZapA, putative 
SAOUHSC_01097 2.0 down Conserved hypothetical protein  
SAOUHSC_01110 5.0 down Fibrinogen-binding protein, putative  
SAOUHSC_01115 2.8 down Fibrinogen-binding protein, putative  
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SAOUHSC_01119 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01120 2.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01140 2.4 down Hypothetical protein of unknown function  
SAOUHSC_01155 2.0 down Hypothetical protein of unknown function - no 
known homologues 
 
SAOUHSC_01173 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01181 3.6 down Conserved hypothetical protein  
SAOUHSC_01230 2.7 down Hypothetical protein of unknown function  
SAOUHSC_01264 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01301 2.7 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01309 3.0 down Hypothetical protein of unknown function  
SAOUHSC_01315 3.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01324 2.0 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01340 2.0 down Conserved hypothetical protein  
SAOUHSC_01349 2.1 down Conserved hypothetical protein  
SAOUHSC_01353 2.0 down Hypothetical protein of unknown function - no 
known homologues 
 
SAOUHSC_01356 2.1 down GlcA/GlcB -family transcription antiterminator  
SAOUHSC_01357 2.0 down Hypothetical protein of unknown function  
SAOUHSC_01403 2.0 down Cold shock protein, CspA, putative  
SAOUHSC_01405 2.0 down Hypothetical protein of unknown function  
SAOUHSC_01421 2.5 down Hypothetical protein of unknown function  
SAOUHSC_01422 2.1 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01428 2.0 down Hypothetical protein of unknown function  
SAOUHSC_01464 2.2 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01468 2.7 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01489 2.0 down Hypothetical protein of unknown function  
SAOUHSC_01503 2.1 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01551 2.0 down Conserved hypothetical phage protein  
SAOUHSC_01560 2.1 down Conserved hypothetical phage protein  
SAOUHSC_01568 2.5 down Hypothetical protein of unknown function  
SAOUHSC_01607 2.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01608 2.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01636 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01665 2.0 down CBS domain-containing protein  
SAOUHSC_01719 2.5 down Conserved hypothetical protein of unknown 
function 
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SAOUHSC_01729 2.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01736 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01769 2.1 down membrane protein AbrB, proposed regulator of 
AidB expression 
 
SAOUHSC_01896 2.0 down Hypothetical protein of unknown function  
SAOUHSC_01899 2.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01930 2.8 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01957 2.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_01963 2.8 down Hypothetical protein of unknown function  
SAOUHSC_01986 3.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02055 2.1 down Conserved hypothetical phage protein  
SAOUHSC_02065 2.2 down Hypothetical protein phiETA_24 [Staphylococcus phage phiETA] 
SAOUHSC_02068 2.8 down Conserved hypothetical phage protein  
SAOUHSC_02071 2.7 down Single-strand DNA-binding protein, putative  
SAOUHSC_02110 2.0 down DNA polymerase III, alpha chain PolC-type/exonuclease 
SAOUHSC_02135 2.0 down Hypothetical protein  
SAOUHSC_02141 2.1 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02145 2.9 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02214 2.2 down Phi SLT orf 24-like protein [Staphylococcus phage phi13] 
SAOUHSC_02248 3.4 down GNAT family acetyltransferase 
SAOUHSC_02249 3.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02256 2.6 down Abortive infection protein  
SAOUHSC_02294 2.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02320 2.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02378 2.0 down Hypothetical protein of unknown function  
SAOUHSC_02416 2.0 down Hypothetical protein of unknown function  
SAOUHSC_02471 3.0 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02473 2.0 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02515 2.2 down Putative membrane protein 
SAOUHSC_02521 2.4 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02523 2.2 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02568 2.2 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02666 2.3 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02668 2.1 down Putative exported protein  
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SAOUHSC_02688 2.2 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_02774 3.8 down Conserved hypothetical protein  
SAOUHSC_03001 2.8 down Ica operon transcriptional regulator IcaR, putative  
SAOUHSC_A0063
5 
2.0 down Hypothetical protein of unknown function - no 
known homologues 
 
SAOUHSC_A0108
1 
2.6 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_A0201
3 
3.7 down Conserved hypothetical protein of unknown 
function 
 
SAOUHSC_A0250
3 
2.0 down Conserved hypothetical protein of unknown 
function 
 
 
  
 
               2
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Table A1.3. Putative integral membrane proteins up-regulated following exposure to Ag
+
 
Gene Fold change 
in 
expression  
Protein/Function Additional comments Number of 
predicted 
transmembrane 
domains 
Presence 
of 
cysteine 
JCVI Cellular Role Category 
SAOUHSC_00010 2.4 up Hypothetical 
protein 
Putative azaleucine resistance 
protein AzlC 
6 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00012 2.3 up Hypothetical 
protein 
Contains AzlD superfamily 
domain. AzlD is known to be 
involved in conferring 
resistance to 4-azaleucine 
although its exact role is 
uncertain. 
3 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00051 3.2 up 1-phosphatidylinosit
ol 
phosphodiesterase 
precursor, putative 
Contains putatative metal 
binding domain - normally 
binds calcium 
1 Yes Fatty acid and phospholipid 
metabolism: Degradation 
SAOUHSC_00053 2.0 up Hypothetical 
protein 
Tandem lipoprotein 1 Yes Cell envelope: Other 
SAOUHSC_00062 3.0 up Hypothetical 
protein 
DMT superfamily 
drug/metabolite transporter 
10 Yes Unknown function: General 
SAOUHSC_00071 2.1 up Lipoprotein, SirC, 
putative 
Permease component of 
ABC-type Fe
3+-
siderophore 
transport system 
8 No Transport and binding proteins: 
Cations and iron carrying 
compounds 
SAOUHSC_00072 3.2 up Lipoprotein, SirB, 
putative 
Permease component of 
ABC-type Fe
3+-
siderophore 
transport system 
9 Yes Transport and binding proteins: 
Cations and iron carrying 
compounds 
SAOUHSC_00078 3.7 up Hypothetical 
protein 
Siderophore staphylobactin 
biosynthesis protein SbnD OR 
MFS family major facilitator 
transporter 
10 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00084 2.0 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
3 Yes Hypothetical proteins/Unknown 
function 
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Table A1.3 (continued) 
SAOUHSC_00089 4.3 up Hypothetical 
protein 
Capsular polysaccharide 
biosynthesis glycosyltransferase 
(sugar transferase) 
1 Yes Cell envelope: Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00091 2.4 up Hypothetical 
protein 
Probable capsular biosynthesis 
protein/O-antigen polymerase 
12 Yes Cell envelope: Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_00099 2.1 up Hypothetical 
protein 
MFS family transporter: 
tetracycline:cation symporter 
11 No Transport and binding proteins: 
Unknown substrate 
SAOUHSC_00102 2.9 up Phosphonates ABC 
transporter, 
permease protein 
CC0363, putative 
Phosphonate ABC transporter, 
permease protein PhnE 
6 Yes Transport and binding proteins: 
Anions 
SAOUHSC_00103 2.8 up Phosphonates ABC 
transporter, 
permease protein 
CC0363, putative 
Phosphonate ABC transporter, 
permease PhnE 
6 Yes Transport and binding proteins: 
Anions 
SAOUHSC_00111 2.0 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
3 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_00138 4.0 up Hypothetical 
protein 
Putative ABC-type nitrate 
sulfonate taurine bicarbonate 
transport system permease 
component 
6 No Transport and binding proteins: 
Anions 
SAOUHSC_00146 2.1 up Hypothetical 
protein 
Integral membrane 
protein - homology to YagU in 
Actinomyces believed to be 
required for acid resistance 
4 Yes Cell envelope: Other 
SAOUHSC_00158 2.9 up PTS system 
component 
Sucrose specific PTS 10 Yes Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
SAOUHSC_00161 2.1 up Hypothetical 
protein 
Hypothetical protein of 
unknown function - no known 
homologues 
3 No Hypothetical proteins/Unknown 
function 
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Table A1.3 (continued) 
SAOUHSC_00168 2.1 up Hypothetical 
protein 
Nickel ABC transporter, 
permease subunit, gene name 
NikB 
9 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00169 3.7 up Peptide ABC 
transporter, 
permease protein, 
putative 
Peptide/nickel transport system 
permease 
9 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00177 2.8 up Maltose ABC 
transporter, 
permease protein, 
putative 
 8 No Transport and binding proteins: 
Unknown substrate 
SAOUHSC_00182 2.1 up Hypothetical 
protein 
Isoprenylcysteine carboxyl 
methyltransferase 
4 Yes Cell envelope: Other 
SAOUHSC_00183 4.1 up Sugar phosphate 
antiporter 
UhpT - known in other species 
as hexose phosphate transport 
protein 
12 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_00193 2.4 up Hypothetical 
protein 
Hypothetical protein of 
unknown function - no known 
homologues 
1 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_00200 2.3 up Hypothetical 
protein 
 8 No Cell envelope: Other 
SAOUHSC_00208 4.0 up Hypothetical 
protein 
Hypothetical protein of 
unknown function - no known 
homologues 
1 No Hypothetical proteins/Unknown 
function 
SAOUHSC_00209 3.0 up PTS system, 
glucose-specific 
IIBC component, 
putative 
 11 Yes Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
SAOUHSC_00216 3.2 up PTS system 
component 
PTS  enzyme IIC component 
galacticol or sorbitol specific 
9 Yes Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
SAOUHSC_00218 2.8 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 No Unknown function: General 
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SAOUHSC_00232 4.0 up Murein hydrolase 
regulator LrgA 
LrgAB inhibit extracellular 
murein hydrolase activity and 
promote penicillin tolerance 
4 Yes Unknown function: General 
SAOUHSC_00233 5.2 up Antiholin-like 
protein LrgB 
LrgAB inhibit extracellular 
murein hydrolase activity and 
promote penicillin tolerance 
7 Yes Regulatory functions: Other 
SAOUHSC_00241 2.0 up Hypothetical 
protein 
Ribose transporter RbsU 9 No Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_00246 3.4 up Drug transporter, 
putative 
MFS family drug transporter 
98% identity to quinolone 
resistance protein 
NorB - regulated by MgrA 
14 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_00255 2.4 up Hypothetical 
protein 
Putative membrane protein 6 Yes Cell envelope: Other 
SAOUHSC_00259 2.2 up Hypothetical 
protein 
Virulence protein EssA 
(component of the 
ESAT-6 secretion system) 
1 No Unclassified: Role category not yet 
assigned 
SAOUHSC_00281 2.5 up Hypothetical 
protein 
FNT family formate-nitrite 
transporter  
6 Yes Transport and binding proteins: 
Anions 
SAOUHSC_00293 3.7 up Hypothetical 
protein 
Nucleoside permease NupC, 
putative. NupC has specificity 
towards the pyrimidine 
nucleosides, adenosine, and 
their deoxy derivatives. 
8 No Transport and binding proteins: 
Nucleosides, purines and 
pyrimidines 
SAOUHSC_00294 4.3 up Hypothetical 
protein 
SSS family solute:sodium (Na
+
) 
symporter 
13 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_00299 3.0 up Hypothetical 
protein 
Putative membrane protein/gate 
domain protein/nucleoside 
recognition domain 
12 Yes Protein fate: Protein and peptide 
secretion and trafficking 
SAOUHSC_00310 2.5 up Ascorbate-specific 
PTS system enzyme 
IIC 
Gene name: UlaA 10 Yes Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
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SAOUHSC_00315 2.1 up Hypothetical 
protein 
Multidrug export protein MepA 12 Yes Transport and binding proteins: 
Other 
SAOUHSC_00317 3.0 up Glycerol-3-phospha
te transporter 
MFS family protein 12 Yes Transport and binding proteins: 
Other 
SAOUHSC_00327 2.3 up Hypothetical 
protein 
Ferrous iron transport permease 
EfeU - functions as part of an 
iron uptake 
mechanism - membrane bound 
protein 
6 Yes Cell envelope: Other 
SAOUHSC_00409 2.4 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
2 Yes Unknown function: General 
SAOUHSC_00420 3.8 up Hypothetical 
protein 
NSS family amino acid:sodium 
(Na
+
) symporter 
11 No Transport and binding proteins: 
Cations and iron carrying 
compounds 
SAOUHSC_00583 3.6 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 Yes Unknown function: General 
SAOUHSC_00932 2.3 up Oligopeptide ABC 
transporter, 
permease protein, 
putative 
  6 No Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_01387 2.7 up Hypothetical 
protein 
Phosphate ABC superfamily 
ATP binding cassette 
transporter, membrane protein 
6 No Transport and binding proteins: 
Anions 
SAOUHSC_01450 2.7 up Hypothetical 
protein 
Amino acid 
permease/transporter protein 
12 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_01494 2.4 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1  Unknown function: General 
SAOUHSC_01641 2.1 up Hypothetical 
protein 
Competence protein 
comgb -DNA transport 
4 Yes Protein fate: Protein and peptide 
secretion and trafficking 
SAOUHSC_01764 2.0 up Hypothetical 
protein 
Peptidase, A24 type IV prepilin 
peptidase family protein 
4 Yes Cell envelope: Surface structures 
SAOUHSC_01935 2.1 up Serine protease 
SplF, putative 
Spl serine proteases are secreted 
proteases and could be a 
virulence factor 
2 No Protein fate: Degradation of proteins, 
peptides, and glycopeptides 
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SAOUHSC_01941 3.6 up Serine protease 
SplB 
Spl serine proteases are secreted 
proteases and could be a 
virulence factor 
1 No Protein fate: Degradation of proteins, 
peptides, and glycopeptides 
SAOUHSC_01984 2.0 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
3 Yes Unknown function: General 
SAOUHSC_02270 2.7 up Ammonium 
transporter 
Ammonia or ammonium uptake 
transporter 
11 Yes Transport and binding proteins: 
Cations and iron carrying compounds 
SAOUHSC_02597 2.3 up PTS system 
component, putative 
Maltose-specific EIICB 
component 
10 Yes Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
SAOUHSC_02658 2.2 up Hypothetical 
protein 
Contains multiple 
membrane-spanning domains 
6 No Transport and binding proteins: 
Unknown substrate 
SAOUHSC_02671 2.4 up Hypothetical 
protein 
Nitrite extrusion protein 12 Yes Transport and binding proteins: 
Anions 
SAOUHSC_02711 2.8 up Hypothetical 
protein 
Biotin biosynthesis protein 
BioX in other organisms 
(80-95% identity) 
4 No Hypothetical proteins: Conserved 
SAOUHSC_02719 2.1 up Hypothetical 
protein 
ABC transporter ATP-binding 
protein 
5 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_02797 2.1 up Hypothetical 
protein 
Major facilitator superfamily 
transporter 
8 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_02806 2.4 up Gluconate 
permease, putative 
 12 No Transport and binding proteins: 
Carbohydrates, organic alcohols, and 
acids 
SAOUHSC_02815 2.1 up Hypothetical 
protein 
MFS family major facilitator 
transporter 
11 No Transport and binding proteins: 
Unknown substrate 
SAOUHSC_02821 2.0 up Membrane spanning 
protein, putative 
Transmembrane protein 
SmpB/lantibiotic protection 
ABC transporter permease 
subunit 
6 No Energy metabolism: Electron 
transport 
SAOUHSC_02863 2.2 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function 
1 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_02864 2.6 up Ferrous iron 
transport protein B 
Involved in iron uptake 10 Yes Transport and binding proteins: 
Cations and iron carrying compounds 
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SAOUHSC_02872 2.6 up Hypothetical 
protein 
 1 No Hypothetical proteins: Conserved 
SAOUHSC_02873 5.3 up Cation transporter 
E1-E2 family 
ATPase CopA 
 8 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_02888 4.5 up Hypothetical 
protein 
Hypothetical 
phosphotransferase system IIC  
component 
10 No Cell envelope: Other 
SAOUHSC_02902 2.7 up Hypothetical 
protein 
FeoB-family ferrous iron (Fe
2+
) 
uptake protein 
4 Yes Protein fate: Protein and peptide 
secretion and trafficking 
SAOUHSC_02948 2.9 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 No Unknown function: General 
SAOUHSC_02967 2.2 up Arginine/ornithine 
antiporter, putative 
 14 Yes Transport and binding proteins: 
Amino acids, peptides and amines 
SAOUHSC_02973 2.6 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 No Hypothetical proteins/Unknown 
function 
SAOUHSC_03000 2.6 up Capsular 
polysaccharide 
biosynthesis,  
 2 Yes Cell envelope: Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_03002 3.3 up N-glycosyltransfera
se, IcaA 
 4 Yes Cell envelope: Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
SAOUHSC_03003 2.9 up Hypothetical 
protein, IcaD 
Gene name:  2 Yes Unknown 
SAOUHSC_03020 2.5 up Hypothetical 
protein 
Membrane protein of unknown 
function 
5 Yes Cell envelope: Other 
SAOUHSC_03035 2.1 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function 
6 No Cell envelope: Other 
SAOUHSC_03037 2.0 up Permease VraD, 
putative 
 Upregulated during cell 
membrane stress 
10 Yes Transport and binding proteins: 
Unknown substrate 
SAOUHSC_03047 4.0 up Hypothetical 
protein 
Conserved membrane protein 4 Yes Hypothetical proteins: Conserved 
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SAOUHSC_03048 4.3 up Hypothetical 
protein 
Conserved membrane protein 4 Yes Hypothetical proteins: Conserved 
SAOUHSC_A00084 4.9 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_A00097 2.4 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
2 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_A00379 6.1 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function 
2 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_A00526 2.8 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function 
1 Yes Hypothetical proteins/Unknown 
function 
SAOUHSC_A02445 2.3 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function 
1 No Hypothetical proteins/Unknown 
function 
SAOUHSC_A02680 2.1 up Hypothetical 
protein 
Conserved hypothetical protein 
of unknown function -no known 
homologues 
2 Yes Unknown function: General 
SAOUHSC_A02795 2.3 up Hypothetical 
protein 
 1 Yes Unknown function: General 
SAOUHSC_A02801 2.6 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 Yes Unknown function: General 
SAOUHSC_A02856 2.6 up Hypothetical 
protein 
Hypothetical protein of 
unknown function 
1 Yes Unknown function: General 
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Appendix 2. Annotation of E. coli NCTC 50110 
Table A2.1. Genes present in contiguous sequences corresponding to plasmid 
pMG101. Annotation and subsystem assignment carried out by the Rapid Annotation 
using Subsystem Technology (RAST) server. Start = nucleotide position corresponding 
to start of the gene. End= nucleotide position corresponding to end of the gene. 
Contig Start Stop Length 
(bp) 
Protein/Function Subsystem category 
51 714 238 477 Lysin - none - 
51 1021 698 324 Phage holin - none - 
51 2276 1698 579 Phage antitermination protein 
Q 
Phage nin 
genes - N-independent 
survival 
51 2983 2318 666 Phage NinI serine/threonine 
phosphatase 
- none - 
51 3167 2961 207 Phage NinH Phage nin 
genes - N-independent 
survival 
51 3361 3164 198 Protein NinG - none - 
51 3938 3768 171 Phage NinF Phage nin 
genes - N-independent 
survival 
51 5144 4254 891 Phage NinC Phage nin 
genes - N-independent 
survival 
51 5563 5123 441 Phage NinB DNA 
recombination 
Phage nin 
genes - N-independent 
survival 
51 5927 5637 291 Ren protein - none - 
51 6625 5924 702 Hypothetical protein - none - 
51 7521 6622 900 Origin specific replication 
initiation factor 
Phage replication 
51 7691 7554 138 Phage repressor - none - 
51 8166 7966 201 Regulatory protein cro - none - 
51 8267 8980 714 Phage repressor - none - 
51 9093 9932 840 RexA protein - none - 
51 10847 11170 324 Phage antitermination protein 
N 
Phage nin 
genes - N-independent 
survival 
51 11998 12120 123 Phage restriction protein ral - none - 
60 1921 1589 333 Programmed cell death toxin 
PemK 
MazEF toxin-antitoxing 
(programmed cell death) 
system 
60 2180 1923 258 Programmed cell death 
antitoxin PemI 
MazEF toxin-antitoxin 
(programmed cell death) 
system 
60 2926 2273 654 Microcin M activity protein 
McmM 
- none - 
60 3164 3024 141 Hypothetical protein - none - 
60 3743 3910 168 Hypothetical protein - none - 
60 4723 3866 858 RepA1 - none - 
60 5281 5027 255 Replication regulatory protein 
repA2 (Protein copB) 
- none - 
60 5654 7195 1542 Mobile element protein - none - 
60 7207 7956 750 Mobile element protein - none - 
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Table A2.1 (continued) 
60 8298 8164 135 Post-segregation killing 
protein 
- none - 
60 9296 9114 183 Hypothetical protein - none - 
60 10072 9512 561 Plasmid conjugative transfer 
fertility inhibition protein 
FinO 
Conjugative transfer, 
Conjugal Transfer 
System 
60 10873 10127 747 Plasmid conjugative transfer 
pilin acetylase TraX 
Conjugative transfer, 
Conjugal Transfer System 
60 16163 10893 5271 Plasmid conjugative transfer 
DNA-nicking and unwinding 
protein TraI 
Conjugative transfer, 
Conjugal Transfer System 
60 18316 16163 2154 Plasmid conjugative transfer 
protein TraD 
Conjugative transfer, 
Conjugal Transfer System 
60 19092 18313 780 YhfA Protein. In Tra region 
of some plasmids 
Conjugative transfer, 
Conjugal Transfer System 
60 20071 19295 777 Plasmid conjugative transfer 
surface exclusion protein 
TraT 
Conjugative transfer, 
Conjugal Transfer System 
60 23393 20574 2820 Plasmid conjugative transfer 
protein TraG 
Conjugative transfer, 
Conjugal Transfer System 
60 24763 23390 1374 Plasmid conjugative transfer 
pilus assembly protein TraH 
Conjugative transfer, 
Conjugal Transfer System 
60 25142 24750 393 Plasmid conjugative transfer 
protein TrbF 
Conjugative transfer, 
Conjugal Transfer System 
60 25410 25123 288 Plasmid conjugative transfer 
protein TrbJ 
Conjugative transfer, 
Conjugal Transfer System 
60 25945 25400 546 Plasmid conjugative transfer 
protein TrbB 
Conjugative transfer, 
Conjugal Transfer System 
60 26168 25932 237 Plasmid conjugative transfer 
protein TraQ 
Conjugative transfer, 
Conjugal Transfer System 
61 756 52 705 Mobile element protein - none - 
61 733 1089 357 Mobile element protein - none - 
61 1089 1547 459 Mobile element protein - none - 
61 1606 1977 372 Mobile element protein - none - 
61 2324 2617 294 Mobile element protein - none - 
61 3986 2676 1311 Glycerol-3-phosphate-bindin
g protein 
- none - 
61 5052 3979 1074 Probable sugar ABC 
transporter, ATP-binding 
protein 
- none - 
61 5882 5058 825 Cyclic-nucleotide 
phosphodiesterase (EC 
3.1.4.17) 
CBSS-342610.3.peg.1794
, cAMP signaling in 
bacteria 
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61 6780 5893 888 Putative SN-glycerol-3-phosphate 
transport system permease 
- none - 
61 7636 6770 867 N-Acetyl-D-glucosamine ABC 
transport system, permease 
protein 
- none - 
61 8006 7779 228 Alcohol dehydrogenase  5-FCL-like protein, 
Butanol 
Biosynthesis, 
Fermentations: 
Mixed acid, 
Glycerolipid and 
Glycerophospholipi
d Metabolism in 
Bacteria 
61 8219 8037 183 Alcohol dehydrogenase 5-FCL-like protein, 
Butanol 
Biosynthesis, 
Fermentations: 
Mixed acid, 
Glycerolipid and 
Glycerophospholipi
d Metabolism in 
Bacteria 
61 8193 8387 195 Putative cytoplasmic protein - none - 
61 8620 9510 891 Dihydrodipicolinate synthase Lysine Biosynthesis 
DAP Pathway, 
Lysine Biosynthesis 
DAP Pathway, GJO 
scratch 
61 9535 9915 381 Probable translational inhibitor 
protein 
- none - 
61 9948 10913 966 2-keto-3-deoxygluconate 
permease (KDG permease) 
D-Galacturonate and 
D-Glucuronate 
Utilization 
61 11711 10959 753 Transcriptional regulator, IclR 
family 
- none - 
61 12316 12600 285 Hypothetical protein - none - 
61 12600 12875 276 FIG01069112: hypothetical 
protein 
- none - 
61 12981 13274 294 Stability (stb) locus of IncFII 
plasmid NR1; similar to 
SwissProt accession number 
P11907 
- none - 
61 14639 13470 1170 FIG00642200: hypothetical 
protein 
- none - 
61 16085 16825 741 Resolvase - none - 
61 18063 17110 954 RepFIB replication protein A - none - 
61 18857 19189 333 Mobile element protein - none - 
61 19489 19836 348 Error-prone, lesion bypass DNA 
polymerase V (UmuC) 
DNA repair, 
bacterial UmuCD 
system 
67 215 84 132 FIG00242751: hypothetical 
protein 
- none - 
67 431 718 288 FIG00638017: hypothetical 
protein 
- none - 
260 
 
 
Table A2.1 (continued) 
67 837 1658 822 Unnamed protein product - none - 
67 2463 1954 510 X polypeptide - none - 
67 3404 4081 678 Plasmid conjugative transfer 
regulator TraJ 
Conjugative transfer, 
Conjugal Transfer System 
67 4214 4396 183 Plasmid conjugative transfer 
regulator TraY 
Conjugative transfer, 
Conjugal Transfer System 
67 4430 4792 363 Plasmid conjugative transfer 
pilin protein TraA 
Conjugative transfer, 
Conjugal Transfer System 
67 4797 5108 312 Plasmid conjugative transfer 
pilus assembly protein TraL 
Conjugative transfer, 
Conjugal Transfer System 
67 5130 5696 567 Plasmid conjugative transfer 
pilus assembly protein TraE 
Conjugative transfer, 
Conjugal Transfer System 
67 5683 6411 729 Plasmid conjugative transfer 
pilus assembly protein TraK 
Conjugative transfer, 
Conjugal Transfer System 
67 6411 7862 1452 Plasmid conjugative transfer 
pilus assembly protein TraB 
Conjugative transfer, 
Conjugal Transfer System 
67 7852 8418 567 Plasmid conjugative transfer 
protein TraP 
Conjugative transfer, 
Conjugal Transfer System 
67 8405 8716 312 Plasmid conjugative transfer 
protein TrbD 
Conjugative transfer, 
Conjugal Transfer System 
67 8716 9231 516 Plasmid conjugative transfer 
pilus assembly protein TraV 
Conjugative transfer, 
Conjugal Transfer System 
67 9366 9587 222 Plasmid conjugative transfer 
protein TraR 
Conjugative transfer, 
Conjugal Transfer System 
67 9541 9684 144 FIG00641102: hypothetical 
protein 
- none - 
67 9747 12374 2628 Plasmid conjugative transfer 
pilus assembly protein TraC 
Conjugative transfer, 
Conjugal Transfer System 
67 1237
1 
12757 387 Plasmid conjugative transfer 
protein TrbI 
Conjugative transfer, 
Conjugal Transfer System 
67 1285
6 
13386 531 Plasmid conjugative transfer 
pilus assembly protein TraW 
Conjugative transfer, 
Conjugal Transfer System 
67 1338
3 
14384 1002 Plasmid conjugative transfer 
pilus assembly protein TraU 
Conjugative transfer, 
Conjugal Transfer System 
67 1479
3 
15098 306 Mobile element protein - none - 
67 1509
8 
15445 348 Mobile element protein - none - 
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67 1546
5 
17036 1572 Mobile element protein - none - 
67 17112 17417 306 Conjugative transfer protein 
PSLT093 
Conjugative transfer, 
Conjugal Transfer System 
67 17426 18064 639 Plasmid conjugative transfer 
protein TrbC 
Conjugative transfer, 
Conjugal Transfer System 
67 18061 19911 1851 Plasmid conjugative transfer 
protein TraN 
Conjugative transfer, 
Conjugal Transfer System 
67 19938 20180 243 Plasmid conjugative transfer 
protein TrbE 
Conjugative transfer, 
Conjugal Transfer System 
72 39 203 165 Hypothetical protein - none - 
72 1281 259 1023 Hypothetical protein CBSS-1496.1.peg.2937 
72 2831 1266 1566 Predicted ATP-dependent 
endonuclease of the OLD 
family 
CBSS-1496.1.peg.2937 
72 3322 2906 417 VagD - none - 
72 3549 3319 231 Virulence-associated protein 
vagC 
- none - 
72 3930 7724 3795 Hypothetical protein - none - 
72 8185 7769 417 VagD - none - 
72 8297 8485 189 VagD - none - 
72 9190 9963 774 K88 minor fimbrial subunit 
faeH precursor 
- none - 
72 10130 11263 1134 Hypothetical protein - none - 
72 11809 11297 513 Hypothetical protein - none - 
72 12086 12199 114 Hypothetical protein - none - 
72 12376 12594 219 CcdA protein (antitoxin to 
CcdB) 
Toxin-antitoxin replicon 
stabilization systems 
72 12596 12901 306 CcdB toxin protein Toxin-antitoxin replicon 
stabilization systems 
72 12950 13708 759 Resolvase - none - 
72 13902 14021 120 Hypothetical protein - none - 
72 14482 15237 756 Replication initiation protein 
RepE 
- none - 
72 15869 15717 153 Hypothetical protein - none - 
72 15825 16991 1167 Chromosome (plasmid) 
partitioning protein ParA 
Bacterial Cell Division, 
Bacterial Cytoskeleton, Cell 
Division Subsystem 
including YidCD, RNA 
modification and 
chromosome partitioning 
cluster 
72 16991 17962 972 Chromosome (plasmid) 
partitioning protein ParB 
Bacterial Cytoskeleton, Cell 
Division Subsystem 
including YidCD, RNA 
modification and 
chromosome partitioning 
cluster 
72 18590 19516 927 Hypothetical protein - none - 
72 19793 19668 126 Hypothetical protein - none - 
262 
 
 
Table A2.1 (continued) 
72 19901 2058
4 
684 Adenine-specific methyltransferase CBSS-257314.1.pe
g.752 
72 20585 2080
6 
222 Putative cytoplasmic protein - none - 
72 20820 2125
4 
435 YcgB - none - 
72 21305 2208
1 
777 Hypothetical protein - none - 
72 22498 2292
3 
426 Putative antirestriction protein - none - 
72 22970 2339
2 
423 Adenine-specific methyltransferase  CBSS-257314.1.pe
g.752 
72 23389 2358
0 
192 Hypothetical protein - none - 
85 544 110 435 Mercuric resistance operon regulatory 
protein, MerR 
Mercury resistance 
operon 
85 616 966 351 Mercuric transport protein, MerT Mercury resistance 
operon 
85 980 1255 276 Periplasmic mercury(+2) binding protein, 
MerP 
Mercury resistance 
operon 
85 1300 1713 414 Mercuric transport protein, MerC Mercury resistance 
operon 
85 1837 3459 1623 Mercuric ion reductase, MerA Mercuric reductase, 
Mercury resistance 
operon 
85 3477 3839 363 Mercuric resistance operon coregulator Mercury resistance 
operon 
85 3836 4072 237 Mercuric transport protein, MerE Mercury resistance 
operon 
85 4108 4776 669 Tn21 protein of unknown function  - none - 
85 5367 6530 1164 TniA putative transposase CBSS-203122.12.p
eg.188 
85 6533 7393 861 TniB NTP-binding protein CBSS-203122.12.p
eg.188 
85 8988 7444 1545 Mobile element protein - none - 
85 9120 1063
4 
1515 Mobile element protein - none - 
85 10624 1140
6 
783 Mobile element protein - none - 
85 11690 1190
8 
219 Hypothetical protein - none - 
85 13049 1221
0 
840 Dihydropteroate synthase  Folate Biosynthesis 
85 14345 1355
4 
792 Streptomycin 3-O-adenylyltransferase 
/Spectinomycin 9-O-adenylyltransferase 
Aminoglycoside 
adenylyltransferase
s, aminoglycoside 
adenylyltransferase
s 
85 15333 1445
8 
876 -lactamase Beta-lactamase 
85 15498 1651
1 
1014 Integron integrase IntI1 Integrons 
85 16864 1706
4 
201 Mobile element protein - none - 
85 17190 1775
0 
561 Resolvase - none - 
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85 17753 2071
9 
2967 Mobile element protein - none - 
85 20786 2116
3 
378 YbjA protein - none - 
85 22023 2136
4 
660 Chloramphenicol acetyltransferase - none - 
94 2541 343 2199 Aerobactin siderophore receptor 
IutA/TonB-dependent siderophore 
receptor 
Siderophore 
Aerobactin, 
Siderophore 
assembly kit, Ton 
and Tol transport 
systems, Ton and 
Tol transport 
systems 
94 3903 2626 1278 L-lysine 6-monooxygenase [NADPH], 
aerobactin biosynthesis protein 
IucD/Siderophore biosynthesis protein, 
monooxygenase 
Siderophore 
Aerobactin, 
Siderophore 
assembly kit 
94 5642 3900 1743 Citrate:6-N-acetyl-6-N-hydroxy-L-lysine 
ligase, alpha subunit, aerobactin 
biosynthesis protein IucA/Siderophore 
synthetase superfamily, group 
C/Siderophore synthetase component, 
ligase 
Siderophore 
Aerobactin, 
Siderophore 
assembly kit 
94 6589 5642 948 N6-hydroxylysine O-acetyltransferase, 
aerobactin biosynthesis protein 
IucB/Siderophore synthetase small 
component, acetyltransferase 
Siderophore 
Aerobactin, 
Siderophore 
assembly kit 
94 8314 6590 1725 Citrate:6-N-acetyl-6-N-hydroxy-L-lysine 
ligase, alpha subunit, aerobactin 
biosynthesis protein IucA/Siderophore 
synthetase superfamily, group 
A/Siderophore synthetase large 
component, acetyltransferase 
Siderophore 
Aerobactin, 
Siderophore 
assembly kit 
94 8450 9643 1194 Hypothetical protein - none - 
94 1109
4 
10744 351 Enolase Entner-Doudoroff 
Pathway, 
Glycolysis and 
Gluconeogenesis 
94 1250
3 
11646 858 Manganese ABC transporter, inner 
membrane permease protein SitD 
- none - 
94 1335
7 
12500 858 Manganese ABC transporter, inner 
membrane permease protein SitC 
- none - 
94 1418
1 
13354 828 Manganese ABC transporter, 
ATP-binding protein SitB 
- none - 
94 1497
2 
14181 792 Manganese ABC transporter, 
periplasmic-binding protein SitA 
- none - 
122 118 276 159 Secreted protein, suppressor for 
copper-sensitivity ScsC 
Copper 
homeostasis: 
copper tolerance 
122 266 772 507 Membrane protein, suppressor for 
copper-sensitivity ScsD 
Copper 
homeostasis: 
copper tolerance 
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122 1009 1770 762 Na(+)-translocating NADH-quinone 
reductase subunit C 
Na(+)-translocating 
NADH-quinone 
oxidoreductase and 
rnf-like group of 
electron transport 
complexes 
122 1767 1886 120 Hypothetical protein - none - 
122 1984 1844 141 Hypothetical protein - none - 
122 2063 4003 1941 Putative high-affinity iron permease - none - 
122 4044 4571 528 Periplasmic protein p19 involved in 
high-affinity Fe
2+ 
transport 
- none - 
122 4675 6054 1380 Putative membrane protein - none - 
122 6057 7340 1284 Hypothetical ABC transporter - none - 
122 7330 8460 1131 Putative membrane protein - none - 
122 8465 9160 696 ABC transporter, ATP-binding subunit 
precursor 
- none - 
122 9147 9632 486 Putative thioredoxin precursor - none - 
122 9657 10142 486 Hypothetical protein - none - 
122 1026
4 
10818 555 Glucose-1-phosphatase - none - 
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Table A2.2. Genes present in contig 10: containing a Tn7-like transposable element 
harbouring the sil operon. Annotation and subsystem assignment carried out by the 
Rapid Annotation using Subsystem Technology (RAST) server 
Start Stop Length (bp) Function Subsystems 
1283 1167 117 FIG00640193: hypothetical 
protein 
- none - 
1811 1386 426 Arsenate reductase Anaerobic respiratory reductases, 
Arsenic resistance, Transcription 
repair cluster 
3113 1824 1290 Arsenic efflux pump protein Arsenic resistance 
3520 3167 354 Arsenical resistance operon 
repressor 
Arsenic resistance 
4232 4059 174 Hypothetical protein - none - 
4227 4343 117 hypothetical protein - none - 
5749 4397 1353 Glutathione reductase Glutathione: Redox cycle 
6663 5821 843 Protein involved in catabolism 
of external DNA 
DNA processing cluster 
6974 8908 1935 Oligopeptidase A Protein degradation 
8916 9668 753 Hypothetical protein - none - 
11186 9717 1470 Di/tripeptide permease DtpB Proton-dependent Peptide 
Transporters 
11937 11503 435 Universal stress protein A Universal stress protein family 
12382 12663 282 Universal stress protein B Universal stress protein family 
12854 12726 129 Hypothetical protein - none - 
14406 12907 1500 Low-affinity inorganic 
phosphate transporter 
Phosphate metabolism 
14638 15840 1203 NAD(FAD)-utilizing 
dehydrogenases 
- none - 
16288 17130 843 Tn7-like transposase TnsA - none - 
17162 19240 2079 Tn7-like transposase TnsB - none - 
19240 20688 1449 Tn7-like transposition protein 
TnsC 
- none - 
20729 22285 1557 Tn7-like transposition protein 
TnsD 
- none - 
22297 23223 927 Conserved hypothetical protein - none - 
24439 26265 1827 Hypothetical protein - none - 
26784 26434 351 Putative exported protein - none - 
27363 26932 432 Periplasmic silver-binding 
protein SilE 
- none - 
29089 27608 1482 Putative membrane 
histidine-kinase silver-sensor 
SilS 
- none - 
29762 29082 681 Putative transcriptional 
regulator/responder SilR 
- none - 
29952 31337 1386 Putative silver-efflux system, 
outer membrane protein SilC 
- none - 
31365 31718 354 Periplasmic silver-binding 
protein SilF 
- none - 
31832 33124 1293 Putative silver-efflux system, 
membrane-fusion protein SilB 
- none - 
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Table A2.2 (continued) 
33135 36281 3147 Putative silver-efflux system, proton/cation 
antiporter SilA 
- none - 
36368 36808 441 CopG protein - none - 
36936 39377 2442 Putative cation-tranporting P-type ATPase SilP - none - 
39418 39615 198 FIG00643033: hypothetical protein - none - 
40386 39649 738 Cell wall endopeptidase, family M23/M37 Glutaredoxins 
41110 40661 450 Hypothetical protein - none - 
41345 43162 1818 Multicopper oxidase Copper homeostasis 
43168 44058 891 Copper resistance protein, PcoB Copper homeostasis 
44140 44478 339 Copper resistance protein PcoC Copper homeostasis 
44590 44465 126 Hypothetical protein - none - 
44669 45412 744 Copper resistance protein PcoD Copper homeostasis 
45467 46147 681 Transcriptional regulatory protein PcoR - none - 
46144 47544 1401 Copper sensor histidine kinase, PcoS Cobalt-zinc-cadmium 
resistance 
47760 48194 435 Periplasmic copper-binding protein PcoE - none - 
49559 48552 1008 FIG00638244: hypothetical protein - none - 
49797 50000 204 FIG01068562: hypothetical protein - none - 
50163 50044 120 FIG00638049: hypothetical protein - none - 
50218 51225 1008 FIG00638558: hypothetical protein - none - 
51855 53477 1623 FIG00637996: hypothetical protein - none - 
53667 53780 114 Hypothetical protein - none - 
53843 54910 1068 Putative membrane protein - none - 
54907 57642 2736 ABC-type multidrug transport system, permease 
component 
- none - 
57642 58766 1125 Putative transporter - none - 
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